Note: Descriptions are shown in the official language in which they were submitted.
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
MICROFLUIDIC MEASUREMENTS OF THE RESPONSE OF AN ORGANISM TO A
DRUG
CROSS-REFERENCE
[0001] This application claims the benefit of U.S. Provisional Application No.
62/075,648,
filed November 5, 2014, which application is incorporated herein by reference
in its entirety.
STATEMENT AS TO FEDERALLY SPONSORED RESEARCH
[0002] This invention was made with support under grant numbers EB012946,
GM074961 and
DP10D003584 awarded by the National Institutes of Health (NIH) and under
cooperative
agreement number HR-0011-11-2-0006 by the Defense Advanced Research Projects
Agency.
The government has certain rights in the invention.
TECHNICAL FIELD
[0003] The present application relates to the field of microfluidics and to
the fields of detection
and amplification of biological entities.
BACKGROUND OF THE INVENTION
[0004] Antibiotic resistance constitutes a major imminent threat to public
health worldwide.
Statistics from the CDC(U. S. Department of Health and Human Services, 2013,
114) and
WHO (Organization, 2014, 257) are alarming and emphasize that the current
paradigm of
liberal and non-selective antibiotic use cannot continue. Emergence of
resistance in Gram-
negative organisms, for which there are limited treatment options, is of
particular concern.
Over-use of broad-spectrum antibiotics in clinics is a major contributor to
the evolution and
spread of drug- resistant pathogens; however, combating resistance requires
diagnostic
development in all settings.
[0005] To improve care, clinical laboratories require rapid tests to identify
the pathogen and
determine its antimicrobial susceptibility. Laboratories currently conduct
identification and
antimicrobial susceptibility tests (AST) via culture-based methods, which take
24-48 hours.
Because the physician does not know in a proximate timeframe what organism is
present, the
bacterial burden, or the susceptibility of the organism to various therapeutic
approaches,
clinicians often choose to treat with broad spectrum (e.g. 2nd and 3rd
generation) antibiotics and
can even treat sub-clinical infection or false positives. Overprescribing
antibiotics is most acute
among complex, recurrent, and specialty cases. These include febrile children,
obstructed
patients, such as men with BPH, nephrolithiasis, especially those with
repeated instrumentation,
women with infection during pregnancy, hospitalized patients, and immune-
compromised
patients. In these situations, clinicians tend to treat more aggressively.
Accelerating turnaround
will allow clinicians to improve patient care by administering the right
antimicrobial regimen
1
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
without delays. Thus, to improve the problem of emerging antimicrobial
resistance and to
improve care, physicians in primary care settings require ultra-rapid tests to
identify the
pathogen and determine its antimicrobial susceptibility. What is needed,
therefore, are devices
and methods for rapidly and accurately diagnosing infection and antimicrobial
resistance or
susceptibility.
SUMMARY OF THE INVENTION
[0006] In one aspect, the invention provides devices and methods can rapidly
identify a cell,
including a cancer cell, or microorganism, including a pathogen, quantify
their load, and
diagnose their susceptibility or resistance to drugs, such as antibiotics. In
some embodiments the
devices can enable phenotypic detection and metabolic profiling of drug
susceptibility or drug
resistance using individual microorganisms or cells which can originate from
various sample
types, including clinical or environmental samples. These sample types can
include, but are not
limited to, blood, cerebral spinal fluid (CSF), saliva and urine and can also
include
environmental samples, such as from water or a hospital surface. In some
embodiments, the
devices enable incubation of cells with drugs, such as antibiotics, and then
rapidly extract and
quantify nucleic acids or other molecules in a contamination-free platform.
The devices can use
digital single- molecule measurements in microfluidics devices, which provide
ultra-sensitive
measurements that improve detection limits while providing quantitative data,
important for
differentiating pathogens from contaminants and enabling earlier
differentiation between drug-
resistant and susceptible organisms or cells. In some embodiments, these
devices can
differentiate the state of individual microorganisms or cells from a clinical
sample, and
understand the timing of their individual responses to drugs, such as for
example antibiotics,
providing ultra-fast drug- susceptibility measurements.
[0007] In some embodiments, the data associated with the sample comprises
measurements
from greater than one spatially-isolated compartment each of the compartments
comprising a
portion of the sample.
[0008] In some embodiments, the sample undergoes a nucleic acid amplification.
In some
embodiments, the nucleic acid amplification reaction is a loop mediated
amplification (LAMP)
reaction. In some embodiments, the nucleic acid amplification reaction is a
PCR reaction. In
some embodiments, the method is performed at about or at a temperature range
of 55-65 C. In
some embodiments, at least a portion of the sample is partitioned into an
array comprising at
least 2 or more. In some embodiments, the array is a SlipChip. In some
embodiments, the
nucleic acid that is amplified is RNA.
2
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
[0009] Also provided herein are methods for detecting and quantifying target
molecules from a
sample, comprising: providing a first sample comprising a target molecule from
a first portion of
a population of bacteria and a second sample comprising a target molecule from
a second portion
of said population of bacteria, wherein the first portion has been treated
with an antibiotic, and
wherein the second portion has not been treated with the antibiotic;
distributing said first sample
among a plurality of first analysis regions; distributing said second sample
among a plurality of
second analysis regions; contacting each of the first and second analysis
regions with a reagent
for performing a reaction to detect the presence or absence of a threshold
number of target
molecules in each of the first and second analysis regions; and detecting the
presence or absence
of the threshold number of target molecules in each of the first and second
analysis regions,
wherein the distribution of each sample among the analysis regions is effected
such that the
threshold number of target molecules is detected in some of the first and
second analysis regions
and is not detected in some of the first and second analysis regions after
said reaction.
[0010] In some embodiments, the threshold number is greater than zero, one,
two, three, four,
or five. In some embodiments, the distribution of each sample among the
analysis regions is
effected such that at least some of the analysis regions do not have the
target molecule, and at
least some of the analysis regions have only one target molecule. In some
embodiments, the
distribution of each sample among the analysis regions is effected such that
at least one of the
analysis regions contains only one target molecule. In some embodiments, the
first sample
comprises said reagent, and wherein contacting the plurality of first analysis
regions with the
reagent comprises said step of distributing said first sample among said
plurality of first analysis
regions. In some embodiments, the second sample comprises said reagent, and
wherein
contacting the plurality of second analysis regions with the reagent comprises
said step of
distributing said second sample among said plurality of second analysis
regions.
[0011] In some embodiments, reaction comprises nucleic acid amplification. In
some
embodiments, the nucleic acid amplification is essentially isothermal. In some
embodiments, the
nucleic acid amplification is a polymerase chain reaction. In some
embodiments, the nucleic acid
amplification is a nucleic acid sequence based amplification (NASBA), self-
sustained sequence
replication (3 SR), loop mediated isothermal amplification (LAMP), strand
displacement
amplification (SDA), whole genome amplification, multiple displacement
amplification, strand
displacement amplification, helicase dependent amplification, nicking enzyme
amplification
reaction, recombinant polymerase amplification, reverse transcription PCR, or
ligation mediated
PCR.
3
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
[0012] In some embodiments, said analysis regions comprise wells. In some
embodiments, the
target molecule is a nucleic acid. In some embodiments, the reagent is a
nucleic acid
amplification reagent. In some embodiments, the method of detecting and
quantifying target
molecules from a sample further comprises exposing each of the analysis
regions to conditions
effective for amplification of the nucleic acid.
[0013] In some embodiments, the target molecule comprises a segment of a
bacterial
chromosome or plasmid. In some embodiments, the target molecule is less than
50 kDa, less than
100 kDa, less than 200 kDa, or less than 400 kDa from the origin of
replication. In some
embodiments, the target molecule comprises a sequence of a gene on said
bacterial chromosome
or plasmid. In some embodiments, the target molecule comprises mRNA. In some
embodiments,
the target molecule is amplified by an amplification reaction, said
amplification reaction
comprising primers complementary to a sequence of the target molecule. In some
embodiments,
the mRNA encodes recA or lexA.
[0014] In some embodiments, the reagent is disposed in a plurality of reagent
regions. In some
embodiments, contacting is effected by placing the plurality of reagent
regions in fluid
communication with the first or second plurality of analysis regions. In some
embodiments,
contacting comprises effecting relative motion between a substrate comprising
the reagent
regions with a substrate comprising the first and second plurality of analysis
regions. In some
embodiments, the method of detecting and quantifying target molecules from a
sample further
comprises analyzing the detection of the presence or the absence of the
threshold number of
target molecules in each plurality of analysis regions to determine a
resistance or susceptibility to
an antibiotic in the population of bacteria.
[0015] In some embodiments, the target molecule has been removed from the
bacteria in the
first sample, and wherein the time between initial exposure of the bacteria to
antibiotic and the
removal of the target molecules is less than the mean doubling time of the
bacteria during a
growth phase. In some embodiments, the detection of the presence or absence of
the threshold
number of target molecules in each of the first and second analysis regions is
performed less than
3 hours, 2 hours, or one hour after the end of exposure of the first sample to
the antibiotic. In
some embodiments, the detection of the presence or absence of the threshold
number of target
molecules in each of the first and second analysis regions is performed less
than 45 minutes, 30
minutes, 15 minutes, or 10 minutes after the end of exposure of the first
sample to the antibiotic.
In some embodiments, the detection of the presence or absence of the threshold
number of target
molecules in each of the first and second analysis regions is performed less
than 3 hours, less
than 2 hours, or less than 1 hour after the end of exposure of the first
sample to the antibiotic. In
4
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
some embodiments, the detection of the presence or absence of the threshold
number of target
molecules in each of the first and second analysis regions is performed less
than 45 minutes, less
than 30 minutes, less than 15 minutes, or less than 10 minutes after the end
of exposure of the
first sample to the antibiotic.
[0016] In some embodiments, the bacteria from said first sample have been
treated with
antibiotic for a period of no more than 2 hours, no more than 1 hour, no more
than 45 minutes,
no more than 30 minutes, no more than 15 minutes, or no more than 10 minutes.
In some
embodiments, the time from the first exposure of the bacteria from the first
sample to an
antibiotic to the detection step is less than 3 hours, less than 2 hours, less
than 1 hour after, less
than 45 minutes, or less than 30 minutes.
[0017] In some embodiments, the first plurality of analysis regions comprises
at least 10, 20,
30, 40, or 50 analysis regions. In some embodiments, the second plurality of
analysis regions
comprises at least 10, 20, 30, 40, or 50 analysis regions. In some
embodiments, the distribution
of the first and second sample into the first and second plurality of analysis
regions is performed
in parallel. In some embodiments, the first sample or second sample comprises
less than 10,000,
5,000, 1,000, 500, 200, 100, 50, 20, or 10 target molecules.
[0018] Also provided herein is a method of determining a resistance or
susceptibility to an
antibiotic in a population of bacteria, comprising: providing a first sample
comprising a target
molecule from a first portion of a population of bacteria and a second sample
comprising a target
molecule from a second portion of said population of bacteria, wherein the
first portion has been
treated with an antibiotic, and wherein the second portion has not been
treated with the
antibiotic; distributing said first sample among a plurality of first analysis
regions; distributing
said second sample among a plurality of second analysis regions; contacting
each of the first and
second analysis regions with a reagent for performing a reaction to detect the
presence or
absence of a threshold number of target molecules in each of the first and
second analysis
regions; detecting the presence or absence of the threshold number of target
molecules in each of
the first and second analysis regions, wherein the distribution of each sample
among the analysis
regions is effected such that the threshold number of target molecules is
detected in some of the
first and second analysis regions and is not detected in some of the first and
second analysis
regions after said reaction; and analyzing the results of the detection to
determine a resistance or
susceptibility to said antibiotic in the population of bacteria.
[0019] Also provided herein is a method of determining a resistance or
susceptibility to an
antibiotic in a population of bacteria, comprising: distributing a population
of bacteria into a
plurality of clonal isolation regions, the distribution being effected such
that at least some of the
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
clonal isolation regions are statistically estimated to each contain a single
isolated bacterium;
expanding each of the single isolated bacteria to generate a plurality of
clonal populations;
distributing each of said plurality of clonal populations into at least one
treatment region from a
plurality of treatment regions and into at least one control region from a
plurality of control
regions; contacting the first plurality of treatment regions with an
antibiotic, the plurality of
control regions not contacted with the antibiotic; for each of the first
plurality of treatment
regions and each of the plurality of control regions, distributing one or more
target molecules
from each clonal population into a distinct plurality of analysis regions;
contacting each of the
analysis regions with a reagent for performing a reaction to detect the
presence or absence of a
threshold number of target molecules in each of the first and second analysis
regions; and
detecting the presence or absence of the threshold number of target molecules
in each of the first
and second analysis regions, wherein the distribution of each sample among the
analysis regions
is effected such that the threshold number of target molecules is detected in
some of the distinct
plurality of analysis regions and is not detected in some of the distinct
plurality of analysis
regions after said reaction.
[0020] In some embodiments, the method of determining a resistance or
susceptibility to an
antibiotic in a population of bacteria further comprises analyzing the results
of the detection to
determine a resistance or susceptibility to said antibiotic in at least some
of said plurality of
clonal populations.
[0021] Also provided herein are methods, comprising: providing a first sample
comprising a
target analyte from a first portion of a population of cells and a second
sample comprising a
target analyte from a second portion of said population of cells, wherein the
first portion has
been treated with a drug, and wherein the second portion has not been treated
with the drug;
distributing said first sample among a plurality of first analysis regions;
distributing said second
sample among a plurality of second analysis regions; contacting each of the
first and second
analysis regions with a reagent for performing a reaction to detect the
presence or absence of a
threshold number of target analytes in each of the first and second analysis
regions; and
detecting the presence or absence of the threshold number of target analytes
in each of the first
and second analysis regions, wherein the distribution of each sample among the
analysis regions
is effected such that the threshold number of target analytes is detected in
some of the first and
second analysis regions and is not detected in some of the first and second
analysis regions after
said reaction.
[0022] Also provided herein are kits comprising: a container comprising a
plurality of analysis
regions, a plurality of reagent regions comprising a component of a nucleic
acid amplification,
6
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
wherein the container comprises a first layer and a second layer configured to
move relative to
the other between a first position, where the plurality of analysis regions
and the plurality of
reagent regions are isolated from each other, and a second position, wherein
at least some of the
plurality of analysis regions is in fluid communication with at least some of
the plurality of
reagent regions; and instructions for use for determining a resistance or
susceptibility to an
antibiotic in a population of bacteria.
[0023] In some embodiments, the component of a nucleic acid amplification
comprises
primers for amplifying recA or lexA mRNA. In some embodiments, the component
of a nucleic
acid amplification comprises primers for amplifying a nucleic acid target on a
bacterial
chromosome or plasmid less than 50kDa, less than 100 kDa, less than 200 kDa,
or less than 400
kDa from the origin of replication. In some embodiments, the container
comprises at least 10, 20,
30, 40, or 50 analysis regions. In some embodiments, the container comprises
at least 10, 20, 30,
40, or 50 reagent regions.
[0024] In some embodiments, the antibiotic is selected from the group
consisting of:
aminoglycosides, cephalosporins, tetracyclines, sulfonamides, macrolides,
vancomycin, and 0-
lactams. In certain of these embodiments, the instructions indicate that a
decrease in nucleic acid
target detection in a portion of the population of bacteria treated with said
antibiotic as compared
to a portion of the population of bacteria not treated with said antibiotic
indicates that the
population of bacteria is susceptible to said antibiotic.
[0025] In some embodiments, the antibiotic is selected from the group
consisting of: HPUra,
hydroxyurea, trimethoprim, ciprofloxacin, and MMC. In certain of these
embodiments, the
instructions indicate that an increase in nucleic acid target detection in a
portion of the
population of bacteria treated with said antibiotic as compared to a portion
of the population of
bacteria not treated with said antibiotic indicates that the population of
bacteria is susceptible to
said antibiotic.
[0026] Also provided herein is a device for processing a sample, comprising an
incubation
module, a sample preparation module, and a digital quantification module,
wherein said device is
configurable to place each module in fluid communication with the other
modules; wherein said
incubation module comprises an incubation chamber configured to incubate an
organism with a
drug, wherein said sample preparation module is configured to extract a
nucleic acid from said
organism; and wherein said digital quantification module comprises a plurality
of reaction areas
configured to perform digital detection of the presence or absence of said
nucleic acid in said
reaction area.
7
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
INCORPORATION BY REFERENCE
[0027] All publications, patents, and patent applications mentioned in this
specification are
herein incorporated by reference to the same extent as if each individual
publication, patent, or
patent application was specifically and individually indicated to be
incorporated by reference.
[0028] Described herein are a number of devices and methods that can be used
individually or
in various combinations for applications including but not limited to those
listed herein.
Furthermore, they can be used in various combinations with previously
disclosed devices and
methods for previously described applications.
[0029] The present application incorporates the following applications by
reference in their
entireties for any and all purposes: United States Application 61/516,628,
"Digital Isothermal
Quantification of Nucleic Acids Via Simultaneous Chemical Initiation of
Recombinase
Polymerase Amplification (RPA) Reactions on Slip Chip," filed on April 5,
2011; United States
Application 61/518,601, "Quantification of Nucleic Acids With Large Dynamic
Range Using
Multivolume Digital Reverse Transcription PCR (RT-PCR) On A Rotational Slip
Chip Tested
With Viral Load," filed on May 9, 2011; United States application 13/257,811,
"Slip Chip
Device and Methods," filed on September 20, 2011; international application
PCT/U52010/028361, "Slip Chip Device and Methods," filed on March 23, 2010;
United States
Application 61/262,375, "Slip Chip Device and Methods," filed on November 18,
2009; United
States Application 61/162,922, "Slip Chip Device and Methods," filed on March
24, 2009;
United States Application 61/340,872, "Slip Chip Device and Methods," filed on
March 22,
2010; United States Application 13/440,371, "Analysis Devices, Kits, And
Related Methods For
Digital Quantification Of Nucleic Acids And Other Analytes," filed on April 5,
2012; United
States Application 13/467,482, "Multivolume Devices, Kits, Related Methods for
Quantification
and Detection of Nucleic Acids and Other Analytes," filed on May 9, 2012;
United States
Application 13/868,028, "Fluidic Devices and Systems for Sample Preparation or
Autonomous
Analysis," filed on April 22, 2013; United States Application 13/868,009,
"Fluidic Devices for
Biospecimen Preservation," filed on April 22, 2013; international application
PCT/U52013/037658, "Fluidic Devices for Biospecimen Preservation," filed on
April 22, 2013;
international application PCT/U52013/037660, "Fluidic Devices and Systems for
Sample
Preparation or Autonomous Analysis," filed on April 22, 2013; United States
application
13/869,856, "Slip-Induced Compartmentalization," filed April 24, 2013;
international
application PCT/U52013/063594, "Methods and Systems for Microfluidics Imaging
and
Analysis," filed on October 4, 2013; international application
PCT/U52014/034728,
"Parallelized Sample Handling," filed on April 18, 2014; international
application
8
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
PCT/US2014/047092, "Digital Assay for Quantifying and Concentrating Analytes,"
filed on July
17, 2014; United States Application 62/038,036, "The Pumping Lid: Devices and
Methods for
Programmable Generation of Positive and Negative Pressures," filed on August
15, 2014; United
States Application 62/050,647, "Digital Microfluidics Methods for Optimizing
Isothermal
Amplification Reactions," filed on Sept. 15, 2014; international application
PCT/U52014/056401, "System and Method for Movement and Timing Control," filed
on Sept.
18, 2014; and International Application No. PCT/U52014/060977 "Enhanced
Nucleic Acid
Identification and Detection" filed on October 16, 2014.
BRIEF DESCRIPTION OF THE DRAWINGS
[0030] The novel features of the invention are set forth with particularity in
the appended
claims. A better understanding of the features and advantages of the present
invention will be
obtained by reference to the following detailed description that sets forth
illustrative
embodiments, in which the principles of the invention are utilized, and the
accompanying
drawings of which:
[0031] Figure 1 shows the mapped position of rDNA genes relative to the origin
of replication
in a Urinary Tract Infection (UTI) Escherichia coli isolates.
[0032] Figure 2 shows circular representation of an example genome sequenced
from an E.
coli isolate from a UTI patient and the location of rRNA genes on the genome.
[0033] Figure 3 illustrates the effect of a drug on DNA and RNA levels based
on proximity to
the origin of replication in susceptible cells.
[0034] Figure 4 depicts the effects of no antibiotic, Antibiotic A, and
antibiotic B on
replication efficiency, replication fork stalls, and digital detection results
for targets with
different distances from the origin of replication from a single cell.
[0035] Figure 5 depicts workflow of determining the resistance or
susceptibility of a cell in a
sample of urine to a drug according to an embodiment of the invention.
[0036] Figures 6A, 6B, and 6C show 3 different views of an integrated device
comprising an
incubation module, according to an embodiment of the invention.
[0037] Figure 7 shows a photograph of blister packs, reagent packs, or other
types of
containers to be used with the integrated device, according to an embodiment
of the invention.
[0038] Figure 8 is a diagram of an operation module with one or more layers to
be driven by a
spring or motor, according to an embodiment of the invention.
[0039] Figure 9 shows a flowchart for performing single¨molecule and single-
cell
measurements to detect changes in individual cells from a heterogeneous
population in response
to drug treatment.
9
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
[0040] Figure 10 depicts a flow chart for a point of care device that provides
an assay and
results from the assay on a sample in a single integrated device.
[0041] Figure 11 shows the fold change in rDNA copy number for ciprofloxacin-
susceptible
E. coli treated with 2.5 ug/mL ciprofloxacin (right bar at each timepoint) and
non-treated (left
bar at each timepoint) samples measured at 10, 20, and 30 minutes as
determined by qPCR.
[0042] Figure 12A shows the fold change in rDNA copy number for ciprofloxacin-
susceptible
E. coli treated with 2.5 ug/mL ciprofloxacin (right bar at each timepoint) and
non-treated (left bar
at each timepoint) samples measured at 0, 15, and 30 minutes as determined by
qPCR. Figure
12B shows the same as determined by digital PCR on a SlipChip.
[0043] Figure 13 shows the fold change in rDNA copy number for ciprofloxacin-
susceptible
E. coli treated with 0.75 ug/mL ciprofloxacin and non-treated samples measured
at 15 minutes as
determined by digital PCR on a SlipChip
[0044] Figure 14A shows the fold change in rDNA copy number for susceptible
and resistant
E. coli treated with tetracycline and non-treated samples measured at 30
minutes as determined
by quantitative PCR. Figure 14B shows the fold change in rDNA copy number for
susceptible
and resistant E.coli treated with trimethoprim/sulfamethoxazoleand non-treated
samples
measured at 45 minutes as determined by quantitative PCR
[0045] Figure 15 shows the relative distance of feoB, recA and DnaInhibitor
protein gene
from oriC in genomes of UTI E. coli isolates. The x axis represents each
individual genome
(organized arbitrarily).
[0046] Figure 16 shows Cycle threshold (Ct) for quantification of DNA
fragments copies
number in UTI clinical isolates E. coli genomes, in susceptible and resistant
of bacteria (A) after
exposure ("treated") to a 2.5 ug/ml of ciprofloxacin for 15 minutes in BHI
medium.
[0047] Figure 17A and Figure 17B show RNA quantification of FeoB and RecA
genes
expression in UTI clinical isolates susceptible (S) and resistant (R) to
ciprofloxacin after 20
minutes of treatment with 2.5ug/mL of ciprofloxacin in BHI medium, versus 20
minutes of being
in BHI medium without antibiotics.
[0048] Figure 18 shows RNA quantification of FeoB and RecA genes expression in
UTI
clinical isolates susceptible and resistant to ciprofloxacin after 20 minutes
of treatment with 10
ug/mL of ciprofloxacin in BHI medium, versus 20 minutes of being in BHI medium
without
antibiotics.
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
DETAILED DESCRIPTION OF THE INVENTION
[0049] Unless defined otherwise, all technical and scientific terms used
herein have the same
meaning as is commonly understood by one of skill in the art to which the
claimed subject matter
belongs. All patents, patent applications, published applications and
publications, GENBANK
sequences, websites and other published materials referred to throughout the
entire disclosure
herein, unless noted otherwise, are incorporated by reference in their
entirety. In the event that
there is a plurality of definitions for terms herein, those in this section
prevail. Where reference
is made to a URL or other such identifier or address, it is understood that
such identifiers can
change and particular information on the intern& can come and go, but
equivalent information is
known and can be readily accessed, such as by searching the intern& and/or
appropriate
databases. Reference thereto evidences the availability and public
dissemination of such
information.
[0050] As used herein, the singular forms "a," "an" and "the" include plural
referents unless
the context clearly dictates otherwise. In this application, the use of the
singular includes the
plural unless specifically stated otherwise. As used herein, the use of "or"
means "and/or" unless
stated otherwise. Furthermore, use of the term "including" as well as other
forms (e.g.,
"include", "includes", and "included") is not limiting.
[0051] As used herein, ranges and amounts can be expressed as "about" a
particular value or
range. About also includes the exact amount. Hence "about 10 degrees" means
"about 10
degrees" and also "10 degrees." Generally, the term "about" can include an
amount that would
be expected to be within experimental error.
ASSAYS
[0052] The devices and methods described herein can be applied for assays for
detection of
drug susceptibility or resistance in an organism. The detection can be
detection of a signal
generated by an assay, for example, an assay to detect a nucleic acid or
quantification of a
nucleic acid associated with a resistance or susceptibility to a drug in an
organism.
[0053] An assay can comprise conducting a reaction (e.g., amplification) on a
nucleic acid
from an organism exposed to a drug and comparing the results of the reaction
(e.g., reaction
outcome, positive or negative signal generation) to a reaction conducted on a
nucleic acid
from an organism that has not been exposed to the drug. This can reveal a
susceptibility or a
resistance of the organism to the drug.
[0054] In certain embodiments, the method comprises exposing a portion of a
sample
containing a microorganism to a drug. In some embodiments, the method further
comprises
extracting nucleic acid from the micro-organism. In some embodiments, the
method comprises
11
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
performing a sequence-specific quantification of a nucleic acid from the
microorganism. The
quantification information is then used for determining or quantifying a
resistance or
susceptibility of a microorganism to a drug.
[0055] Assays can be conducted in a digital format, that is, assays can be
conducted on a
sample divided into partitions (i.e., analysis regions) such that some of the
partitions provide no
signal, while other partitions provide a signal. In some embodiments, the
partitions contain one
or zero target analytes (e.g., a target cell, a portion of a cell, or a target
molecule, such as nucleic
acid molecules or proteins). In some cases, some partitions can contain more
than one target
analyte. In some embodiments, the reaction efficiency is such that a threshold
number of target
analytes is required to achieve a positive signal. In these cases, the format
is digital if some of
the partitions contain a number of target analytes above the threshold, and
some of the partitions
contain a number of target analytes below the threshold. In some embodiments,
the threshold
can vary between partitions, such that some partitions with fewer target
analytes generate a
signal, while some partitions with more target analytes do not generate
signal. In these cases,
digital detection can still be performed based on a probabilistic threshold
applied over a plurality
of wells, as long as some partitions do not produce a signal, and some do.
[0056] In some cases, the majority of partitions contain one or zero target
analytes. This digital
or single molecule format can be used in conjunction with assays described
herein, including
identification, detection, genotyping, SNP detection, rare allele detection,
and quantification of
nucleic acids.
[0057] An assay can be conducted in less than or equal to about 600 minutes,
540 minutes, 480
minutes, 420 minutes, 360 minutes, 300 minutes, 240 minutes, 180 minutes, 120
minutes, 110
minutes, 100 minutes, 90 minutes, 80 minutes, 70 minutes, 60 minutes, 50
minutes, 40 minutes,
30 minutes, 20 minutes, 15 minutes, 10 minutes, 9 minutes, 8 minutes, 7
minutes, 6 minutes, 5
minutes, 4 minutes, 3 minutes, 2 minutes, or lminute. An assay can have an
accuracy of at least
about 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 99.99%. The
rates of
false positives can be below 10%, below 1%, below 0.1%, below 0.01%, below
0.001%, or
below 0.0001%. The rates of false negatives can be below 10%, below 1%, below
0.1%, below
0.01%, below 0.001%, or below 0.0001%.
[0058] Assays can be used for detecting copy number variations (CNVs). CNVs
are a form of
structural variation, alterations of the DNA of a genome that changes the
number of copies of
one or more sections of the DNA. CNVs can correspond to relatively large
regions of the
genome that have been deleted or duplicated on certain chromosomes. Like other
types of
genetic variation, some CNVs have been associated with susceptibility or
resistance to
12
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
disease. Gene copy number can be elevated in cancer cells. The methodology
described herein
also allows identifying genetic changes at chromosome level.
[0059] Antibiotic susceptibility testing method through measuring DNA
replication (e.g.
detecting CNV) is applicable to evaluation of response to antibiotics, and
other agents impairing
cell growth and genomic DNA replication in all the unicellular and
multicellular organisms,
including eukaryotes. The measurement of "relative chromosomal DNA replication
rate" is a
useful measurable parameter to distinguish between susceptible cells growing
in the presence
versus absence of a drug (e.g., an antibiotic) and resistant cells growing in
the presence versus
absence of a drug. In some embodiments, differences in these markers can be
observed using the
devices and methods disclosed herein within a time period that is shorter than
the average time
of division of a cell, enabling the detection of cellular replication in that
cell earlier than methods
of detection that are dependent on cell-division. Therefore, methods and
devices described herein
enable one to rapidly distinguish between cells that are drug resistant and
drug susceptible. The
methods and devices provided herein can also be applied to any drug-screening,
including
screening of human cells (such as e.g. in the monitoring of a tumor biopsy in
response to
treatment).
[0060] In one embodiment, copy number of rDNA within cells is measured after
cells are
incubated for short periods of time, with and without the presence of
antibiotics, and the
difference in the magnitude of this change is used to determine drug
resistance and susceptibility
of the cells. In some embodiments, the change in rDNA copy is determined using
a nucleic acid
amplification technique (such as for example qPCR or digital PCR or digital
isothermal
amplification), and the results used to determine resistance or susceptibility
to the drug. In some
embodiments, the method for determining drug susceptibility uses digital
quantification. In some
embodiments average DNA fragments copies originated from individual cells, are
digitally
quantified to measure proximal to origin/distant to origin selected gene
rates.
[0061] In some embodiments, drug susceptibility testing is based on RNA, such
as by
comparing transcription levels. In some embodiments, drug susceptibility
testing is based on
RNA, such as by comparing transcription levels using digital quantification.
In some
embodiments, quantification strategies (such as e.g. NASBA, qRT-PCR,
sequencing,
nanostring, among others) can be appropriate. In some embodiments RNA from
cells obtained
from samples is quantified in a digital format. In some embodiments gene
target expression
levels in each individual cell are quantified through single cell measurements
on a device, such
as the devices described herein.
13
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
[0062] An assay can be used for quantitative detection of nucleic acids, such
as recA mRNA.
For example, a method can be used comprising the steps of taking a sample from
the patient,
accessing RNA in the sample or extracting RNA from the sample, using at least
one RT- LAMP
primer to reverse transcribe and amplify the mRNA in a qualitative and/or in a
quantitative
format, and testing for amplification to confirm presence of nucleic acids
including but not
limited to recA mRNA.
[0063] In some embodiments, relative RNA and/or DNA amplification is used. In
some
embodiments, relative RNA and/or DNA quantification is used. In some
embodiments digital
detection is used for RNA and/or DNA quantification. In some embodiments,
multiple reliable
RNA and / or DNA targets will be used simultaneously in multiplex format In
some
embodiments, RNA targets and/or their genes involved in the same physiological
process or
antibiotic response mechanism can be used.
[0064] In some embodiments, this invention could be applied to drug resistance
testing of
tumor cells. In some embodiments, this invention be applied to drug resistance
testing of
cancerous cells. The devices describe herein are applicable for use with a
variety of sample
types, including clinical sample types, (such as, for example, in-patient vs
out-patient, pre-treated
vs treatment-naïve), infection levels (such as, for example, negative vs
positive vs
contaminated), and sample storage/handling (such as, for example, fresh vs
borate-preserved vs
refrigerated).
[0065] In some embodiments, a slow growing microorganism's drug resistance is
possible to
assess through a combination of staining and genetic markers using the devices
and methods
described herein. In some embodiments, a combination of genetic markers of
cell growth and
genetic markers of antibiotic susceptibility can be used to determine the
genetic antibiotic
resistance of slow-growing cells.
[0066] The assays, reactions, and techniques described herein can be performed
on any
suitable platform, including but not limited to tubes, capillary tubes,
droplets, microfluidic
devices (e.g., SlipChip devices), wells, well plates, microplates,
microfluidic wells,
microfluidic droplets, emulsions, solid supports (e.g., beads or microarrays),
microchips, or
gels (e.g., 2D gels, 3D gels) and reactions inside gels including "polonies"
as in polony PCR
on surfaces and in gels.
[0067] In one embodiment, an assay to determine the resistance or
susceptibility of a cell is
performed as follows: Cells are pre-cultured (e.g. at 37 C) to a desired
density (e.g. 101
cells/mL, 102 cells/mL, 103 cells/mL, 104 cells/mL, 105 cells/mL, 106
cells/mL, 107 cells/mL, 108
cells/mL, or 109 cells/mL) in various matrices (e.g. a Bacto Brain-Heart
Infusion broth (BHI), a
14
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
mix of BHI and pooled human urine, and/or whole human urine) before being
diluted and
incubated with or without a drug. In some embodiments, incubation is performed
at a desired
temperature (e.g. 37 C) and then treated with a desired concentration of
antibiotics. Cells can be
incubated with and without antibiotics for a period of time (e.g. <10 minutes,
10 minutes, 15
minutes, 20 minutes, 30 minutes, 45 minutes, 60 minutes, or >60 minutes)
before an aliquot of
the culture or the original test sample is used for nucleic acid extraction.
Nucleic acids can be
extracted using standard methods (such as e.g. a one-step DNA extraction
buffer or a one-step
RNA extraction buffer (e.g. available from Epicentre), among others). In some
embodiments,
following extraction, nucleic acids are quantified using nucleic acid
amplification techniques,
such as e.g. quantitative PCR or digital PCR. To quantify 23S genes in
Enterobacter, the
following 23S primers specific for Enterobacter can be used:
TGCCGTAACTTCGGGAGAAGGCA; TCAAGGACCAGTGTTCAGTGTC; 428 bp product.
(See, Matsuda K, Tsuji H, Asahara T, Kado Y, Nomoto K. Sensitive Quantitative
Detection of
Commensal Bacteria by rRNA-Targeted Reverse Transcription-PCR. Applied and
Environmental Microbiology. 2007;73(1):32-39. doi:10.1128/AEM.01224-06). The
E. coli
genome contains seven distinct operons with minor sequence differences, such
as ( such as (
rrnA, rrnB, anC, rrnD. rrnE, rrnG ( aka rrnF) and rrnH. The term "rDNA," as
used herein, refers
to rRNA operons sequences. This term includes both coding sequences and non-
coding
sequences/spacers. In some embodiments, this invention takes advantage of rDNA
to provide
both most conservative sequences and variable enough sequences to design
primers targeting
specific species. A typical operon coding for rRNA (such as GenBank: J01695.2)
codes for 5S,
16S and 23S rRNA as well as tRNA, and has spacers in between these sequences.
When using
rDNA genes as replication markers, primers either for the coding parts of the
rRNA operons, or
for the spacers between them, or both, can be selected.
Samples
[0068] Disclosed herein are methods, devices and systems related to analysis
of samples. In
some embodiments, methods of the invention comprises obtaining a sample from
an organism. A
sample can be obtained from a subject (e.g., a patient or a pet) and can
include blood, feces,
urine, saliva or other bodily fluid. The sample can be obtained by the patient
or by a medical
professional. Examples of medical professionals include, but are not limited
to, physicians,
emergency medical technicians, nurses, first responders, psychologists,
medical physics
personnel, nurse practitioners, surgeons, dentists, and any other medical
professional. The
sample can be obtained from any bodily fluid, for example, amniotic fluid,
aqueous humor, bile,
lymph, breast milk, interstitial fluid, blood, blood plasma, cerumen (earwax),
Cowper's fluid
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
(pre-ejaculatory fluid), chyle, chyme, female ejaculate, menses, mucus,
saliva, urine, vomit,
tears, vaginal lubrication, sweat, serum, semen, sebum, pus, pleural fluid,
cerebrospinal fluid,
synovial fluid, intracellular fluid, and vitreous humour. In an example, the
sample is obtained by
a blood draw, where the medical professional draws blood from a subject, such
as by a syringe.
[0069] Samples can be collected in a sample collection container. In some
embodiments the
sample collection container is coded with information that can be detected.
For example a
detector can recognize a barcode. The barcode can have information about where
a sample was
collected or from which individual a sample was collected. A detector can take
this information
and use it to process or transmit data generated regarding a sample. For
example a camera-
phone can take a photo of a sample collection container. The camera-phone can
recognize a
barcode on the container which identifies a patient. The camera-phone can then
link date
generated regarding the sample to the patient from which the sample was
obtained. The linked
data can then be transmitted to the patient or to the patient's physician. In
some embodiments a
single image is generated of the sample collection container and a sample
analysis unit.
[0070] Food samples can also be analyzed. Samples can be any composition
potentially
comprising a target organism. Sources of samples include, but are not limited
to, geothermal and
hydrothermal fields, acidic soils, sulfotara and boiling mud pots, pools, hot-
springs and geysers
where the enzymes are neutral to alkaline, marine actinomycetes, metazoan,
endo and
ectosymbionts, tropical soil, temperate soil, arid soil, compost piles, manure
piles, marine
sediments, freshwater sediments, water concentrates, hypersaline and super-
cooled sea ice, arctic
tundra, Sargasso sea, open ocean pelagic, marine snow, microbial mats (such as
whale falls,
springs and hydrothermal vents), insect and nematode gut microbial
communities, plant
endophytes, epiphytic water samples, industrial sites and ex situ enrichments.
Additionally, a
sample can be isolated from eukaryotes, prokaryotes, myxobacteria
(epothilone), air, water,
sediment, soil or rock, a plant sample, a food sample, a gut sample, a
salivary sample, a blood
sample, a sweat sample, a urine sample, a spinal fluid sample, a tissue
sample, a vaginal swab, a
stool sample, an amniotic fluid sample, a fingerprint, aerosols, including
aerosols produced by
coughing, skin samples, tissues, including tissue from biopsies, and/or a
buccal mouthwash
sample. Other sample types include samples for clinical testing (such as, for
example, in-patient
vs out-patient, pre-treated vs treatment-naIve), infection level testing (such
as, for example,
negative vs positive vs contaminated), and storage / handling testing (such
as, for example, fresh
vs borate-preserved vs refrigerated).
16
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
[0071] Samples can comprise organisms. Samples can comprise microorganisms.
The number
of microorganisms in a sample can be less than 10, less than 100, less than
1,000, less than 104,
less than 105, or less than 106. In some embodiments, the sample is a
processed sample (e.g.,
concentrated, filtered, etc.).
[0072] Samples can comprise target analytes from the organisms. Target
analytes can
comprise, for example, cells, portions of cells, polypeptides, or nucleic
acids. Nucleic acids can
be cell-free nucleic acids. Nucleic acids can be isolated from cells. Nucleic
acids can be single or
double stranded. Target analytes can comprise DNA or RNA. In some cases, the
RNA is tRNA,
mRNA, rRNA, trRNA, snRNA, snoRNA, smY, scaRNA, gRNA, RNase P, RNase MRP, aRNA,
crRNA, incRNA, miRNA, piRNA, siRNA, tasi RNA, rasiRNA, 7SK, vRNA or any
combination
thereof The DNA can be ssDNA, dsDNA, cDNA, or any combination thereof. In some
cases,
the DNA comprises a gene or a gene fragment. The gene or gene fragment can
comprise a
mutation. The mutation can comprise point mutations, insertions, deletions,
amplifications,
translocations, inversions, copy number variations, and/or other mutations. In
some cases, the
DNA comprises a non-coding region. The noncoding region can comprise
functional sequences,
regulatory elements, intrans, exons, pseudogenes, repeat sequences,
transposons, viral elements,
telomeres, genetic switches, transcription factor sites, operators, enhancers,
silencers, promoters,
insulators, and/or other regions. In some cases, the DNA comprises cDNA. In
some cases, the
DNA is from bacteria or viruses. In some cases, the DNA is collected from a
cell. In some
examples, the DNA is intracellular. In some cases, the DNA is extracellular.
[0073] Target analytes can comprise RNA. In some cases, the RNA comprises
mRNA. In
some cases, the RNA comprises noncoding RNA (ncRNA). The noncoding RNA can
comprise
transfer RNA (tRNA), ribosomal RNA (rRNA), transfer-messenger RNA (tmRNA),
small
nucleolar RNA (snoRNA), microRNA (miRNA), small interlering RNA (siRNA), small
nuclear
RNA (snRNA), piwi-interacting RNA (piRNA), long ncRNA (lncRNA), and/or other
types of
ncRNA. In some cases, the RNA is from bacteria or viruses. In some cases, the
RNA is collected
from a cell. In some examples, the RNA is intracellular. In some cases, the
RNA is extracellular.
[0074] The terms "nucleic acid" and "nucleic acid molecule" as used
interchangeably herein,
refer to a molecule comprised of nucleotides, i.e., ribonucleotides,
deoxyribonucleotides, or both.
The term includes monomers and polymers of ribonucleotides and
deoxyribonucleotides, with
the ribonucleotide and/or deoxyribonucleotides being connected together, in
the case of the
polymers, via 5' to 3' linkages. However, linkages can include any of the
linkages known in the
nucleic acid synthesis art including, for example, nucleic acids comprising 5'
to 2' linkages. The
nucleotides used in the nucleic acid molecule can be naturally occurring or
can be synthetically
17
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
produced analogues that are capable of forming base-pair relationships with
naturally occurring
base pairs. Examples of non-naturally occurring bases that are capable of
forming base-pairing
relationships include, but are not limited to, aza and deaza pyrimidine
analogues, aza and deaza
purine analogues, and other heterocyclic base analogues, wherein one or more
of the carbon and
nitrogen atoms of the purine and pyrimidine rings have been substituted by
heteroatoms, e.g.,
oxygen, sulfur, selenium, phosphorus, and the like. Nucleic acids can be
detected from a sample.
[0075] The term "oligonucleotide" as used herein refers to a nucleic acid
molecule comprising
multiple nucleotides. An oligonucleotide can comprise about 2 to about 300
nucleotides.
[0076] Target analytes can comprise genetic markers of cell growth and genetic
markers of
antibiotic susceptibility. Target analytes can include markers for drug
resistance or susceptibility
to tumor cells. Target analytes can include markers for oxidative stress that
can be detected
with, e.g., oxidation¨sensitive dyes to assay cell viability in response to
treatment with a drug.
In some embodiments, target analytes comprise polypeptides or proteins. In
some embodiments,
target analytes include cell membrane or cell membrane associated molecules,
wherein a change
in the cell membrane or cell membrane associated molecule is linked to the
response of an
organism to a drug.
Organisms
[0077] The term "organism" refers to any organisms or microorganism, including
bacteria,
yeast, fungi, viruses, protists (protozoan, micro-algae), archaebacteria,
plants and eukaryotes.
Eukaryotes can be a single-celled eukaryotic cell. Bacteria include gram-
positive and gram-
negative bacteria. The term "organism" refers to living matter and viruses
comprising nucleic
acid that can be detected and identified by the methods of the invention.
Organisms include, but
are not limited to, bacteria, archaea, prokaryotes, eukaryotes, viruses,
protozoa, mycoplasma,
fungi, plants and nematodes. Different organisms can be different strains,
different varieties,
different species, different genera, different families, different orders,
different classes, different
phyla, and/or different kingdoms. Organisms can be isolated from environmental
sources
including soil extracts, marine sediments, freshwater sediments, hot springs,
ice shelves,
extraterrestrial samples, crevices of rocks, clouds, attached to particulates
from aqueous
environments, and can be involved in symbiotic relationships with
multicellular organisms.
Examples of such organisms include, but are not limited to Streptomyces
species and
uncharacterized/unknown species from natural sources. Organisms can include
genetically
engineered organisms or genetically modified organisms. Organisms can include
transgenic
plants. Organisms can include genetically modified crops. Any organism can be
genetically
18
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
modified. Examples of organisms which can be genetically modified include
plantains, yams,
sorghum, sweet potatoes, soybeans, cassava, potatoes, rice, wheat, or corn.
[0078] Organisms can include bacterial pathogens such as: Aeromonas hydrophila
and other
species (spp.); Bacillus anthracis; Bacillus cereus; Botulinum neurotoxin
producing species of
Clostridium; Brucella abortus; Brucella melitensis; Brucella suis;
Burkholderia mallei (formally
Pseudomonas matte* Burkholderia pseudomallei (formerly Pseudomonas
pseudomallei);
Campylobacter jejuni; Chlamydia psittaci; Clostridium botulinum; Clostridium
botulinum;
Clostridium perfringens; Coccidioides immitis; Coccidioides posadasii; Cowdria
ruminantium
(Heartwater); Coxiella burnetii; Enterovirulent Escherichia co//group (EEC
Group) such as
Escherichia coll¨enterotoxigenic (ETEC), Escherichia coll¨enteropathogenic
(EPEC),
Escherichia coli-0157:H7 enterohemorrhagic (EHEC), and Escherichia
co/i¨enteroinvasive
(EIEC); Ehrlichia spp. such as Ehrlichia chaffeensis; Francisella tularensis;
Legionella
pneumophilia; Liberobacter africanus; Liberobacter asiaticus; Listeria
monocytogenes;
miscellaneous enterics such as Klebsiella, Enterobacter, Proteus, Citrobacter,
Aerobacter,
Providencia, and Serratia; Mycobacterium bovis; Mycobacterium tuberculosis;
Mycoplasma
capricolum; Mycoplasma mycoides ssp mycoides; Peronosclerospora
philippinensis;
Phakopsora pachyrhizi; Plesiomonas shigelloides; Ralstonia solanacearum race
3, biovar 2;
Rickettsia prowazekii; Rickettsia rickettsii; Salmonella spp.; Schlerophthora
rayssiae varzeae;
Shigella spp.; Staphylococcus aureus; Streptococcus; Synchytrium endobioticum;
Vibrio
cholerae non-01; Vibrio cholerae 01; Vibrio parahaemolyticus and other
Vibrios; Vibrio
vulnificus; Xanthomonas oryzae; Xylella fastidiosa (citrus variegated
chlorosis strain); Yersinia
enterocolitica and Yersinia pseudotuberculosis; and Yersinia pestis.
[0079] A non-limiting list of pathogens with known drug-resistance properties
that can be
detected and analyzed with the methods and devices disclosed herein include
Clostridium
difficile, carbapenem-resistant Enterobacteriaceae (CRE), drug-resistant
Neisseria gonorrhoeae,
multidrug-resistant Acinetobacter, drug-resistant Campylobacter, fluconazole-
resistant Candida
(a fungus), extended spectrum13-lactamase producing Enterobacteriaceae
(ESBLs),
vancomycin-resistant Enterococcus (VRE), multidrug-resistant Pseudomonas
aeruginosa, drug-
resistant Non-typhoidal Salmonella, drug-resistant Salmonella Typhi, drug-
resistant Shigella,
methicillin-resistant Staphylococcus aureus (MRSA), drug-resistant
Streptococcus pneumoniae,
drug-resistant M. tuberculosis, vancomycin-resistant Staphylococcus aureus
(VRSA),
erythromycin-resistant Group A Streptococcus, and clindamycin-resistant Group
B
Streptococcus.
19
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
Antimicrobial / Antibiotic Compounds
[0080] Organisms are incubated with a drug to determine a response to indicate
their resistance
or susceptibility to the drug. In some embodiments, the drug includes
compounds for the
treatment of a tumor. In some embodiments, the drug is an antibiotic compound
or an
antimicrobial compound. As used herein, the term antimicrobial is meant to
include any
substance of natural, semisynthetic or synthetic origin that is used to kill
or inhibit the growth of
a microorganism. In preferred embodiments, antimicrobials do not harm a host
of the
microorganism. As used herein, the term "antimicrobial" and the term
"antibiotic" are
interchangeable. Examples of antimicrobial or antibiotic compounds include,
but are not limited
to: Amikacin, Gentamicin, Kanamycin, Neomycin, Netilmicin, Tobramycin,
Paromomycin,
Streptomycin, Spectinomycin(Bs), Geldanamycin, Herbimycin, Rifaximin,
Loracarbef,
Ertapenem, Doripenem, Imipenem/Cilastatin, Meropenem, Cefadroxil, Cefazolin,
Cefalotin
/Cefalothin, Cefalexin, Cefaclor, Cefamandole, Cefoxitin, Cefprozil,
Cefuroxime, Cefixime ,
Cefdinir, Cefditoren, Cefoperazone , Cefotaxime, Cefpodoxime, Ceftazidime ,
Ceftibuten,
Ceftizoxime, Ceftriaxone , Cefepime, Ceftaroline fosamil, Ceftobiprole,
Teicoplanin,
Vancomycin, Telavancin, Dalbavancin, Oritavancin, Clindamycin, Lincomycin,
Daptomycin,
Azithromycin, Clarithromycin, Dirithromycin, Erythromycin, Roxithromycin,
Troleandomycin,
Telithromycin, Spiramycin, Aztreonam, Furazolidone, Nitrofurantoin(Bs),
Linezolid, Posizolid,
Radezolid, Torezolid, Amoxicillin, Ampicillin, Azlocillin, Carbenicillin,
Cloxacillin,
Dicloxacillin, Flucloxacillin, Mezlocillin, Methicillin, Nafcillin, Oxacillin,
Penicillin G,
Penicillin V, Piperacillin, Penicillin G, Temocillin, Ticarcillin,
Amoxicillin/clavulanate,
Ampicillin/sulbactam, Piperacillin/tazobactam, Ticarcillin/clavulanate,
Bacitracin, Colistin,
Polymyxin B, Ciprofloxacin, Enoxacin, Gatifloxacin, Gemifloxacin,
Levofloxacin,
Lomefloxacin, Moxifloxacin, Nalidixic acid, Norfloxacin, Ofloxacin,
Trovafloxacin,
Grepafloxacin, Sparfloxacin, Temafloxacin, Mafenide, Sulfacetamide,
Sulfadiazine, Silver
sulfadiazine, Sulfadimethoxine, Sulfamethizole, Sulfamethoxazole,
Sulfanilimide (archaic),
Sulfasalazine, Sulfisoxazole, Trimethoprim-Sulfamethoxazole (Co-trimoxazole)
(TMP-SMX),
Sulfonamidochrysoidine (archaic), Demeclocycline, Doxycycline, Minocycline,
Oxytetracycline,
Tetracycline, Clofazimine, Dapsone, Capreomycin, Cycloserine, Ethambutol(Bs),
Ethionamide,
Isoniazid, Pyrazinamide, Rifampicin (Rifampin in US), Rifabutin, Rifapentine,
Streptomycin,
Arsphenamine, Chloramphenicol(Bs), Fosfomycin, Fusidic acid, Metronidazole,
Mupirocin,
Platensimycin, Quinupristin/Dalfopristin, Thiamphenicol, Tigecycline(Bs),
Tinidazole, and
Trimethoprim(Bs).
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
[0081] Different antibiotics or antimicrobials may have different mechanisms
of action and
can affect replication propagation and replication re-initiation differently.
Some bacteriostatic
antibiotics ( such as aminoglycosides, cephalosporins, tetracyclines,
sulfonamides, and
macrolides) inhibit protein synthesis, while bactericidal antibiotics can act
on the cell wall (eg,
vancomycin and 13-lactams),or bacterial DNA (eg, fluoroquinolones). Some
antibiotics, such as
trimethoprim and sulfamethoxazole interfere with a metabolic pathways and
affect DNA
replication indirectly, and some ( nitrofurantoin) affect multiple process in
a cell, including DNA
replication.
[0082] In some embodiments, treatment conditions will be adjusted to intensify
an effect of
antibiotics on DNA replication for every antibiotics group. In some
embodiments, treatment
conditions will be adjusted to speed up observation of an effect of
antibiotics on DNA replication
for every antibiotics group. In some embodiments, the method described in this
disclosure tests
for antibiotic susceptibility though relative gene quantification.
Targets / Target Analytes
[0083] In some embodiments the methods and devices provided herein target
analytes (e.g.,
markers) indicative of growth of the microorganism in response to the presence
or absence of an
antimicrobial. In some embodiments, the change in expression and in copy
numbers of the of
genes close to OriC (such as for example competence genes) is measured. Our
methods and
devices enable rapid and sensitive quantification of total gene copy number
proximal to on for
each bacterial species of interest.
[0084] Slowly growing cells can replicate their chromosomes more slowly,
allowing the
differentiation between cells effected by the antibiotic, and those killed by
it. In addition, cells
with impaired metabolism can generate more or less of specific RNA targets.
Selection and
quantification of these targets is described herein.
[0085] In some embodiments, the target analyte of interest is DNA. In some
embodiments,
DNA regions, such as those represented in multiple copies in published
bacterial genomes, are
selected as targets (such as rDNA). In some embodiments, more than one target
(such as a DNA
fragment or gene) is selected for simultaneous quantification; these targets
can be located close
to the origin of replication and/or can involve both directions of
replication. In some
embodiments, more than one target (such as a DNA fragment or gene) is selected
for
simultaneous quantification; one or more of these targets is located close to
the origin of
replication and one or more targets is far from the origin of replication. By
measuring the ratio
of these targets at certain times (in some cases, before replication is
complete), replication can be
detected rapidly in some embodiments without the need to measure the number of
cells
21
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
independently. This becomes valuable when very few cells are present in the
sample, and or
when very few cells are analyzed, and or when the accuracy with which the
number of cells
present in each part of a split sample is limited by Poisson statistics.
[0086] In some embodiments, detecting gene duplications due to antimicrobial
treatment
would allow detection of susceptible strains. In some embodiments, targets for
a gene dosage
approach can include On or genes positioned in proximity to OriC (such as e.g.
within 50 kb,
within 100 kbõ within 150 kb, within 200 kb, and/or within 300 kb from OriC.
In some
embodiments the DNA/gene dosage in drug-susceptible cells will increase rather
than decrease.
[0087] In some embodiments, DNA targets represented in single or in multiple
copies in
published bacterial genomes are selected as targets (such as e.g. rDNA, feoB
gene, rpoB gene,
competence genes, among others). In some embodiments, more than one target
(such as a DNA
fragment or gene) is selected for simultaneous quantification; these can be
preferentially located
close to the origin of replication in both directions In some embodiments, the
target of interest is
ribosomal DNA, rDNA, sequence. Ribosomal gene sequences, while being well
conserved
among bacteria, can be used as a target for identification and/or group
identification, such as by
selecting specific probes and/or primers
[0088] In some rapidly growing bacterial species, it has been shown that
ribosomal genes (and
many genes associated with transcription and translation) tend to be
preferentially located close
to the origin of replication, suggesting the presence of evolutionary
pressure, which is shown to
be relevant to genome stability (Etienne Couturier, Eduardo P. C. Rocha.
Replication-associated
gene dosage effects shape the genomes of fast-growing bacteria but only for
transcription and
translation genes, 2006, Molecular microbiology, Volume 59, Issue 5, Pages
1506-1518 , DOI:
10.1111/j.1365-2958.2006.05046.) . These genes can be used as targets for
quantification of
replication, thus enabling the detection of organisms exposed to growth
conditions over short
time periods, such as a time period that is shorter than the cell replication
period. Using these
genes as targets for digital quantification, even incomplete DNA replication
(that happens before
cells divide) can be detected.
[0089] For example, in a subset of 11 available genome-sequenced E. coli
strains linked to
UTI infections the position of rDNA genes relative to the origin of
replication were mapped.
Figure 1 shows the relative distance of rDNA from oriC in UTI E. coli
isolates. Red dots (top
and bottom row) illustrate the genome size by showing the distance from OriC
to termination of
replication in a circular chromosome for both replichores. The rare examples
of having
ribosomal genes at different distribution belong to the genomes of bacteria
which underwent
artificial selection in laboratory conditions, such as the genome fifth from
the left on the graph,
22
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
which is not a UTI clinical isolate but E. coli from UTI patient gut selected
for nitrofurantoin
resistance (GenBank: CP007265.1). These show a trend of rDNA genes being
clustered near the
origin of replication.
[0090] Another example of rDNA clustering near the origin of replication is
shown in Figure
2, showing a circular representation of an example genome sequenced from a UTI
patient.
Ribosomal RNA coding regions of the genome are marked with red. The origin of
replication
(OriC) is marked at the top of Figure 2. rDNA is preferentially clustered near
the origin of
replication.
[0091] In some embodiments, the method disclosed herein takes advantage of the
fact that in at
least some cells of interest, there can be a specific time order of
chromosomal splitting. For
example, in E. coli, chromosome dynamics determines splitting of the certain
parts of the
chromosomes in a specific time order. In some embodiments the quantification
of gene targets
that are replicated earlier will allow higher resolution or faster
determination of resistant versus
susceptible bacteria. In addition, the origin and terminus of replication
divide the genome into
replichores, having different strands as leading strands. In some embodiments,
target genes on
the leading and lagging strands can be selectively targeted to measure their
different transcription
levels when replication is impaired versus non-impaired.
[0092] In some embodiments, quantification of DNA fragments and genes located
in
proximity to the origin of replication ( e.g., the origin itself or proximate
genes such as gln udhA
dnaB or some rDNA) is performed. In some embodiments, the difference in copy
number per
cell between antibiotic treated and non-treated cells can be detected by the
methods and devices
described herein (e.g., digital amplification).
[0093] In some embodiments, DNA targets located in proximity to the
termination site of
replication (ter) are quantified. Because they are the last parts of the
genome to replicate, these
regions tend to show lesser variation in copy number based on cell growth
state, or the presence
of antibiotics. In some embodiments, measurement of replication of DNA targets
near ter can be
used to standardize data obtained from other targets. For example, in some
embodiments, at short
drug exposure times, not sufficient to replicate the entire genome, these ter-
proximal regions can
be used as a measure of the loaded cell numbers while regions closer to on can
be used to access
DNA replication and resistance to the drug; this is useful for example when
the number of cells
loaded is low (for example, less than 100 or less than 10) and therefore
difficult to measure. In
some embodiments, variations in copy number of these regions with and/or
without treatment
with a drug are used to distinguish resistant from susceptible bacteria.
Drugs, such as
antimicrobials, that cause the replication fork to fail can further amplify
this effect. In some
23
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
embodiments, replication of a target nucleic acid sequence can be used to
determine the
resistance profile of genes in cells (such as bacteria) incubated in the
presence of a drug (such as
an antibiotic).
[0094] In some embodiments, the relative quantification of these targets with
and/or without
treatment with antibiotics will be used to determine antibiotic
susceptibility. This can enable the
very rapid differentiation between resistant and susceptible strains.
[0095] In some embodiments, such as when a cell's new replication fork starts
from origin of
replication, other older replication forks can continue replication
independently on re-initiation
event. (Fossum, S., E. Crooke, et al. (2007). "Organization of sister origins
and replisomes
during multifork DNA replication in Escherichia coil." The EMBO Journal
26(21): 4514-4522.
Mohan C. Joshi, et al, 2010, "Escherichia coli sister chromosome separation
includes an abrupt
global transition with concomitant release of late-splitting intersister
snaps", PNAS, vol. 108 no.
7,2765-2770). Thus, in some embodiments, a gene target used for drug
resistance/susceptibility
testing can be located distantly from the origin (e.g. oriC would still be
replicated fast enough for
determination of drug resistance/susceptibility).
[0096] By using targets close to the origin of replication, the relative
copies number of those
genes in total genetic material in the cells can be quantified to identify
susceptible and resistant
cells under antibiotic treatment earlier prior to completion of DNA
replication or prior to
completion of cell division. In some embodiments, the copy number of the
target genes of the
susceptible organism treated with a drug is less than the copy number of the
target genes of the
resistant organism or the non-treated organism as exposure to the drug in a
susceptible organism
decreases replication. However, some antibiotics cause certain regions of
chromosomal DNA to
increase in copy number in susceptible cells. Figure 3 illustrates the effect
of susceptible cells to
antibiotic dosing, specifically the relative DNA copy number in E. coli after
treatment with
trimethoprim as compared to the distance from the origin of replication
(oriC), shown as the line
that intersects with 0 at both ter regions. (Slager, J., M. Kjos, et al.
(2014). "Antibiotic-Induced
Replication Stress Triggers Bacterial Competence by Increasing Gene Dosage
near the Origin."
Cell 157(2): 395-406). Figure 3 shows that DNA copy number peaks close to the
origin of
replication after exposure to trimethoprim as compared to baseline level of
zero.
[0097] Many antibiotics (such as quinolones) induce a replication fork
stalling. As a direct
consequence of replication fork stalling while DNA replication initiation
continues, all
antibiotics targeting DNA replication up-regulate origin-proximal genes copy
number and induce
a global changes in transcription in bacteria. This produces a result contrary
to those antibiotics
that slow DNA replication in susceptible organisms treated with a drug,
providing an increase in
24
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
the number of positive results. Predicted results of the digital assay
described herein for
antibiotics that slow growth, and those that induce a replication fork
stalling are shown in Figure
4. In Figure 4, "Antibiotic A" represents antimicrobials that result in a
reduced replication
efficiency in susceptible cells, thus lowering the number of gene copy near
the origin of
replication compared to resistant cells. "Antibiotic B" represents
antimicrobials that result in a
replication fork stalling in a cell, resulting in an increase in initiation of
new replication near the
origin of replication, thus increasing the copy number of genes near the
origin of replication in
susceptible cells as compared to resistant cells.
[0098] "Antibiotic A," as represented in Figure 4, includes bacteriostatic
antibiotics ( such as
aminoglycosides, cephalosporins, tetracyclines, sulfonamides, and macrolides)
that inhibit
protein synthesis, and bactericidal antibiotics that act on the cell wall (eg,
vancomycin and 0-
lactams). For these antibiotics that slow DNA replication, in some
embodiments, the antibiotic
exposure is altered to induce oxidation stress in the cells, e.g., by
controlling concentrations of
Ferrous iron, pH and Magnesium ions, and ensuring aerobic conditions.
[0099] "Antibiotic B," as represented in Figure 4, includes antibiotics that
cause certain
regions of chromosomal DNA to increase in copy number in susceptible cells.
For example,
oriC-ter ratios are known to be affected by some antibiotics treatment (e.g.,
HPUra, hydroxyurea,
trimethoprim, ciprofloxacin, and MMC) in B. cereus, S. aureus, and E. coli and
S. pneumoniae.
These antibiotics are known to impair chromosome replication, as trimethoprim
affects DNA
replication indirectly. Nitrofurantoin directly impairs many cell processes
including replication.
6(p-Hydroxyphenylazo)-uracil (HPUra) is a selective inhibitor of gram-positive
bacteria DNA.
Hydroxycarbamide decreases the production of deoxyribonucleotides.
Ciprofloxacin is a
fluoroquinolone that stalls the replication fork and causes DNA fragmentation
due to its
interactions with DNA gyrase and topoisomerase. (Slager, J., M. Kjos, et al.
(2014). "Antibiotic-
Induced Replication Stress Triggers Bacterial Competence by Increasing Gene
Dosage near the
Origin." Cell 157(2): 395-406, and Tamayo M, Santiso R, Gosalvez J, Bou G,
Fernandez JL.
Rapid assessment of the effect of ciprofloxacin on chromosomal DNA from
Escherichia coli
using an in situ DNA fragmentation assay. BMC Microbiology. 2009;9:69).
[00100] The resistance or susceptibility of a call to either type of
antibiotic can be detected
using the methods and devices described herein. Furthermore, digital PCR will
provide a
different result depending upon whether or not the genes copied before the
replication fork stall
are fragmented from the chromosomal or plasmid DNA. If they are not
fragmented, they cannot
separate into distinct wells, thus providing an additional level of resolution
to characterize the
cells. The DNA fragments liberated from the nucleoid under different
antibiotics treatment are
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
estimated to be of 50 to 100 kb size (Tamayo M, Santiso R, Gosalvez J, Bou G,
Fernandez JL.
Rapid assessment of the effect of ciprofloxacin on chromosomal DNA from
Escherichia coli
using an in situ DNA fragmentation assay. BMC Microbiology. 2009;9:69) similar
to the
presumed size of the DNA loops of the nucleoid and to the prominent DNA gyrase-
mediated
cleavage sites (Snyder M, Drlica K. DNA gyrase on the bacterial chromosome:
DNA cleavage
induced by oxolinic acid. J Mol Biol. 1979;131(2):287-302, Condemine, Smith
CL.
Transcription regulates oxolinic acid-induced DNA gyrase cleavage at specific
sites on the E.
coli chromosome. Nucleic Acids Res. 1990;18(24):7389-7396, and Hsu Y-H, Chung
M-W, Li
T-K. Distribution of gyrase and topoisomerase IV on bacterial nucleoid:
implications for
nucleoid organization. Nucleic Acids Res. 2006;34(10):3128-3138.).
[00101] In some embodiments, the method disclosed herein is used to detect
genes and gene
fragments that are locally amplified in short timeframes to distinguish drug
resistant from drug
susceptible cells. In some embodiments, the method makes use of the fact that
some antibiotics
cause the preferential amplification of DNA fragments located near origin of
replication, such as
some competence genes and the origin of replication itself In some embodiments
DNA
fragments or genes located within 50-200 kb from the origin of replication in
both replichores
will be quantified in digital format from a small number of cells to determine
their drug
susceptibility. In some embodiments, the method makes use of the fact that
some antibiotics
cause accumulation of DNA fragments. This has been shown to be caused by
antibiotics that
cause the replication fork to stall. This can be analyzed through
quantification of genes inside the
accumulated region, outside the accumulated region, or a ratio between both.
[00102] In some embodiments, the change in the relative replication rates for
selected positions
on the chromosome can be detected in susceptible isolates after less than 20
minutes of exposure
to a drug. In some embodiments, the difference in in the relative replication
rates for selected
positions on the chromosome can be discernable only after a certain time
point, which can differ
for different antibiotics types, organisms, cells and/or drugs. In some
embodiments, the change
in relative replication rates for selected positions on the bacterial
chromosome can be detected in
susceptible isolates after less than 5, 10, 15, 20, 25, 30, 45, 60, 90, 120,
150, or 180 minutes of
exposure to a drug.
[00103] In some embodiments shift up protocol (for example one that adds
nutrients and
signaling molecules to stimulate growth and gene expression and DNA
replication), can be used
to ensure some control over the time of re-initiation of replication.
[00104] In some embodiments, changes in gene expression are used as markers of
antimicrobial
susceptibility or resistance in an organism. In some embodiments, drug
susceptibility testing is
26
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
based on RNA, such as by comparing transcription levels. In some embodiments,
drug
susceptibility testing is based on RNA, such as by comparing transcription
levels using digital
quantification. In some embodiments, markers associated with a resistance or
susceptibility in
response to an antimicrobial can be measured.
[00105] in some embodiments, genes differently regulated in response to a drug
or antibiotic can
be used. The genes can include for example, the recA and LexA (Barczak, et aL,
2012,
Proceedings of the National Academy of Sciences, 6217- 6222) genes induced by
Ox-..õ,R and
SoxS in response to antibiotic-induced oxidative stress (Dwyer, et al., 2014,
Proceedings of the
National Academy of Sciences, E2100-E2109).
[00106] In susceptible bacteria, many RNA targets have been shown to be either
upregulated or
downregulated in response to drug exposure over a short time. Many such genes
also show
significant changes in expression level as a response to variations in culture
conditions and from
isolate to isolate. Some genes expression (e.g., recA, involved in the SOS
response) are up-
regulated in several species in response to multiple antibiotics, whereas
other transcriptional
changes are organism and/or mechanism specific.
[00107] Changes in RNA targets RNA levels ( through qPCR, micro arrays, RNAseq
) can be
difficult to detect using existing methods after a short time of drug /
antibiotic treatment in bulk
(such as by routine reverse transcription and isothermal or PCR amplification)
due to the
presence of non-specific nucleic acids from the host's cells or from other
microorganisms, as
well as due to the presence of inhibitors from the clinical sample, and due to
the short time of
treatment. In some embodiments, binary, digital and multivolume digital
formats can be used to
isolate targets in volumes where local concentration is high, enabling the
fast and reliable
quantification even in such samples.
[00108] In some embodiments, DNA targets with a higher copy number present in
cells will be
used to enable the detection of resistance profiles even in very low numbers
of cells (such as in
blood or cerebral spinal fluid). For example, while in genome of most of the
E. coli strains and
isolates there are ¨7 copies of rDNA, due to the presence of at least two, but
potentially
numerous replication forks, one could expect to have , in some cases, from 12
to 35 rDNA
copies per cell, depending on its growth rate (E. coli and Salmonella,
cellular and molecular
biology. Frederic C. Neidhardt, editor in Chief. v2. ASM press, Washington DC.
1996). In some
embodiments, using genes with higher copy number in the cell will enable the
increased
statistical resolution of quantification to determine antibiotic resistance
when very low numbers
of cells are present. In some embodiments, this is quantification is performed
by amplification.
In some embodiments, this quantification makes use of digital amplification
methods.
27
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
[00109] In some embodiments, additional targets are evaluated from publically
available studies
such as those published by the Broad Institute. In some embodiments, targets
for analysis are
generated from analysis of DNA/RNA-seq data. In some embodiments,
quantification strategies
(such as e.g. NASBA, qRT-PCR, sequencing, nanostring, among others) can be
used. In some
embodiments RNA from cells obtained from samples in a digital format is
quantified. In some
embodiments gene target expression levels in each individual cell is
quantified through single
cell measurements.
[00110] An exemplary list of RNA targets that can be used for multiplexed
and/or individual
use for evaluating a cells' response to a drug (e.g., ciprofloxacin) are
provided in Table 1
Table 1
Gene Response to Ciprofloxacin
EcHS A0999 dmsA anaerobic dimethyl sulfoxide reductase Same or Downregulated
,_A _subunit
EcHS A1247_pepT_peptidase T Same or Downregulated
EcHS A1333 narK nitrite extrusion_protein 1 Same or Downregulated
EcHS A1334 narG nitrate reductase, alpha subunit Same or Downregulated
EcHS A1335 narH nitrate reductase, beta subunit Same or Downregulated
EcHS A1557 fdnG formate dehydrogenase, nitrate inducibl Same or Downregulated
e, alpha subunit, selenocysteine-containing
EcHS A1755 - hypothetical_protein Same or Downregulated
EcHS A1987 flhC transcriptional activator FlhC Same or Downregulated
EcHS A1988 flhD transcriptional activator FlhD Same or Downregulated
EcHS A2346 napF ferredoxin-type_protein Same or Downregulated
EcHS A2342 napH quinol dehydrogenase membrane comp Significantly
onent Downregulated
EcHS A2343 napG quinol dehydrogenase_periplasmic com Significantly
ponent Downregulated
EcHS A2380 glpT sn-glycerol-3-phosphate transporter Significantly
Downregulated
EcHS A2381 - hypothetical_protein Significantly
Downregulated
EcHS A2382 glpA sn-glycerol-3- Significantly
phosphate dehydrogenase subunit A Downregulated
28
CA 02966575 2017-05-01
WO 2016/085632
PCT/US2015/059344
EcHS A2597 aegAl oxidoreductase Fe-S binding subunit Significantly
Downregulated
EcHS A3117 ansB L-asparaginase II Significantly
Downregulated
EcHS A3561 nirB nitrite reductase [NAD(P)FI], large subu Significantly
nit Downregulated
EcHS A3562 nirD nitrite reductase small subunit Significantly
Downregulated
EcHS A3605 feoA ferrous iron transport_protein A Significantly
Downregulated
EcHS A3606 feoB ferrous iron transport_protein B Significantly
Downregulated
EcHS A3607 - hypothetical_protein Significantly
Downregulated
EcHS A3616 malT transcriptional regulator MalT Significantly
Downregulated
EcHS A4395 frdD fumarate reductase subunit D Significantly
Downregulated
EcHS A1940 - DNA damage-inducible_protein YebG Significantly Upregulated
EcHS A2835 recA recombinase _A Significantly Upregulated
EcHS A4283 lexA LexA repressor Significantly Upregulated
EcHS A4284 dinF DNA-damage- Significantly Upregulated
inducible SOS response_protein
EcHS A4300 uvrA excinuclease ABC subunit A Significantly Upregulated
EcHS A2341 napB citrate reductase cytochrome c- Requires Evaluation
type subunit
EcHS A2344 napA nitrate reductase catalytic subunit Requires Evaluation
EcHS A3610 gntX gluconate_periplasmic binding_protein Requires Evaluation
EcHS A3612 - hypothetical_protein Requires Evaluation
EcHS A3821 secB_preprotein translocase subunit SecB Requires Evaluation
EcHS A4404 rsgA ribosome-associated GTPase Requires Evaluation
EcHS A4424 - 23S rRNA (guanosine-2'-0+ Requires Evaluation
methyltransferase
29
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
23S rRNA Requires Evaluation
EcHS A3544 - hypothetical_protein Requires Evaluation
EcHS A0467_phoB transcriptional regulator PhoB Requires Evaluation
EcHS A0468_phoR_phosphate regulon sensor_protein Requires Evaluation
EcHS A1067 sulA SOS cell division inhibitor Requires Evaluation
EcHS A3855 DNA-damage-inducible protein D DinD Requires Evaluation
EcHS A2357 two-component response regulator RscB Requires Evaluation
EcHS A1184 dinI DNA damage-inducible_protein I Requires Evaluation
EcHS A4417 FtsH_protease regulator HflC Requires Evaluation
[00111] In some embodiments of the devices, reactive species can be used to
detect an oxidative
stress in every single cell. Because non-viable cells cannot maintain a
reducing environment in
the cytoplasm, oxidation-sensitive dyes make up the majority of viability
assays.
[00112] In some embodiments the devices and methods disclosed herein can be
used to detect
an increase in expression of genes up- regulated by OxyR and SoxR
transcription factors as an
evidence of antibiotic-induced oxidative stress response. These genes examples
are such as for
example sodA (encoding Mn- cofactored superoxide dismutase) and acrAB
(encoding a
multidrug efflux pump), soxS ( secondary transcription factor), and KatG and
Ahp genes, OxyS,
RecA.
[00113] In some embodiments RNA targets and/or their genes involved in Fe ions
transport
and regulation are selected. In some embodiments, RNA targets and/or their
genes involved in
oxidation stress response are selected.
[00114] FeoB is a ferrous iron uptake system belonging to the Ferrous Iron
Uptake (FeoB)
transporter family (Kammler M, Schon C, Hantke K. Characterization of the
ferrous iron uptake
system of Escherichia coll. Journal of Bacteriology. 1993;175(19):6212-6219).
FeoB is one of
the numerous genes which transcription is reported to be down-regulated in
response to
ciprofloxacin treatment in RNAseq analysis of E. coli isolates total RNA
expression. (Shishkin,
A. A., G. Giannoukos, et al. (2015). "Simultaneous generation of many RNA-seq
libraries in a
single reaction." Nat Meth 12(4): 323-325). FeoB transcription is known to be
under repression
by Fur. In some embodiments, targets are selected out of those genes activated
or repressed by
Fur.
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
[00115] FeoB expression is also activated by RstAB two component system. In
some
embodiments, targets will be selected out of those genes activated or
repressed by the RastAB
two component system.
[00116] In some embodiments, the pH and Mg2+ concentrations of medium used to
expose
cells to antibiotic will be increased or decreased in conjunction with methods
described herein to
enhance the cellular response to antibiotics. In some embodiments bacterial
cells are treated in
relatively low Mg 2+, low pH ( mild acidic conditions), and different selected
controlled levels
of Fe, to increase amplitude of changes in FeoB expression in response to
antibiotics.
[00117] In some embodiments, the methods described herein comprise the steps
of 1) pre-
incubating cells in low Mg and low Fe (2+) and low pH (mild acidic
conditions), and 2) adding
antibiotic together with high Fe(2+). In some embodiments, the method
comprises 1) pre-
incubating cells low Mg and high Fe (2+) and low pH (mild acidic conditions),
and 2) adding
antibiotic.
[00118] In some embodiments, tuning of dissolved oxygen, PH, Fe2+, silver ions
concentrations, Mg2+ concentrations, and other salts concentrations is
performed to optimize
conditions for the fastest/most reliable AST through measuring FeoB expression
levels. These
variations can be combined with the gene expression targets mentioned in this
document. This
will enable the higher resolution determination of antibiotic susceptibility
by quantification of
these targets. In some embodiments air/oxygen is provided to the bacteria
incubated in a
presence of antibiotics. In some embodiments, oxidative stress is enhanced in
the bacteria via
addition of peroxides.
[00119] In some embodiments, the target analyte can comprises an individual
target or a group
of targets, e.g. RNA from a group of genes coding for the proteins with the
similar function
(such as group of genes mentioned above and linked to iron metabolism)
responding to pH, Mg2 '
and oxidative stress. In some embodiments, the target analyte will comprise
RNA from a group
of genes relevant to oxidative stress (oxidation stress).
[00120] In some embodiments the recA gene and/or recA RNA are quantified to
determine
antibiotic susceptibility. In some embodiments, other genes in the SOS
response are used as
targets for quantification to determine antibiotic susceptibility. In some
embodiments FeoB RNA
and/or recA RNA are quantified to determine antibiotic susceptibility. In some
embodiments
FeoB RNA and recA RNA are quantified, detecting their ratio to determine
antibiotic
susceptibility and resistance. In some embodiments other genes up regulated
and down regulated
in response to antibiotics are quantified together and their ratio is detected
to determine antibiotic
susceptibility or resistance in a microorganism.
31
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
[00121] In some embodiments, the devices use a combination of precursor rRNA
and ribosomal
RNA markers for detecting resistant and susceptible cells or microorganisms
with real-time RT-
PCR on single cells. In some embodiments, the devices can integrate a
combination of
markers for universal drug-susceptibility and/or specific drug-resistance
detection.
SAMPLE PROCESSING
[00122] In some embodiments, the microorganism is exposed to a drug to assay
its response to
the drug and determine whether the microorganism is resistant or susceptible
to the drug. In
some embodiments, isolates can be pre-cultured in or pre-exposed to a variety
of matrices (such
as for example bacterial culture media or human urine, among others), and can
be subsequently
incubated in the presence or absence of various drugs (e.g. antibiotics, such
as ciprofloxacin,
nitrofurantoin, trimethoprim, tetracycline, and sulfamethoxazole, and others.)
where exposure to
multiple drugs and / or multiple additives is performed on the same device
substantially
simultaneously. In some embodiments, microorganisms do not substantially
divide during
exposure to a drug. In some embodiments, microorganisms confined as single
cells, or being in
the small group and / or aggregate of cells, respond to a drug faster than an
average population.
[00123] Devices and methods described herein can include those when some of
the
microorganisms confined as single cells, or as a small group and / or
aggregate of cells, such as
for example fewer than 3 cells, fewer than 10 cells, fewer than 30 cells,
fewer than 100 cells in
the same compartment. The volume of the compartment can be in the range of 100
fL to 1 nL, 1
nL to 100 nL, or 100 nL to 500 nL.
[00124] In some embodiments, digital assays can use the confinement of single
cells from a
sample into clonal isolation regions. In some embodiments, each of the
isolated cells are
cultured in the clonal isolation regions to generate a plurality of clonal
populations from the
sample. In some embodiments, the isolated cells are treated with a drug before
or after
expansion. In some embodiments, after culture and expansion from an isolated
cell, the clonal
population is divided into two or more treatment regions. As such, at least
one portion of the
clonal population can be treated with a drug, while another portion of the
clonal population is not
treated with a drug. Then, the assays described herein can be performed to
determine whether
the cells in the clonal population are susceptible or resistant to one or more
drugs.
[00125] In some embodiments, specific culturing conditions are used to speed
up a
microorganism's response to a drug (e.g. quorum sensing molecules, gas partial
pressures,
temperature, etc). In some embodiments, the microorganism is exposed gases or
gas mixtures,
e.g., containing H2S, CO, and NO. Such gases are known, for example, to affect
susceptibility of
32
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
microorganisms to antibiotics. Such gases can be diluted with a gas mixture
which could be
anaerobic, aerobic, or microoxic. Such gas mixture can contain CO2.
[00126] In some embodiments, co-culturing of the microorganism with eukaryotic
cell and/or
other microorganism is used to speed up a microorganism's response to a drug.
[00127] In some embodiments, measures to control the average number and/or
location and/or
time of initiation of replication in culture are performed. For example, cells
can be placed into
high- or low-nutrient conditions prior to exposure to antibiotics. In some
embodiments, the
acclimatization of cells to changes in growing conditions (such as, for
example, mixing infected
blood with nutrient rich media) will cause variation in the rate of DNA
replication. In some
embodiments, this effect can be mitigated by the modification of growth media.
In some
embodiments, data analyses can allow the capture of changes in replication
rates over this noise.
In some embodiments, the effects of media on replication can be used to
enhance the effect of a
drug treatment.
[00128] In some embodiments, cells are exposed to antibiotics as follows:
Cells are pre-cultured
at 37 C to a density of up to 109 cells/mL in various matrices including Bacto
Brain-Heart
Infusion broth (BHI), a mix of BHI and pooled human urine, and whole human
urine before
being diluted and incubated with or without antibiotics. The antibiotics used
for treatment
include ciprofloxacin, nitrofurantoin, trimethoprim, tetracycline, and
sulfamethoxazole.
Incubations were performed at 37 C at starting concentrations ranging from
105 - 108 cells/mL,
and then treated with concentrations of antibiotics ranging from 0.75 ug/mL -
156 ug/mL
depending on the treatment. Cells were incubated with and without antibiotics
for a period of
time including 10 minutes, 15 minutes, 20 minutes, 30 minutes, 45 minutes, or
60 minutes before
an aliquot of the culture was used for nucleic acid extraction.
[00129] In some embodiments, the microorganism is exposed to a drug for a time
less than 4
hours, less than 3 hours, less than 2 hours, less than 1 hour, less than 30
minutes, less than 15
minutes, less than 10 minutes, less than 5 minutes, less than 3 minutes, or
less than 1 minute.
[00130] The nucleic acids can be extracted before analysis. The exact protocol
used to extract
nucleic acids depends on the sample and the exact assay to be performed.
Extracting nucleic
acids from target bacteria usually involves a cell lysis step followed by
nucleic acid purification.
The cell lysis step disrupts the cell and nuclear membranes, releasing the
genetic material. This is
often accomplished using a lysis detergent, such as sodium dodecyl sulfate,
which also denatures
the large amount of proteins present in the cells.
[00131] The nucleic acids can then be purified with an alcohol precipitation
step, usually ice-
cold ethanol or isopropanol, or via a solid phase purification step, typically
on a silica matrix in a
33
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
column, resin or on paramagnetic beads in the presence of high concentrations
of a chaotropic
salt, prior to washing and then elution in a low ionic strength buffer. An
optional step prior to
nucleic acid precipitation is the addition of a protease which digests the
proteins in order to
further purify the sample.
[00132] In some embodiments, nucleic acids are extracted using standard
methods including a
one-step DNA extraction buffer or a one-step RNA extraction buffer (available
from Epicentre).
Following extraction, nucleic acids were quantified using nucleic acid
amplification techniques
including quantitative PCR and digital PCR.
[00133] In some embodiments, the microorganisms of the sample are lysed. In
some
embodiments, inhibitors are removed from the sample. In some embodiments,
inhibitors in the
sample are inactivated. In some embodiments, the sample is exposed to
conditions or reagents
for preventing degradation of the nucleic acid. In some embodiments, the
sample undergoes
ribosomal RNA depletion. IN some embodiments, unwanted RNA is removed from the
sample.
IN some embodiments, microorganisms in the sample are treated with a reagent
that binds to and
prevents amplification of free nucleic acids, such as PMA and EMA. In some
embodiments, the
sample is irradiated to initiate photochemical reaction to prevent the
amplification of unwanted
nucleic acids. In some embodiments, extracted nucleic acids are further
purified prior to
quantification.
[00134] In some embodiments sample preparation before the quantification
reaction takes less
than two hours, less than one hour, less than 30 minutes, less than 15
minutes, less than 10
minutes, less than 5 minutes, less than 3 minutes , less than 1 minute, or
less than 30 seconds
[00135] In some embodiments techniques such as denaturation, restriction
digestion,
fragmentation, digestion of replicated DNA fragments are used before digital
quantification. This
enables enhanced isolation of individual genes into individual volumes for
detection and
amplification. In some embodiments, a restriction digest in between genes is
used to facilitate
isolation into individual volumes of DNA molecules carrying target genes. For
example, in some
embodiments, using as the target rDNA in E. coli with 7 copies per genome, a
digital experiment
can only show one positive volume per large genome fragment. When the genome
is denatured,
fragmented, and/or digested, each gene could be isolated into individual
volumes, giving 24 to
70 template-positive volumes for analyses in a device from a single genome.
[00136] In some embodiments agents inhibiting amplification of nucleic acids
from dead cells
will be used (e.g., propidium monoazide (PMA) or ethidium monoazide). In some
embodiments,
cells will be treated with such agents inhibiting amplification of nucleic
acids from dead cells
34
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
prior to incubation with antibiotics. In some embodiments, cells will be
treated with such agents
inhibiting amplification of nucleic acids from dead cells after incubation
with antibiotics.
[00137] In some embodiments, a restriction digest of chromosomal DNA is done
prior to
quantification, such as to separate fragments of DNA containing multiple
replicated copies of the
target gene while preserving the fragments of interest to be suitable for
detection and
quantification.
[00138] In some embodiments, one or more denaturation steps are done, such as
to duplicate the
number of positive templates ( for example if in a given sample E. coli cells
could have from 12
to 35 copies of rDNA genes under certain conditions (depending on a growth
rate, individual
ages and individual states) ¨ and yield for example 24-70 fragments after
denaturation; this can
in some cases improve visualization in digital approaches.)
[00139] In some embodiments, denaturation or digestion can be used to separate
DNA at
replication forks¨pieces of newly replicated DNA can partition into different
wells¨such as to
increase the resolution between inhibited cells and actively replicating
cells.
[00140] In some embodiments, digital assays can use the confinement of a few
or single target
nucleic acid molecules into individual reaction volumes. Prior to the
completion of replication,
denaturing agents (such as e.g. heat, urea, Guanidinium Chloride, acids,
bases, mechanical strain,
enzymes, restriction enzymes, among others) can be used to enhance the
separation of target
DNA strands into independent volumes. This can be of particular use for
example in cases
where multiple target regions are present within a single genome.
[00141] In some embodiments, denaturation of a whole chromosomal DNA is
performed before
performing digital quantification.
Amplification
[00142] In some embodiments, a nucleic acid amplification reaction is
performed to amplify the
target analyte (e.g., a target nucleic acid). Amplification reaction can
include polymerase chain
reaction (PCR), nucleic acid sequence based amplification (NASBA), self-
sustained sequence
replication (3 SR), loop mediated isothermal amplification (LAMP), strand
displacement
amplification (SDA), whole genome amplification, multiple displacement
amplification, strand
displacement amplification, helicase dependent amplification, nicking enzyme
amplification
reaction, recombinant polymerase amplification, reverse transcription PCR or
ligation mediated
PCR. Amplification or detection methods for nucleic acids can include but are
not limited to
PCR, RT-PCR, or other methods including isothermal amplification methods.
Isothermal nucleic
acid amplification methods can include but are not limited to strand
displacement amplification
(SDA), transcription mediated amplification, nucleic acid sequence based
amplification
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
(NASBA), recombinase polymerase amplification (RPA), rolling circle
amplification,
ramification amplification, helicase-dependent isothermal DNA amplification,
loop mediated
isothermal amplification (LAMP), methods based on both signal amplification
and target
amplification such as branched-DNA-based detection methodologies,
hybridization chain
reaction, or nucleic acid- based logic gates and DNA circuits (see, e.g., Qian
and Winfree,
Scaling Up Digital Circuit Computation with DNA Strand Displacement Cascades,
Science
2011; 6034: 1196-1201).
[00143] The amplification reaction assay can be PCR. PCR is well known in this
field and
comprehensive description of this type of reaction is provided in E. van Pelt-
Verkuil et al.,
Principles and Technical Aspects of PCR Amplification, Springer, 2008.
[00144] PCR is a powerful technique that amplifies a target DNA sequence
against a
background of complex DNA. If RNA is to be amplified (by PCR), it must be
first transcribed
into cDNA (complementary DNA) using an enzyme called reverse transcriptase.
Afterwards, the
resulting cDNA is amplified by PCR.
[00145] PCR is an exponential process that proceeds as long as the conditions
for sustaining the
reaction are acceptable. The components of the reaction are:
1. pair of primers¨short single strands of DNA with around 10-30 nucleotides
complementary
to the regions flanking the target sequence
2. DNA polymerase¨a thermostable enzyme that synthesizes DNA
3. deoxyribonucleoside triphosphates (dNTPs)¨provide the nucleotides that are
incorporated
into the newly synthesized DNA strand
4. buffer¨to provide the optimal chemical environment for DNA synthesis.
[00146] In embodiments using PCR, the components of the reaction can be in
contact with
sample. The components of the reaction can be added to a container that holds
the sample. The
components of the reaction can be present in a container, and the sample can
be added. In some
embodiments, a kit can comprise a plurality of small containers, at least one
container holding
the components of a PCR reaction. A kit can comprise a SlipChip and the
components of the
reaction.
[00147] PCR typically involves placing these reactants in a small tube (10-50
microlitres)
containing the extracted nucleic acids. The tube is placed in a thermal
cycler; an instrument that
subjects the reaction to a series of different temperatures for varying
amounts of time. The
standard protocol for each thermal cycle involves a denaturation phase, an
annealing phase, and
an extension phase. The extension phase is sometimes referred to as the primer
extension phase.
In addition to such three-step protocols, two-step thermal protocols can be
employed, in which
36
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
the annealing and extension phases are combined. The denaturation phase
typically involves
raising the temperature of the reaction to 90-95 C. to denature the DNA
strands; in the
annealing phase, the temperature is lowered to -50-60 C. for the primers to
anneal; and then in
the extension phase the temperature is raised to the optimal DNA polymerase
activity
temperature of 60-72 C. for primer extension. This process is repeated
cyclically around 20-40
times, the end result being the creation of millions of copies of the target
sequence between the
primers.
[00148] The amplification reaction assay can be a variant of PCR. The
amplification reaction
assay can be selected from the group of variants to the standard PCR protocol
such as multiplex
PCR, linker-primed PCR, direct PCR, tandem PCR, real-time PCR and reverse-
transcriptase
PCR, amongst others, which have been developed for molecular diagnostics.
[00149] The amplification reaction assay can be multiplex PCR. Multiplex PCR
uses multiple
primer sets within a single PCR mixture to produce amplicons of varying sizes
that are specific
to different DNA sequences. By targeting multiple genes at once, additional
information can be
gained from a single test-run that otherwise would require several
experiments.
[00150] In some embodiments, a multiplexed PCR reaction is performed where a
plurality of
primer sets are added to a reaction mixture and each amplify their specified
target within the
same volume, for example. In other embodiments a sample is split into a
plurality of smaller
volumes into which single primer sets are introduced.
[00151] The amplification reaction assay can be linker-primed PCR, also known
as ligation
adaptor PCR. Linker-primed PCR is a method used to enable nucleic acid
amplification of
essentially all DNA sequences in a complex DNA mixture without the need for
target-specific
primers. The method firstly involves digesting the target DNA population with
a suitable
restriction endonuclease (enzyme). Double-stranded oligonucleotide linkers
(also called
adaptors) with a suitable overhanging end are then ligated to the ends of
target DNA fragments
using a ligase enzyme. Nucleic acid amplification is subsequently performed
using
oligonucleotide primers which are specific for the linker sequences. In this
way, all fragments of
the DNA source which are flanked by linker oligonucleotides can be amplified.
[00152] The amplification reaction assay can be direct PCR. Direct PCR
describes a system
whereby PCR is performed directly on a sample without any, or with minimal,
nucleic acid
extraction. With appropriate chemistry and sample concentration it is possible
to perform PCR
with minimal DNA purification, or direct PCR. Adjustments to the PCR chemistry
for direct
PCR include increased buffer strength, the use of polymerases which have high
activity and
processivity, and additives which chelate with potential polymerase
inhibitors.
37
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
[00153] The amplification reaction assay can be tandem PCR. Tandem PCR
utilizes two distinct
rounds of nucleic acid amplification to increase the probability that the
correct amplicon is
amplified. One form of tandem PCR is nested PCR in which two pairs of PCR
primers are used
to amplify a single locus in separate rounds of nucleic acid amplification.
The amplification
reaction assay can be nested PCR. The first pair of primers hybridize to the
nucleic acid
sequence at regions external to the target nucleic acid sequence. The second
pair of primers
(nested primers) used in the second round of amplification bind within the
first PCR product and
produce a second PCR product containing the target nucleic acid, that can be
shorter than the
first one. The logic behind this strategy is that if the wrong locus were
amplified by mistake
during the first round of nucleic acid amplification, the probability is very
low that it would also
be amplified a second time by a second pair of primers and thus increases
specificity.
[00154] The amplification reaction assay can be real-time PCR. The
amplification reaction
assay can be quantitative PCR. Real-time PCR, or quantitative PCR, is used to
measure the
quantity of a PCR product in real time. By using a fluorophore-containing
probe or fluorescent
dyes along with a set of standards in the reaction, it is possible to quantify
the starting amount of
nucleic acid in the sample. This is particularly useful in molecular
diagnostics where treatment
options can differ depending on the pathogen load in the sample.
[00155] The amplification reaction assay can be reverse-transcriptase PCR (RT-
PCR). Reverse-
transcriptase PCR (RT-PCR) is used to amplify DNA from RNA. Reverse
transcriptase is an
enzyme that reverse transcribes RNA into complementary DNA (cDNA), which is
then
amplified by PCR. RT-PCR can be used in expression profiling, to determine the
expression of a
gene or to identify the sequence of an RNA transcript, including transcription
start and
termination sites. It can be used to amplify RNA viruses such as human
immunodeficiency virus
or hepatitis C virus.
[00156] The amplification reaction assay can be isothermal. Isothermal
amplification is a form
of nucleic acid amplification which does not rely on the thermal denaturation
of the target
nucleic acid during the amplification reaction and hence may not require
multiple rapid changes
in temperature. Isothermal nucleic acid amplification methods can therefore be
carried out inside
or outside of a laboratory environment. A number of isothermal nucleic acid
amplification
methods have been developed, including but not limited to Strand Displacement
Amplification
(SDA), Transcription Mediated Amplification (TMA), Nucleic Acid Sequence Based
Amplification (NASBA), Recombinase Polymerase Amplification (RPA), Rolling
Circle
Amplification (RCA), Ramification Amplification (RAM), Helicase-Dependent
Isothermal
DNA Amplification (HDA), Circular Helicase-Dependent Amplification (cHDA),
Loop-
38
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
Mediated Isothermal Amplification (LAMP), Single Primer Isothermal
Amplification (SPIA),
Signal Mediated Amplification of RNA Technology (SMART), Self-Sustained
Sequence
Replication (35R), Genome Exponential Amplification Reaction (GEAR) and
Isothermal
Multiple Displacement Amplification (IMDA). Further examples of such
amplification
chemistries are described in, for example, ("Isothermal nucleic acid
amplification technologies
for point-of-care diagnostics: a critical review, Pascal Craw and Wamadeva
Balachandrana Lab
Chip, 2012, 12, 2469-2486, DOI: 10.1039/C2LC40100B,") incorporated here in its
entirety by
reference. Isothermal amplification methods that operate at temperatures lower
than PCR
operating temperatures can be used, e.g., to improve compatibility of
restriction enzymes with
the amplification process if the restriction enzyme is not sufficiently stable
under typical PCR
operating temperatures.
[00157] Furthermore, detection methods based on both signal amplification and
target
amplification, such as branched-DNA-based detection methodologies, can be used
in this
approach. For example, for branched-DNA-based detection methodologies, using
an enzyme
that can cleave the target in a position located between two positions used
for binding of the
capture extender and the label extender (e.g., as described in Tsongalis,
Branched DNA
Technology in Molecular Diagnostics, Am J Clin Pathol 2006; 126: 448-453), can
reduce the
signal obtained in the assay when a restriction enzyme recognizes and cleaves
the target.
[00158] The amplification reaction assay can be Strand Displacement
Amplification (SDA).
Strand Displacement Amplification (SDA) can rely on the ability of certain
restriction enzymes
to nick the unmodified strand of hemi-modified DNA and the ability of a 5'-3'
exonuclease-
deficient polymerase to extend and displace the downstream strand. Exponential
nucleic acid
amplification can then achieved by coupling sense and antisense reactions in
which strand
displacement from the sense reaction serves as a template for the antisense
reaction. The use of
nickase enzymes which do not cut DNA in the traditional manner but produce a
nick on one of
the DNA strands, such as N. Alwl, N. BstNB1 and Mlyl, for example, can be used
in this
reaction. SDA has been improved by the use of a combination of a heat-stable
restriction enzyme
(Aval) and heat-stable Exo-polymerase (Bst polymerase). This combination has
been shown to
increase amplification efficiency of the reaction from 108 fold amplification
to 1010 fold
amplification so that it is possible using this technique to amplify unique
single copy molecules.
[00159] The amplification reaction assay can be Transcription Mediated
Amplification (TMA).
The amplification reaction assay can be Nucleic Acid Sequence Based
Amplification (NASBA).
Transcription Mediated Amplification (TMA) and Nucleic Acid Sequence Based
Amplification
(NASBA) can use an RNA polymerase to copy RNA sequences but not corresponding
genomic
39
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
DNA. The technology can use two primers and two or three enzymes, RNA
polymerase, reverse
transcriptase and optionally RNase H (if the reverse transcriptase does not
have RNase activity).
One primer can contain a promoter sequence for RNA polymerase. In the first
step of nucleic
acid amplification, this primer hybridizes to the target ribosomal RNA (rRNA)
at a defined site.
Reverse transcriptase can create a DNA copy of the target rRNA by extension
from the 3' end of
the promoter primer. The RNA in the resulting RNA:DNA duplex can be degraded
by the RNase
activity of the reverse transcriptase if present or the additional RNase H.
Next, a second primer
binds to the DNA copy. A new strand of DNA is synthesized from the end of this
primer by
reverse transcriptase, creating a double-stranded DNA molecule. RNA polymerase
recognizes
the promoter sequence in the DNA template and initiates transcription. Each of
the newly
synthesized RNA amplicons re-enters the process and serves as a template for a
new round of
replication.
[00160] The amplification reaction assay can be Recombinase Polymerase
Amplification
(RPA). In Recombinase Polymerase Amplification (RPA), the isothermal
amplification of
specific DNA fragments is achieved by the binding of opposing oligonucleotide
primers to
template DNA and their extension by a DNA polymerase. Heat is not always
required to
denature the double-stranded DNA (dsDNA) template. Instead, RPA can employ
recombinase-
primer complexes to scan dsDNA and facilitate strand exchange at cognate
sites. The resulting
structures are stabilized by single-stranded DNA binding proteins interacting
with the displaced
template strand, thus preventing the ejection of the primer by branch
migration. Recombinase
disassembly leaves the 3' end of the oligonucleotide accessible to a strand
displacing DNA
polymerase, such as the large fragment of Bacillus subtilis Poll (Bsu), and
primer extension
ensues. Exponential nucleic acid amplification is accomplished by the cyclic
repetition of this
process.
[00161] The amplification reaction assay can be Helicase-dependent
amplification (HDA).
Helicase-dependent amplification (HDA) mimics the in vivo system in that it
uses a DNA
helicase enzyme to generate single-stranded templates for primer hybridization
and subsequent
primer extension by a DNA polymerase. In the first step of the HDA reaction,
the helicase
enzyme traverses along the target DNA, disrupting the hydrogen bonds linking
the two strands
which are then bound by single-stranded binding proteins. Exposure of the
single-stranded target
region by the helicase allows primers to anneal. The DNA polymerase then
extends the 3' ends
of each primer using free deoxyribonucleoside triphosphates (dNTPs) to produce
two DNA
replicates. The two replicated dsDNA strands independently enter the next
cycle of HDA,
resulting in exponential nucleic acid amplification of the target sequence.
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
[00162] The amplification reaction assay can be Rolling Circle Amplification
(RCA). Other
DNA-based isothermal techniques include Rolling Circle Amplification (RCA) in
which a DNA
polymerase extends a primer continuously around a circular DNA template,
generating a long
DNA product that consists of many repeated copies of the circle. By the end of
the reaction, the
polymerase generates many thousands of copies of the circular template, with
the chain of copies
tethered to the original target DNA. This allows for spatial resolution of
target and rapid nucleic
acid amplification of the signal. Up to 1012 copies of template can be
generated in 1 hour.
Ramification amplification is a variation of RCA and utilizes a closed
circular probe (C-probe)
or padlock probe and a DNA polymerase with a high processivity to
exponentially amplify the
C-probe under isothermal conditions.
[00163] The amplification reaction assay can be Loop-mediated isothermal
amplification
(LAMP). LAMP offers high selectivity and employs a DNA polymerase and a set of
four
specially designed primers that recognize a total of six distinct sequences on
the target DNA. An
inner primer containing sequences of the sense and antisense strands of the
target DNA initiates
LAMP. The following strand displacement DNA synthesis primed by an outer
primer releases a
single-stranded DNA. This serves as template for DNA synthesis primed by the
second inner and
outer primers that hybridize to the other end of the target, which produces a
stem-loop DNA
structure. In subsequent LAMP cycling one inner primer hybridizes to the loop
on the product
and initiates displacement DNA synthesis, yielding the original stem-loop DNA
and a new stem-
loop DNA with a stem twice as long. The cycling reaction continues with
accumulation of many
copies of target in less than an hour. The final products are stem-loop DNAs
with several
inverted repeats of the target and cauliflower-like structures with multiple
loops formed by
annealing between alternately inverted repeats of the target in the same
strand.
[00164] In some embodiments, the amplification is a one-step digital reverse-
transcription loop-
mediated isothermal amplification (dRT-LAMP) reaction for quantifying mRNA
with all
reactions performed. LAMP produces a bright fluorescence signal through
replacement of
manganese with magnesium in calcein. In some embodiments, this fluorescence
can then be
detected and counted using a commercial cell phone camera.
[00165] Nucleic acid-based logic gates and DNA circuits can be used for
nucleic acid
amplification. The use of restriction enzymes with nucleic acid-based logic
gates and DNA
circuits can reduce or stop the intrinsic leakage problem for DNA networks.
Combining the
molecular recognition ability of both restriction enzymes and DNA networks,
restriction enzyme
logic gates can be highly active components for the design and construction of
biocomputational
41
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
devices (see e.g., Qian and Winfree, Scaling Up Digital Circuit Computation
with DNA Strand
Displacement Cascades, Science 2011; 6034: 1196-1201).
[00166] In some embodiments the amplification employed can take place in a
variety of
different mediums, such as for example, aqueous solution, polymeric matrix,
solid support, etc
Detection
[00167] Assay results can comprise a readout or detection mechanism chosen
from a range of
readouts used to detect progress or results of reactions, including but not
limited to optical
techniques, electrical techniques or magnetic techniques. Examples include but
are not limited
to electrochemical readouts, optical readouts, including for example
fluorescence readouts,
colorimetric readouts, chemiluminescence, electrical signals, quenching, probe
binding, probe
hybridization, metal labeling, contrast agent labeling, absorbance, mass
spectrometry,
sequencing, lateral flow strips, and the generation of a heterogeneous
substance (e.g.,
precipitation, gas bubble).
[00168] A readout mechanism can comprise fluorescence. For example fluorescent
dye can be
used to label nucleic acids; reactions with more nucleic acid product can
yield more fluorescence
signal. Fluorescent dyes can include but are not limited to ethidium bromide,
berberine,
proflavine, daunomycin, doxorubicin, thalidomide, YOYO-1, SYBR Green I, SYBR
Green II,
oxazole yellow (YO), thiazole orange (TO), PicoGreen (PG), TOTO, TO-PRO,
SYTOX, SYTO,
other cyanine dyes, and calcein. The fluorescence intensity can be measured at
an end-point or in
real-time, allowing measurement of the reaction progress. For example, a given
level of
fluorescence can be set as the threshold for a positive signal from a digital
or quasi-digital
compartment.
[00169] In some cases, signal can be generated from molecules with reporter
moieties and
affinity moieties that are applied to digital units to bind to captured target
analyte. The reporter
molecule or reporter moiety can be fluorescent. The digital units or capture
regions can be
washed to remove unbound reporter. In some cases, the reporter molecule can be
calcein or
calcein with cetyl trimethyl ammonium bromide (calcein-CTAB). In some cases,
the reporter can
be an intercalating dye. Target analytes can be labeled with enzymes which can
produce an
electrical signal, for example by electro-activating a substrate molecule
which can be oxidized
and reduced. Labeling can occur by binding with an affinity agent, for example
as in a sandwich
assay. Labeling can occur by intercalating dyes.
[00170] A readout mechanism can comprise mass spectrometry. For example,
nucleic acids of
different sizes (e.g. from restriction digestion or ligation) can be
distinguished and/or counted by
mass spectrometry. Alternatively, a readout mechanism can operate without mass
spectrometry.
42
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
[00171] A readout mechanism can comprise electrophoresis, including gel
electrophoresis. For
example, nucleic acids of different sizes (e.g. from restriction digestion or
ligation) can be
identified or distinguished by electrophoresis. Alternatively, a readout
mechanism can operate
without electrophoresis.
[00172] A readout mechanism can comprise sequencing. Sequencing, or sequence
determination techniques, can be performed by methods including but not
limited to Sanger
sequencing, Illumina (Solexa) sequencing, pyrosequencing, next generation
sequencing,
Maxam-Gilbert sequencing, chain termination methods, shotgun sequencing, or
bridge PCR;
next generation sequencing methodologies can comprise massively parallel
signature
sequencing, polony sequencing, SOLiD sequencing, Ion Torrent semiconductor
sequencing,
DNA nanoball sequencing, Heliscope single molecule sequencing, single molecule
real time
(SMRT) sequencing, nanopore DNA sequencing, tunneling currents DNA sequencing,
sequencing by hybridization, sequencing with mass spectrometry, microfluidic
Sanger
sequencing, microscopy- based techniques, RNA polymerase sequencing or in
vitro virus high-
throughput sequencing.
[00173] The signal can be electromagnetic. The signal can comprise the
presence or absence of
a physical object, such as a bead. Captured target analytes can be labeled
with a fluorescent
agent or a contrast agent. Target analytes can be labeled with enzymes which
can produce a
fluorescent signal. Target analytes can be labeled with enzymes which can
produce a color
change in a substrate, producing a colorimetric signal. In some cases, signal
can be generated
from reporter molecules that are bound to affinity molecules and applied to
digital units to bind
to captured target analyte.
[00174] Sequencing reads can be used to identify reaction products, and the
number of
sequencing reads generated for a given nucleic acid product can be used to
evaluate the reaction.
For example, a given number of sequencing reads can be set as the threshold
for a positive signal
from a digital or quasi-digital compartment. Alternatively, a readout
mechanism can operate
without sequencing.
[00175] Multiplexed signal detection ensure that in multiplexed signal
detection there is the
ability to distinguish the amplification of many signals within the same
volume as well as the
ability to distinguish different signals from different volumes.
Binary Quantification / Digital Amplification
[00176] In some embodiments, the methods and assays described herein use
digital and binary
quantification methods; digital methods enable quantification of targets in
samples containing
low concentrations of cells (such as for example, when a sample (e.g. blood)
has low
43
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
concentrations of a pathogen (e.g. 1 bacterial cell per mL or 10 cells / mL)
in a range that is still
clinically relevant or even represent a life threatening illness). In some
embodiments, the digital
methods described herein can be used to ensure reliable quantification
resolution between
susceptible and resistant cells.
[00177] The process of binary quantification begins with a sample that can
contain a target
analyte. The target analyte can be a molecule to be quantified or searched
for, for instance a
particular nucleic acid, a particular nucleic acid sequence, a gene, or a
protein, for example. The
sample can be partitioned into many separate reaction volumes. In some
embodiments, the
reaction volumes are separate analysis regions. In some embodiments, the
separate reaction
volumes are physically separated in separate wells, chambers, areas on the
surface of a slide,
droplets, beads, or aliquots, for example. In some embodiments, the separate
reaction volumes
can be in the same container, for instance, the target analyte can be affixed
to a substrate or
attached to a bead. The reaction volumes can be on beads, on the surface of a
slide, or attached to
a substrate. The sample is distributed to many separate reaction volumes such
that some, but not
all of the reaction volumes generate a positive signal.
[00178] The sample is distributed to many separate reaction volumes such that
each individual
reaction volume contains a number of target analytes either below or above the
threshold value
for generating a positive signal. Generation of a positive signal from a
reaction volume can
depend on the number or concentration of target analytes captured, trapped, or
bound by that
reaction volume. In some cases, a threshold number of target analytes
captured, trapped, or
bound by a reaction volume allows a positive signal to be generated from that
reaction volume.
The threshold number of target analytes to allow positive signal generation
can be at least about
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,
23, 24, 25, 26, 27, 28, 29,
30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48,
49, 50 or more target
analytes. The threshold number of target analytes to allow positive signal
generation can be at
most about 1,2, 3,4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,
20, 21, 22, 23, 24, 25, 26,
27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45,
46, 47, 48, 49, or 50
target analytes. In some cases, the threshold number of target analytes to
allow positive signal
generation can be from 1 to 19 target analytes. In some cases, the threshold
number of target
analytes to allow positive signal generation can be from 2 to 19 target
analytes. In some cases,
the threshold number of target analytes to allow positive signal generation
can be from 3 to 19
target analytes. In some cases, the threshold number of target analytes to
allow positive signal
generation can be from 4 to 19 target analytes. In some cases, the threshold
number of target
analytes to allow positive signal generation can be from 5 to 19 target
analytes. In some cases,
44
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
the threshold number of target analytes to allow positive signal generation
can be from 6 to 19
target analytes. In some cases, the threshold number of target analytes to
allow positive signal
generation can be from 7 to 19 target analytes. In some cases, the threshold
number of target
analytes to allow positive signal generation can be from 8 to 19 target
analytes. In some cases,
the threshold number of target analytes to allow positive signal generation
can be from 9 to 19
target analytes. In some cases, the threshold number of target analytes to
allow positive signal
generation can be from 10 to 19 target analytes. In some cases, a threshold
concentration of
analytes captured, trapped, or bound by a reaction volume allows a positive
signal to be
generated from that reaction volume. The threshold concentration of target
analytes to allow
positive signal generation can be at least about zero zeptomolar (zM), 1 zM,
10 zM, 100 zM, 1
attomolar (aM), 10 aM, 100 aM, 1 femtomolar (fM), 10 fM, 100 fM, 1 pM, 10 pM,
100 pM, 1
nM, 10 nM, 100 nM, 1 M, 10 M, 100 M, 1 mM, 10 mM, 100 mM, 1 M, or more. The
threshold concentration of target analytes to allow positive signal generation
can be at most
about 1, fM, 10 fM, 100 fM, 1 pM, 10 pM, 100 pM, 1 nM, 10 nM, 100 nM, 1 M, 10
M, 100
M, 1 mM, 10 mM, 100 mM, 1 M, or less. The threshold number or concentration of
target
analytes to allow positive signal generation from a reaction volume can be
controlled. Inhibitors
can be used with reaction volumes to control the threshold number or
concentration. For
example, the number or concentration of target analytes can be required to be
higher than the
number or concentration of inhibitors in a reaction volume in order for a
signal to be produced
from that reaction volume.
[00179] In some cases, the probability of a positive signal being generated
from a reaction
volume depends on the number or concentration of target analytes captured,
trapped, or bound
by that reaction volume. The probability of a positive signal being generated
from a reaction
volume can be controlled. For example, the efficiency of a signal generating
reaction can be
controlled, thereby controlling the probability of signal generation; a lower
efficiency reaction
can result in a lower probability of signal generation for a given number or
concentration of
target analytes.
[00180] In some embodiments, the sample is distributed to many separate
reaction volumes
such that each individual reaction volume contains either zero individual
occurrences of the
target analyte, or one or more individual occurrences of the target analyte.
One or more
molecules can mean a non-zero number of molecules. One or more molecules can
mean one
molecule. In some embodiments, one or more molecules can mean one molecule,
two molecules,
three molecules, four molecules... etc. In some embodiments, each separate
reaction volume is
contained in a well. In some embodiments, the sample is distributed such that
each reaction
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
volume, on average comprises less than one individual molecule of the target
analyte. In some
embodiments, the sample is distributed such that most reaction volumes
comprise either zero or
one molecules of the target analyte. Next, a qualitative "yes or no" test can
be done to
determine whether or not each reaction volume contains one or more target
analytes by reading
the pattern of discrete positive and negative reaction volumes. A positive
reaction volume can be
a reaction volume determined to contain one or more target analytes. A
positive reaction volume
can be a reaction volume determined to have a signal that correlates to the
presence of one or
more target analytes. A positive reaction volume can be a reaction volume
determined to have a
signal above a threshold that correlates to the presence of one or more target
analyte. In some
embodiments, a positive reaction volume is quantified as 1, or a simple
multiple of 1 such as 2,
3, etc. while a negative reaction volume is quantified as 0, or less than a
threshold. In some
embodiments, a positive reaction volume is quantified as 1 and a negative
reaction volume is
quantified as 0. A negative reaction volume can be a reaction volume
determined to contain zero
target analyte. A negative reaction volume can be a reaction volume that does
not have a signal
that correlates to the presence of one or more target analyte. A negative
reaction volume can be
a reaction volume that does not have a signal above the threshold that
correlates to the presence
of one or more target analyte. The determination and/or designation of each
reaction volume as a
positive or a negative reaction volume can be referred to as a binary assay or
a digital assay. This
"yes or no test" or test like this can be referred to as a binary assay. This
qualitative analysis of
which reaction volume are negative reaction volume and which reaction volume
are positive
reaction volume can then be translated into a quantitative concentration of
target analyte in the
sample using Poisson analysis. A high dynamic range can be achieved through
using many
reaction volumes. A high dynamic range can be achieved by using a device that
has reaction
volume of different sizes. A high dynamic range can be achieved by
partitioning the sample into
many wells and/or into wells of different sizes.
[00181] This overall process can be called binary quantification of nucleic
acids. This process
can be called counting numbers of target analyte. In some embodiments, binary
quantification is
the process of partitioning a sample into a plurality of reaction volume such
that each reaction
volume contains either zero or a non-zero number of target analyte;
determining and/or
designating which reaction volume are positive reaction volume and which
reaction volume are
negative reaction volume with respect to the target analyte; and translating
the information about
positive and negative reaction volume into information about the quantity or
concentration of the
target analyte in the sample. In some embodiments, the absolute number of
target analyte is
determined. In some embodiments, the translation of the information about
which reaction
46
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
volume are positive reaction volume and which reaction volume are negative
reaction volume to
information about the amount, absolute number of molecules, or concentration
of the target
analyte in the sample is called digital quantification of the target analyte.
In some embodiments,
the target analyte is a nucleic acid. In some embodiments, the binary
quantification of nucleic
acids is achieved. In some embodiments, binary quantification of a nucleic
acid target analyte is
determined wherein the sample is partitioned into several reaction volumes,
wherein the reaction
volumes are on a SlipChip.
[00182] In some embodiments, a binary quantification of target analyte in a
sample can be
achieved without spatially separating the sample into multiple reaction
volumes. In these
embodiments, the target analyte can be counted by informational separation. In
some
embodiments, target analyte in the sample undergo a binary quantification
through a process
wherein the target analyte are tagged with a pool of information-carrying
molecules, amplified or
copied, and the number of distinct information-carrying molecules that were
amplified or copied
is counted in to get a quantification of the starting number of target analyte
(see e.g. WO
2012148477). In some embodiments, the information-carrying molecule can be a
pool of
chemical barcodes. In some embodiments, the information-carrying molecule can
be a set of
nucleic acid sequences.
[00183] Digital analyses can be achieved using the polymerase chain reaction
(PCR),
recombinant polymerase amplification (RPA), and loop mediated amplification
(LAMP) as a
way of quantifying RNA or DNA concentrations. Amplifications such as RPA and
LAMP,
which can use isothermal chemistries, can be well suited for home and limited-
resource setting
use. LAMP chemistry in particular is an attractive candidate for use in a home
or limited-
resource setting platform as it can have a relatively broad temperature
tolerance range, can work
with simple and cheap chemical-based heaters and phase-change materials, and
can have a
fluorescence gain with positive wells.
Robustness
[00184] Robustness can be the degree to which a series of repeated
quantitative measurements
provides a set of similar measurements under varying experimental conditions.
For example a
cell phone camera can be used to successfully perform similar measurements on
a SlipChip
under a variety of conditions found in the real world. Similar measurements
can be identical
measurements. Similar measurements can be the same diagnosis. Similar
measurements can be
the same answer. Similar measurements can mean more than one measurement
within
experimental error of each other. Similar measurements can yield a consistent
outcome with
statistical significance. Similar measurements can be of similar numerical
size, for instance
47
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
within 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%,
1,000% of each other. Robust assays can produce similar measurements more
often than 25%,
30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%,
99.99%, for example, of instances measured under a given set of conditions.
[00185] Different types of assays can be robust assays. A nucleic acid
amplification and
quantification assay can be robust. An assay to detect a protein or other
target such as a cell,
exosome, liposome, bacteria, virus, etc. can be robust. A LAMP assay can be
robust. A RT-
LAMP assay can be robust. A dRT-LAMP assay can be robust. A binary LAMP
reaction can be
robust. A binary, two-step LAMP reaction can be robust. A PCR reaction can be
robust. A qPCR
assay can be robust. A quantitative nucleic acid amplification reaction can be
robust. A
qualitative nucleic acid amplification reaction can be robust. A method to
diagnosis a health
outcome based on the amplification of a nucleic acid sequence can be robust. A
process within a
SlipChip can be robust. The imaging and analysis of a SlipChip after a LAMP
reaction can be a
robust process.
[00186] The absolute efficiency of dRT-LAMP can be increased over 10-fold,
e.g. from -2 %
to -28 %, by i) using a more efficient reverse transcriptase, ii) introducing
RNase H to break up
the DNA-RNA hybrid, and iii) adding only the BIP primer during the RT step.
dRT-LAMP can
be compatable with a plastic SlipChip device and used this two-step method to
quantify HIV
RNA. The dRT-LAMP quantification results were in some cases very sensitive to
the sequence
of the patient's HIV RNA.
[00187] Assays can be robust with respect to experimental variables. An assay
can be robust
with respect to a given temperature range. An assay can be robust of over a
temperature range.
Some non-limiting ranges, over which an assay can be robust include 1 C, 2
C, 3 C, 4 C, 5 C,
6 C, 7 C, 8 C, 9 C, 10 C, 11 C, 12 C, 16 C, 20 C, 24 C, 28 C, 32 C, 40
C, 50 C, 60
C,80 C, 100 C, 150 C ,200 C, 250 C, or 300 C, for example. The
temperature range of
which an assay is robust can be centered on temperature on an absolute
temperature scale. Some
non-limiting temperatures that could be the center of the temperature range
that an assay is
robust to include -40 C,-30 C,-20 C, -10 C, 0 C, 10 C, 20 C, room
temperature, 25 C, 30
C, 35 C, body temperature, 37 C,40 C, 45 C, 50 C, 55 C, 60 C, 65 C, 70 C, 80
C, 90
C,100 C, 110 C, 150 C, or 200 C, for example. In some embodiments, a
binary LAMP assay
is used to amplify and subsequently image and quantify a nucleic acid sequence
in a sample. In
these embodiments, the assay can be a robust quantification of a nucleic acid
sequence with over
a temperature range of 9 C centered at about 60 C. A binary LAMP assay used
to amplify and
subsequently image and quantify a nucleic acid sequence in a sample can be
robust over the
48
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
temperature range from about 55 C to about 66 C. In some embodiments, a
SlipChip can be
imaged and the data can be processed to give robust findings over a range of a
temperature from
about 5 C to about 70 C.
[00188] An assay can be robust with respect to time. An assay can give
consistent results over a
range of time points. An assay can require only end-point readout. A binary
DNA amplification
experiment can require only end-point readout. The endpoint read out can be
obtained near the
completion of amplification, or at a time after this time point. A robust DNA
amplification assay
can give consistent results at a time point near the end of the reaction
and/or at a timepoint after
the reaction is complete. A non-limiting range of reaction time that an assay
could be robust over
includes 0.01 min, 0.1 min, 0.5 min, 1 min, 2 min, 3 min, 4 min, 5 min, 6 min,
7 min, 8 min, 9
min, 10 min, 12 min, 14 min, 16 min, 20 min, 24 min, 28 min, 32 min, 40 min,
45 min, 50 min,
1.0 hour, 2 hour, 3 hour, 4 hour, 5 hour, 6 hour, 8 hour, 10 hour, 12 hour, 16
hour, 18 hour, 1
day, 2 day, 3 day, 7 days, 1 month, or 1 year, for example. In some cases,
binary DNA
amplification experiments do not require exact knowledge of time. The output
of a binary DNA
amplification can be robust to variation in reaction time beyond the optimal
reaction time. In
some embodiments, a d-LAMP assay on a SlipChip is robust over a 20 minute time
period
between 40 minutes and 60 minutes after the LAMP reaction begins, for example.
[00189] An assay can be robust with respect to variations in atmospheric
humidity. In some
embodiments, an assay can be robust regardless of the atmospheric humidity. In
some
embodiments, an assay can be robust over a range of atmospheric humidity. The
range of
humidity can be from about 0% to 100% relative humidity. The range of
atmospheric humidity
at which an assay can be robust can be from about 0 to about 40 grams water
per cubic meter of
air at about 30 C. In some embodiments, an assay can be robust from about 0%
humidity to
about 40%, 50%, 60%, 70%, 80%, 90%, or 100% humidity, for example. In some
embodiments,
an assay can be robust over a humidity range of about 40%, 50%, 60%, 70%, 80%,
90%, or
100% humidity. In some embodiments, a d-LAMP assay run in a SlipChip can be
imaged and
analyzed as a robust assay over a range of humidity from about 0% to about
100% atmospheric
humidity.
[00190] In some embodiments, the assay provides a quantitative analytical
measurement. For
instance, the invention can measure and display the amount and/or the
concentration of a nucleic
acid sequence within a sample as a quantitative amount. This measurement can
be robust with
respect to the experimental conditions present during the chemical
amplification of the nucleic
acid sequence, during the measurement of the optical data, and/or during the
processing of the
data, for instance.
49
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
[00191] In some embodiments, small differences in the concentration of a
target can be resolved
with greater statistical significance by quantifying the response of two or
more genes to
antibiotic treatment. For example, in a scenario in which two genes experience
a 1.2-fold change
in concentration when comparing samples treated with a drug versus samples
that are untreated.
If quantification yields this 1.2-fold difference with a p-value of around
0.10, then the difference
will not be statistically significant when analyzed independently. However,
using Fisher's
method to combine the results from several independent tests that have the
same overall null
hypothesis (that the treated and untreated bacterial nucleic acids are the
same) will result in a
lower p-value than each individual test. The test statistic used to combine
the p-values from
separate tests is x2 and the formula is
k
I
7
-'` --i. 11g)
. %
Xlk = 7t
[00192] For example, if two independent tests with p-values of 0.10 each are
combined using
this method, the overall p-value will now be 0.05, which is significant at the
95% confidence
level. In some embodiments, digital NA (nucleic acid) quantification is more
amenable to POC
diagnostics
[00193] In some embodiments, a ratio of the RNA from multiple genes is used to
determine
drug susceptibility. In some embodiments, this approach can include the use of
housekeeping
genes to measure relative changes in gene expression. In some embodiments,
this includes the
use of a ratio between genes upregulated and genes downregulated in response
to drug treatment.
In some embodiments, ratios of genes are used to enable higher sensitivity of
quantification of
responses when few cells are present in the sample, in some embodiments as few
as 1 cells.
Analysis
[00194] It is to be understood that the exemplary methods and systems
described herein can be
implemented in various forms of hardware, software, firmware, special purpose
processors, or a
combination thereof. These instructions and programs can be executed by and/or
stored on non-
transitory computer readable media. Methods herein can be implemented in
software as an
application program tangibly embodied on one or more program storage devices.
The application
program can be executed by any machine, device, or platform comprising
suitable architecture. It
is to be further understood that, because some of the systems and methods
described herein are
implemented in software, the actual connections between the system components
(or the process
steps) can differ depending upon the manner in which the present invention is
programmed.
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
[00195] The number or concentration of target analytes in a sample can be
calculated based on
the signal generated from the reaction volumes. The number, location, type, or
a combination
thereof of positive reaction volumes can be used to calculate the number or
concentration of
target analytes in a sample. The number, location, type, or a combination
thereof of positive
capture regions can be used to calculate the number or concentration of target
analytes in a
sample.
[00196] Assay results can be determined by comparison of results to
theoretical models. For
example, Poisson statistical analysis can be applied to quantify the number of
fluorescent and
non-fluorescent regions. Combining the results from wells of different volumes
fully minimizes
the standard error and provides high-quality analysis across a very large
dynamic range.
[00197] The computer components, software modules, functions, data stores and
data structures
described herein can be connected directly or indirectly to each other in
order to allow the flow
of data needed for their operations. It is also noted that the meaning of the
term module includes
but is not limited to a unit of code that performs a software operation, and
can be implemented
for example as a subroutine unit of code, or as a software function unit of
code, or as an object
(as in an object-oriented paradigm), or as an applet, or in a computer script
language, or as
another type of computer code. The software components and/or functionality
can be located on
a single computer or distributed across multiple computers depending upon the
situation at hand.
In yet another aspect, a computer readable medium is provided including
computer readable
instructions, wherein the computer readable instructions instruct a processor
to execute the
methods described herein. The instructions can operate in a software runtime
environment. In
yet another aspect, a data signal is provided that can be transmitted using a
network, wherein the
data signal includes data calculated in a step of the methods described
herein. The data signal can
further include packetized data that is transmitted through wired or wireless
networks. In an
aspect, a computer readable medium comprises computer readable instructions,
wherein the
instructions when executed carry out a calculation of the probability of a
medical condition in a
patient based upon data obtained from the sample. The computer readable
instructions can
operate in a software runtime environment of the processor. In some
embodiments, a software
runtime environment provides commonly used functions and facilities required
by the software
package. Examples of a software runtime environment include, but are not
limited to, computer
operating systems, virtual machines or distributed operating systems although
several other
examples of runtime environment exist. The computer readable instructions can
be packaged
and marketed as a software product, app, or part of a software package. For
example, the
instructions can be packaged with an assay kit.
51
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
[00198] The computer readable medium can be a storage unit. Computer readable
medium can
also be any available media that can be accessed by a server, a processor, or
a computer. The
computer readable medium can be incorporated as part of the computer-based
system, and can be
employed for a computer-based assessment of a medical condition.
[00199] In some embodiment, the calculations described herein can be carried
out on a
computer system. The computer system can comprise any or all of the following:
a processor, a
storage unit, software, firmware, a network communication device, a display, a
data input, and a
data output. A computer system can be a server. A server can be a central
server that
communicates over a network to a plurality of input devices and/or a plurality
of output devices.
A server can comprise at least one storage unit, such as a hard drive or any
other device for
storing information to be accessed by a processor or external device, wherein
the storage unit can
comprise one or more databases. In an embodiment, a database can store
hundreds to millions of
data points corresponding to a data from hundreds to millions of samples. A
storage unit can also
store historical data read from an external database or as input by a user. In
an embodiment, a
storage unit stores data received from an input device that is communicating
or has
communicated with the server. A storage unit can comprise a plurality of
databases. In an
embodiment, each of a plurality of databases corresponds to each of a
plurality of samples. An
individual database can also comprise information for a plurality of possible
sample containment
units. Further, a computer system can comprise multiple servers. A processor
can access data
from a storage unit or from an input device to perform a calculation of an
output from the data. A
processor can execute software or computer readable instructions as provided
by a user, or
provided by the computer system or server. The processor can have a means for
receiving patient
data directly from an input device, a means of storing the subject data in a
storage unit, and a
means for processing data. The processor can also include a means for
receiving instructions
from a user or a user interface. The processor can have memory, such as random
access memory.
In one embodiment, an output that is in communication with the processor is
provided. After
performing a calculation, a processor can provide the output, such as from a
calculation, back to,
for example, the input device or storage unit, to another storage unit of the
same or different
computer system, or to an output device. Output from the processor can be
displayed by data
display. A data display can be a display screen (for example, a monitor or a
screen on a digital
device), a print-out, a data signal (for example, a packet), an alarm (for
example, a flashing light
or a sound), a graphical user interface (for example, a webpage), or a
combination of any of the
above. In an embodiment, an output is transmitted over a network (for example,
a wireless
network) to an output device. The output device can be used by a user to
receive the output from
52
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
the data-processing computer system. After an output has been received by a
user, the user can
determine a course of action, or can carry out a course of action, such as a
medical treatment
when the user is medical personnel. In some embodiments, an output device is
the same device
as the input device. Example output devices include, but are not limited to, a
telephone, a
wireless telephone, a mobile phone, a PDA, a flash memory drive, a light
source, a sound
generator, a computer, a computer monitor, a printer, and a webpage. The user
station can be in
communication with a printer or a display monitor to output the information
processed by the
server.
[00200] A client-server, relational database architecture can be used in
embodiments of the
invention. A client server architecture is a network architecture in which
each computer or
process on the network is either a client or a server. Server computers are
typically powerful
computers dedicated to managing disk drives (file servers), printers (print
servers), or network
traffic (network servers). Client computers include PCs (personal computers),
cell phones, or
workstations on which users run applications, as well as example output
devices as disclosed
herein. Client computers rely on server computers for resources, such as
files, devices, and even
processing power. In some embodiments of the invention, the server computer
handles all of the
database functionality. The client computer can have software that handles all
the front-end data
management and can also receive data input from users.
[00201] Subject data can be stored with a unique identifier for recognition by
a processor or a
user. In another step, the processor or user can conduct a search of stored
data by selecting at
least one criterion for particular patient data. The particular patient data
can then be retrieved.
Processors in the computer systems can perform calculations comparing the
input data to
historical data from databases available to the computer systems. The computer
systems can then
store the output from the calculations in a database and/or communicate the
output over a
network to an output device, such as a webpage, a text, or an email. After a
user has received an
output from the computer system, the user can take a course of medical action
according to the
output. For example, if the user is a physician and the output is a
probability of cancer above a
threshold value, the physician can then perform or order a biopsy of the
suspected tissue. A set of
users can use a web browser to enter data from a biomarker assay into a
graphical user interface
of a webpage. The webpage is a graphical user interface associated with a
front end server,
wherein the front end server can communicate with the user's input device (for
example, a
computer) and a back end server. The front end server can either comprise or
be in
communication with a storage device that has a front-end database capable of
storing any type of
data, for example user account information, user input, and reports to be
output to a user. Data
53
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
from each user can be then be sent to a back end server capable of
manipulating the data to
generate a result. For example, the back end server can calculate a
corrections for similar cell
phones or compile data generated from similar sample collection units. The
back end server can
then send the result of the manipulation or calculation back to the front end
server where it can
be stored in a database or can be used to generate a report. The results can
be transmitted from
the front end server to an output device (for example, a computer with a web
browser or a cell
phone) to be delivered to a user. A different user can input the data and
receive the data. In an
embodiment, results are delivered in a report. In another embodiment, results
are delivered
directly to an output device that can alert a user.
[00202] The information from the assay can be quantitative and sent to a
computer system of
the invention. The information can also be qualitative, such as observing
patterns or
fluorescence, which can be translated into a quantitative measure by a user or
automatically by a
reader or computer system. In an embodiment, the subject can also provide
information other
than sample assay information to a computer system, such as race, height,
weight, age, gender,
eye color, hair color, family medical history, identity, location and any
other information that can
be useful to the user.
[00203] In some embodiments additional information is provided by sensors
associated with the
device. For example global positioning data, acceleration data, air pressure,
or moisture levels
can be measured by a device comprising the image sensor. This additional
information can be
used by the computer systems of the invention.
[00204] Information can be sent to a computer system automatically by a device
that reads or
provides the data from image sensor. I n another embodiment, information is
entered by a user
(for example, the subject or medical professional) into a computer system
using an input device.
The input device can be a personal computer, a mobile phone or other wireless
device, or can be
the graphical user interface of a webpage. For example, a webpage programmed
in JAVA can
comprise different input boxes to which text can be added by a user, wherein
the string input by
the user is then sent to a computer system for processing. The subject can
input data in a variety
of ways, or using a variety of devices. Data can be automatically obtained and
input into a
computer from another computer or data entry system. Another method of
inputting data to a
database is using an input device such as a keyboard, touch screen, trackball,
or a mouse for
directly entering data into a database.
[00205] In an embodiment, a computer system comprises a storage unit, a
processor, and a
network communication unit. For example, the computer system can be a personal
computer,
laptop computer, or a plurality of computers. The computer system can also be
a server or a
54
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
plurality of servers. Computer readable instructions, such as software or
firmware, can be stored
on a storage unit of the computer system. A storage unit can also comprise at
least one database
for storing and organizing information received and generated by the computer
system. In an
embodiment, a database comprises historical data, wherein the historical data
can be
automatically populated from another database or entered by a user.
[00206] In an embodiment, a processor of the computer system accesses at least
one of the
databases or receives information directly from an input device as a source of
information to be
processed. The processor can perform a calculation on the information source,
for example,
performing dynamic screening or a probability calculation method. After the
calculation the
processor can transmit the results to a database or directly to an output
device. A database for
receiving results can be the same as the input database or the historical
database. An output
device can communicate over a network with a computer system of the invention.
The output
device can be any device capable delivering processed results to a user.
[00207] Communication between devices or computer systems of the invention can
be any
method of digital communication including, for example, over the internet.
Network
communication can be wireless, ethernet-based, fiber optic, or through fire-
wire, USB, or any
other connection capable of communication. In an embodiment, information
transmitted by a
system or method of the invention can be encrypted.
[00208] It is further noted that the systems and methods can include data
signals conveyed via
networks (for example, local area network, wide area network, internet), fiber
optic medium,
carrier waves, wireless networks for communication with one or more data
processing or storage
devices. The data signals can carry any or all of the data disclosed herein
that is provided to or
from a device.
[00209] Additionally, the methods and systems described herein can be
implemented on many
different types of processing devices by program code comprising program
instructions that are
executable by the device processing subsystem. The software program
instructions can include
source code, object code, machine code, or any other stored data that is
operable to cause a
processing system to perform methods described herein. Other implementations
can also be
used, however, such as firmware or even appropriately designed hardware
configured to carry
out the methods and systems described herein.
[00210] A computer system can be physically separate from the instrument used
to obtain
values from the subject. In an embodiment, a graphical user interface also can
be remote from
the computer system, for example, part of a wireless device in communication
with the network.
In another embodiment, the computer and the instrument are the same device.
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
[00211] An output device or input device of a computer system can include one
or more user
devices comprising a graphical user interface comprising interface elements
such as buttons, pull
down menus, scroll bars, fields for entering text, and the like as are
routinely found in graphical
user interfaces known in the art. Requests entered on a user interface are
transmitted to an
application program in the system (such as a Web application). In one
embodiment, a user of
user device in the system is able to directly access data using an HTML
interface provided by
Web browsers and Web server of the system.
[00212] A graphical user interface can be generated by a graphical user
interface code as part of
die operating system or server and can be used to input data and/or to display
input data. The
result of processed data can be displayed in the interface or a different
interface, printed on a
printer in communication with the system, saved in a memory device, and/or
transmitted over a
network. A user interface can refer to graphical, textual, or auditory
information presented to a
user and can also refer to the control sequences used for controlling a
program or device, such as
keystrokes, movements, or selections. In another example, a user interface can
be a touch screen,
monitor, keyboard, mouse, or any other item that allows a user to interact
with a system of the
invention.
Use of Antibiotic Susceptibility Data
[00213] In yet another aspect, a method of taking a course of medical action
by a user is
provided including initiating a course of medical action based on sample
analysis. The course of
medical action can be delivering medical treatment to said subject. The
medical treatment can be
selected from a group consisting of the following: a pharmaceutical, surgery,
organ resection,
and radiation therapy. The pharmaceutical can include, for example, a
chemotherapeutic
compound for cancer therapy. The course of medical action can include, for
example,
administration of medical tests, medical imaging of said subject, setting a
specific time for
delivering medical treatment, a biopsy, and a consultation with a medical
professional. The
course of medical action can include, for example, repeating a method
described above. A
method can further include diagnosing the medical condition of the subject by
said user with said
sample. A system or method can involve delivering a medical treatment or
initiating a course of
medical action. If a disease has been assessed or diagnosed by a method or
system of the
invention, a medical professional can evaluate the assessment or diagnosis and
deliver a medical
treatment according to his evaluation. Medical treatments can be any method or
product meant to
treat a disease or symptoms of the disease. In an embodiment, a system or
method initiates a
course of medical action. A course of medical action is often determined by a
medical
professional evaluating the results from a processor of a computer system of
the invention. For
56
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
example, a medical professional can receive output information that informs
him that a subject
has a 97% probability of having a particular medical condition. Based on this
probability, the
medical professional can choose the most appropriate course of medical action,
such as biopsy,
surgery, medical treatment, or no action. In an embodiment, a computer system
of the invention
can store a plurality of examples of courses of medical action in a database,
wherein processed
results can trigger the delivery of one or a plurality of the example courses
of action to be output
to a user. In an embodiment, a computer system outputs information and an
example course of
medical action. In another embodiment, the computer system can initiate an
appropriate course
of medical action. For example, based on the processed results, the computer
system can
communicate to a device that can deliver a pharmaceutical to a subject. In
another example, the
computer system can contact emergency personnel or a medical professional
based on the results
of the processing. Courses of medical action a patient can take include self-
administering a drug,
applying an ointment, altering work schedule, altering sleep schedule,
resting, altering diet,
removing a dressing, or scheduling an appointment and/or visiting a medical
professional. A
medical professional can be for example a physician, emergency medical
personnel, a
pharmacist, psychiatrist, psychologist, chiropractor, acupuncturist,
dermatologist, urologist,
proctologist, podiatrist, oncologist, gynecologist, neurologist, pathologist,
pediatrician,
radiologist, a dentist, endocrinologist, gastroenterologist, hematologist,
nephrologist,
ophthalmologist, physical therapist, nutritionist, physical therapist, or a
surgeon.
[00214] Once the number of positive wells or reaction chambers has been
determined, that
number is processed using Poisson statistics and prior knowledge about the
chip in question to
determine the original concentration of sample in the chip. This information
is then
automatically sent via email to any valid email account and is then received
by the original
person who took the image regardless of where they are in the world relative
to the computer that
performs the image analysis. The time that elapses between the taking of the
image and the
receipt of email confirmation has been performed in well under 1 minute,
although actual time is
subject to the upload speed on the network of the cell phone and download
speed on the network
of the computer. This is important, because if an error is detected in the
course of an analysis,
such as not being able to find all 4 spots, the user needs to be quickly
alerted that another image
must be taken. The software has been programmed to do such, and the user
typically knows in
under 1 minute to take another image. Having the ability to notify by email
can give the ability to
notify via text. Cell phone providers can have a service that will send the
body of an email as a
text to specific users. Other servers that can be leveraged as SMS messengers.
The analysis
process can use computer automation to notify a user if the image can be used.
The notification
57
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
can be an SMS message, email message, phone call, web posting, or electronic
message for
example. In some embodiments, the amount of time from the uploading of the
image until the
user is notified can be referred to as the analysis process. The analysis
process can take less than
min, 4 min, 3 min, 2 min, 1 min, 50 sec, 45 sec, 40 sec, 30 sec, 20 sec, 10
sec, 9 sec, 8 sec, 7
sec, 6 sec, 5 sec, 4 sec, 3 sec, 2 sec, 1 sec, 0.5 sec, 0.4 sec, 0.3 sec, 0.2
sec, or 0.1 sec, for
example. In some embodiments, the analysis process takes less than 1 min.
[00215] At least one calibration source for providing a calibration emission,
and at least one
calibration photodiode for sensing the calibration emission wherein the
control circuitry has a
differential circuit for subtracting the calibration photodiode output from
each of the detection
photodiode outputs can be provided in some embodiments.
[00216] A communication interface can be a universal serial bus (USB)
connection such that
the outer casing is configured as a USB drive.
[00217] In some instances the information is transmitted back to the mobile
device which was
used for imaging. For example an image can be obtained, send to a separate
computer for
analysis, and then the image or date related to the image can be transmitted
back to the mobile
device. In some embodiments an image and/or a processed image and/or resulting
data the user
is transmitted to a separate device, e.g. a physician's mobile device can
receive the information.
In some instances two or sets of information are transmitted to two or more
devices. The two or
more sets of information can be the same information, or in some embodiments,
separate data is
sent to each user. For example a patient can receive some information related
to an image while
the patient's doctor receives information more suitable for a physician's
analysis.
[00218] While offloading the analysis of images to "the cloud" provides a
number of benefits,
including traceability and archiving of raw data, global access, and
compatibility with virtually
all smartphone operating systems, it requires a wireless data connection of
sufficiently high
bandwidth; thus, direct on-phone analysis could be preferable in some
scenarios.
58
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
Platforms / Devices
[00219] Provided herein are devices (e.g., microfluidic devices) and methods
that can rapidly
identify a cell, including a cancer cell, or microorganism, including a
pathogen, quantify their
load, and diagnose their susceptibility or resistance to drugs, such as
antibiotics. In some
embodiments the devices can enable phenotypic detection and metabolic
profiling of drug
susceptibility or drug resistance using individual microorganisms or cells
which can originate
from various sample types, including clinical or environmental samples. These
sample types can
include, but are not limited to, blood, cerebral spinal fluid (CSF), saliva
and urine and can also
include environmental samples, such as from water or a hospital surface. In
some embodiments,
the devices enable incubation of cells with drugs, such as antibiotics, and
then rapidly extract and
quantify nucleic acids or other molecules in a contamination-free platform.
The devices can use
digital single- molecule measurements in microfluidics devices, which provide
ultra-sensitive
measurements that improve detection limits while providing quantitative data,
important for
differentiating pathogens from contaminants and enabling earlier
differentiation between drug-
resistant and susceptible organisms or cells. In some embodiments, these
devices can
differentiate the state of individual microorganisms or cells from a clinical
sample, and
understand the timing of their individual responses to drugs, such as for
example antibiotics,
providing ultra-fast drug- susceptibility measurements.
[00220] In some embodiments the devices and methods can be used in assessing
gene
duplications measurements for each given cells, as in response to antibiotic
stress some microbes
can replicate antibiotic resistant genes (like lactamases) to 100s of copies,
allowing them to
undergo evolution.
[00221] In some embodiments, the devices and methods allow identification of
drug-resistant
bacteria from a pool of bacteria, such as a clinical sample, that can include
drug-susceptible
bacteria and/or drug-resistant bacteria and/or contamination with pathogenic
and/or
nonpathogenic bacteria ¨ or some combination of these types. In some
embodiments the devices
can be used to incubate cells with drugs and then rapidly extract and quantify
nucleic acids, such
as for example RNA, in a contamination-free platform to determine drug
susceptibility. In some
embodiments, the methods and devices provided herein enable microbial and cell
identification
and drug susceptibility testing outside of CLIA clinical laboratories
[00222] Devices can comprise channels and flowpaths, such as microfluidic
channels. Devices
can comprise inlets, outlets, or any combination thereof Devices can comprise
wells, reservoirs,
or any combination thereof Devices can comprise reaction volumes. Devices can
comprise pre-
loaded reagents. In some cases, the microfluidic device comprises a SlipChip
device, as
59
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
described for example in U.S. Patent Application No. 13/257,811, in PCT
Application No.
PCT/US2010/028361, in US Patent Publication No. 20120329038 Al, and in
International
Patent Publication No. WO 2013072069 Al, each of which is hereby incorporated
by
reference in its entirety. In some embodiments, the samples are contacted with
a reagent for
performing a reaction. As used herein, "contacting" refers to introducing a
substance or
maintaining a substance in an area or in a solution comprising the entity the
substance is to
be contacted to. For example, contacting a region for the amplification of a
target nucleic
acid with a reagent for performing the reaction can include flowing the
reagent into the
chamber, either separately or already together with the target nucleic acid,
or having the
reagent already preloaded into the region for amplification. Contacting can
occurs when
two substances are interacting under conditions to bind, touch, facilitate a
reaction, or
otherwise maintain proximity under desired conditions.
[00223] Platforms can comprise fluid handling mechanisms enabling loading,
unloading,
mixing, and other handling of sample volumes, reagent volumes, and other
fluids. For
example, a microfluidic device can be used comprising channels for loading
fluids into wells
or droplets, for mixing contents of wells or droplets, or for off-loading of
contents of wells or
droplets.
[00224] Some platforms are useful for conducting assays in a digital or quasi-
digital format,
as described herein. For example, wells, well plates, microwells, microfluidic
droplets,
emulsions, beads, and microarrays can provide a useful platform for conducting
a digital or
quasi-digital assay. In such an assay, the compartments can comprise
individual wells,
droplets, beads, or microarray spots.
[00225] In some embodiments, devices described herein incorporate SlipChip
digital
amplification technology and SlipChip sample preparation technology (Shen, et
at, 2010,
Analytical Chemistry, 4606-4612, Shen, et al., 2010, Lab on a Chip, 2666-2672,
Shen, et al.,
2011, Analytical Chemistry. 3533- 3540. Shen, et al., 2011, .1 Am Chem Soc,
17705-47712)
and can perform rapid single- molecule identification, and quantification of
nucleic acids from
cells and microorganisms, such as for example Klebsiella pneumonia,
Pseudomonas aeruginosa,
and extra-intestinal pathogenic E. coli. Samples can be obtained from a
variety of human bodily
fluids, such as for example blood, plasma, saliva, CSF or urine, or a variety
of environmental
samples, such as for example water or hospital surfaces.. In some embodiments,
this can enable
clinical validation of workflow that in some embodiments provides a
differential diagnosis of an
infection, such as for example a UTI. In some embodiments, this device can
provide
quantification of total cell load and species and/or strain identification. In
some embodiments,
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
the results of the assay can be available in less than 45 minutes, less than
30 minutes, less than
20 minutes, less than 10 minutes, less than 5 minutes, less than 3 minutes, or
less than 1 minute.
[00226] In some embodiments, the technology described here enables
identification and
quantification of nucleic acids, such as for example bacterial DNA and RNA
extracted from
urine samples spiked with a cell culture of reference strains. Reference
strains are those are used
routinely in clinical labs as part of their quality control protocol, such as
for example K.
pneumoniae (ATCC 700603), P. aeruginosa (ATCC 27853), and E. coli (ATCC
25922).(Institute., 2012, M07-A09) In some embodiments the technology and
devices described
in this disclosure can be integrated with standard bench methods and kits
(Qiagen Qiamp DNA
kit) to extract nucleic acids, and previously published universal primers can
be used to target
genes, such as for example the conserved region of the 16S gene, in order to
quantify nucleic
acid concentration (Clifford, et at., 2012, PLoS ONE, e48558, Nadkarni, et
at., 2002,
Microbiology, 257-266),. For example, the technology can be used to target
hyper-variable
regions of the 16S gene to quantify and identify microorganisms (Baker, et
at., 2003, Journal of
Microbiological Methods, 541-555, Hansen, et at., 2013, PLoS ONE, e61439,
Spilker, et at.,
2004, Journal of Clinical Microbiology, 2074-2079).
[00227] In some embodiments, the devices described herein allow identification
of drug-
resistant bacteria from a pool of bacteria, such as a clinical sample, that
can include drug-
susceptible bacteria and/or drug-resistant bacteria and/or contamination with
pathogenic and/or
nonpathogenic bacteria, or any combination thereof.
[00228] In some embodiments, the technology can be used for bacterial DNA and
RNA
amplification assays using the digital SlipChip over a dynamic range of, for
example, 1,000 to
lx107 copies/mL with, for example, three-fold resolution and a 95% confidence
interval. This
dynamic range is well covered by the digital SlipChip that is commercially
manufactured, which
contains 10,240 of 0.84 nL wells with a dynamic range of 450 to 9.7x107
copies/mL and a
detection limit of 120 copies/mt.
[00229] A workflow of determining the resistance or susceptibility of a cell
in a sample of urine
to a drug according to an embodiment of the invention is shown in Figure 5. In
some
embodiments, the device enables assays that perform both sample prep (e.g.,
exposure of
organism in the sample to a drug and extraction of target nucleic acids from
the sample) and
digital amplification (e.g., distributing and amplifying target nucleic acids
to quantify the target
nucleic acids present in the sample to determine a susceptibility or
resistance of the organism to
the drug).
61
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
Integrated Devices
[00230] In some embodiments, the devices provided herein are integrated
devices comprising
one or more modules. These modules include, but are not limited to, an
incubation module, a
sample preparation module, an amplification module, and a readout module. Each
of these
modules is described herein. In some embodiments, the integrated device
combines 2 or more
modules to provide a simplified processing flow for detecting the properties
of an organism in a
cell in response to a drug. An example of an integrated device comprising an
incubation chamber
and devices to regulate flow of the sample into the incubation chamber is
depicted in Figures
6A, 6B, and 6C.
Incubation Module
[00231] In some embodiments, the integrated device comprises an incubation
module. The
incubation module can contain an incubation chamber for, e.g., exposing a
microorganism to a
drug (see Figures 6A, 6B, and 6C). In some embodiments, the incubation module
contains inlets
allowing for the inserting of fluids, such as sample, media, reagents, or
other solutions. These
solutions are pushed into the SlipChip-like device through some means, an
example being
positive pressure from a pumping lid or plunger as shown in Figure 6C. In some
embodiments,
the layer adjacent to the SlipChip layer contains channels through which the
sample can flow. In
some embodiments, the uppermost layer has one or more openings for venting and
controlling
pressures. In some embodiments, the openings of the SlipChip layer are filled
with solution,
splitting the sample into different volumes. This layer is then slipped, the
openings of the
SlipChip layer are moved to form a connection with a separate layer, for
example an opening to
incubation chambers. The samples can be transported from the central SlipChip
layer and mixed
with solution, such as media or antibiotics, contained within the incubation
chambers. In some
embodiments, the incubation chambers can be sitting in a heated bath or
otherwise in contact
with heating elements for incubation. In some embodiments, membranes such as
hydrophobic
films are used for venting. In some embodiments, one or more openings are
present in one or
more layers of the device for controlling pressures. In some embodiments, the
layer containing
the incubation chamber can also be slipped. In some embodiments, fluids from
the incubation
chambers are transported to a separate module, such as the amplification
module. In some
embodiments, one or more SlipChip layers are used, for example, below the
incubation
chambers with openings to the sample prep or other module. In some
embodiments, the
integrated device has additional incubation modules.
[00232] In some embodiments, the incubation chamber in the incubation module
is used for
antibiotic susceptibility testing. In some embodiments, cells are pre-sorted
through a filter. In
62
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
some embodiments, a filter is used to capture bacterial cells. In some
embodiments, mammalian
cells are lysed selectively without lysing bacterial cells of interest. In
some embodiments,
selective lysis and filtration steps are combined. In some embodiments, the
incubation chamber
comprises an array of sub-chambers for confinement of cells.
[00233] In some embodiments, the incubation chamber is a module configured to
perform one
or more of the following: (i) partitioning the sample, (ii) partitioning the
drug/antibiotic, (iii)
combining the sample with the drug/antibiotic, (iv) mixing, (v) incubating the
sample, or (vi)
transporting the fluids to a separate chamber.
[00234] In some embodiments, digital assays can use the confinement of cells
from a sample
into an incubation chamber or a clonal isolation regions. In some embodiments,
the isolated
cells are cultured in individual incubation chamber to generate a plurality of
clonal populations
from the sample. In some embodiments, the isolated cells are treated with a
drug before or after
expansion. In some embodiments, after culture and expansion from an isolated
cell, the clonal
population is divided into two or more treatment regions. As such, at least
one portion of the
clonal population can be treated with a drug, while another portion of the
clonal population is not
treated with a drug. Then, the assays described herein can be performed to
determine whether
the cells in the clonal population are susceptible or resistant to one or more
drugs.
[00235] In some embodiments, splitting is performed through a SlipChip design
utilizing dead-
end filling. In some embodiments, to achieve dead-end channel filling with an
aqueous solution,
a hydrophobic membrane can be used at the end of the channel which blocks the
flow of aqueous
solution but allows non-aqueous liquid and gas to flow through.
[00236] In some embodiments, slipping (i.e., movement of the layers) can be
actuated
automatically using a rotating shaft. In some embodiments, this shaft can be
controlled by a
motor, optionally encoded or programmed to specific speeds, directions, and/or
rotation angles.
[00237] In some embodiments, combination and mixing of the sample with the
drug/antibiotic
is performed by pressurization of a chamber which transports one or more of
the solutions into
the other solution. In some embodiments, pressurization of chambers is
generated by a pumping
lid which creates a seal and changes the volume in that compartment; this can
be actuated
manually or through a rotating shaft, among other actuations. In some
embodiments, transport of
fluids into or out of the growth chamber module can be performed by
pressurization of the
chamber, such as for example by a pumping lid (either manually or
automatically), the opening
of a valve, or by other methods, such as e.g. pipetting.
63
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
[00238] In some embodiments, the incubation chamber module contains a heating
element.
Some examples of heating element control include a circuit board with a means
to control the
temperature and timing or phase change material
[00239] In some embodiments, the incubation chamber is designed to process
between 1 mL
and 10 mL. In some embodiments, the incubation chamber is designed to process
between 100
ILIL and 3 mL. In some embodiments, the incubation chamber is designed to
process between 10
ILIL and 100 mL. In some embodiments, the incubation chamber is designed to
process samples
likely containing single cells.
Sample Preparation Module
[00240] In some embodiments, the device comprises a sample preparation module.
In some
embodiments, samples can be split into different compartments that may or may
not contain a
drug of interest (such as an antibiotic). In some embodiments, after
incubation of the sample
with/without antibiotic drug, the cells of interest (such as for example those
of a bacterial
pathogen) are lysed (such as by lysis buffer) in order to extract RNA and/or
DNA. In some
embodiments, the sample-preparation module can be used to automatically
extract nucleic acids
from urine. In some embodiments, for sample preparation, a filter column can
be used to capture
RNA/DNA from a lysed sample and wash away cell debris or other components
present in the
lysed sample.
[00241] In some embodiments, an automated or semi-automated sample preparation
module is
provided. In some embodiments, the automated or semi-automated sample
preparation module
generates pressure to the lysed sample in a sealed environment, forcing the
lysed sample through
a filter column (e.g., a nucleic acid-binding column, such as a glass fiber
column).
[00242] In some embodiments, the sample prep module is designed to process
between lmL
and 10 mL. In some embodiments, the sample prep module is designed to process
between 100
ILIL and 100 mL. In some embodiments, the sample prep module is designed to
process between
ILIL and 1 L. In some embodiments, the sample prep module is designed to
process between 1
ILIL and 1 mL. In some embodiments, the sample preparation module can be made
of plastic and
in some embodiments does not require external power or active user
intervention.
Digital Quantification Module
[00243] In some embodiments, devices contain digital (or binary)
quantification modules, such
as modules containing multiple detection elements in which 0, 1, or more
target (e.g.
RNA/DNA) molecules are captured per each detection element and are suitable
for integration.
64
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
[00244] In some embodiments, enriched target (e.g. DNA/RNA) are recovered from
the device
for use in subsequent or parallel experiments. In some embodiments, the
integrated device has a
plurality of quantification modules.
[00245] In some embodiments, the quantification module is designed to process
between 30 L
and 60 L. In some embodiments, the quantification module is designed to
process between 1
L and 100 L. In some embodiments, the quantification module is designed to
process between
100nL and lmL. In some embodiments, the quantification module is designed to
process
between lOnL and 10mL.
Reagent Storage
[00246] In some embodiments, the integrated device comprises stored reagents.
In some
embodiments, the liquids in the devices (including those described above) can
be stored, such as
in blister packs, reagent packs, or other types of containers in which they
are sealed (Figure 7).
[00247] In some embodiments, the device comprises a reagent pack suitable for
preparing
nucleic acid of the cell or microorganism for nucleic acid quantification
reaction. In some
embodiments, the device comprises a reagent pack suitable for nucleic acid
quantification
reaction. In some embodiments, the reagent pack comprises enzymes for
performing a nucleic
acid quantification reaction. In some embodiments, the reagent pack comprises
primers for
performing a nucleic acid quantification (e.g., for PCR or isothermal
amplification)
[00248] Exemplary reagents in the reagent pack can include, but are not
limited to, lysis
solutions, wash solutions, elution solutions, rehydration solutions, enzyme
solutions (e.g.,
nucleic acid amplification enzymes, polymerase enzymes, restriction enzymes),
buffers, liquid,
powder, pellets, a gel, microbeads, probes, primers, nucleic acids, DNA, RNA,
polypeptides,
nucleoside triphosphates (NTPs), antibodies, a sacrificial reagent or any
combination thereof. A
sacrificial reagent can comprise an aqueous solution, a lubricant, an oil, an
aqueous-immiscible
liquid, a gel, a gas, a fluorocarbon oil, a surfactant, gas, air, or any
combination thereof. For
example, the air can be used to generate air bubble for mixing. As another
example, air and
immiscible liquid can be used to remove leftover solution (dead volume) in the
matrix. Reagents
can be mixed to change their composition. For example, one type of buffer can
be mixed with
another buffer or a dry reagent to change its composition to another buffer.
[00249] In some embodiments, the device comprises a reagent pack for assaying
enzyme
presence and/or activity, such as, for example, monobromobimane, 7-
Diethylamino-3-(4'-
Maleimidylpheny1)-4-Methylcoumarin, N-(7-Dimethylamino-4-Methylcoumarin-3-
yl))Maleimide), NiWa blue (1 -B enzyl 4-methyl 5-(tert-butoxycarbonylamino)-2-
(2,5- dioxo-2,5-
dihydropyrrol-1-yl)terephthalate), NiWa Blue II (Dimethyl 5-acetamido-2-(2,5-
dioxo-2,5-
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
dihydropyrrol-1- yl)terephthalate), NiWa orange (Dimethyl 2-amino-5-((2,5-
dioxo-2,5-dihydro-1
H-prrol-'- yl)ethyl)amino)terephthalate), Ellman's reagent/DTNB (5,5'-
dithiobis-(2-nitrobenzoic
acid)), Umbelliferone-derived cephalosporins, Fluorescein-derived
cephalosporins, Resorufin-
derived cephalosporins, Rhodamine-derived cephalosporins, Imipenem, and p-
nitrophenol
releasing substrates
[00250] In some embodiments, the device comprises a reagent pack containing
one or more
drugs at one or more concentration. In some embodiments, the device comprises
a reagent pack
containing one or more antibiotics at one or more concentration. In some
embodiments, the
device comprises a reagent pack containing components suitable for
accelerating response of a
cell or microorganism to a drug (e.g. quorum sensing molecules, etc.). In some
embodiments, the
device comprises a reagent pack containing culture media to enhance cell
growth.
[00251] In some embodiments, the device comprises a reagent pack containing
gases or gas
mixtures, containing H2S, CO, and NO. Such gases are known, for example, to
affect
susceptibility of microorganisms to antibiotics. Such gases can be diluted
with a gas mixture
which could be anaerobic, aerobic, or microoxic. Such gas mixture can contain
CO2. In some
embodiments, the device comprises a reagent pack containing lysis reagents to
expose
intercellular components.
[00252] In some embodiments, these containers avoid evaporation of solutions.
In some
embodiments, reagents can be released from one or more container by piercing
certain regions of
the containers, or by selectively opening parts of the containers at the
appropriate times. In some
embodiments, the generated pressure in the device can release the contents of
the
blisters/containers; in some embodiments these fluids are transported to other
parts of the device.
In some embodiments, reagents (such as e.g. amplification reagents) are stored
as dried reagents,
on device, in blister packs, or in containers (or some combination thereof).
The reagents can be
lyophilized, stored with sugars (e.g. sucrose, trehalose, among others),
and/or stored with beads.
Operation Module
[00253] In some embodiments, the device contains an operation module, such as
for example a
module to operate devices (including integrated devices). In some embodiments,
an operation
module can perform one or more of the following functions: motor control,
shaft rotation,
heating, image capture, and image processing. In some embodiments, an
operation module can
use one or more motors and shafts. In some embodiments, an operation module
can use one or
more rotary valves.
[00254] In some embodiments, an operation module consists of one or multiple
components, of
which one or multiple components can be driven/rotated by a spring or motor
(Figure 8). In some
66
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
embodiments, a spring or motor can be used to rotate a threaded part, which
can be connected to
a separate lid/plunger with the inverse thread of the former part (as
described in pumping lid
patent application). In some embodiments, as the spring or motor rotates the
first threaded part,
the plunger/lid can move and change the volume and pressure present in one or
more cavities. In
some embodiments, the lid/plunger forms a hermetic seal within one or more
cavities. In some
embodiments, the generated pressure can be used to flow a liquid sample that
is present in the
cavity through a filter column.
Fluid Management
[00255] In some embodiments, the device is configured to transport a volume of
lysed samples
out of device for a separate or parallel experiment. In some embodiments,
valves for generating
pressure to control the flow of solutions through the device (such as in which
different solutions
are flowed through the column or temporarily prevented from flowing through
the column) are
incorporated into the device. In some embodiments, negative pressures are
utilized during device
operation. In some embodiments, chambers within the device can be pressurized
or
depressurized prior to the initiation of the device.
[00256] In some embodiments, a one-step or multistep process can be
controlled, such as by
placing a filter column in the rotating layer of the device. In some
embodiments, as the filter
column is rotated in the device, the sample can be moved to different chambers
in the device that
can contain different reagents; these fluids can flow sequentially or
nonsequentially through the
filter column. In some embodiments, the liquid present in one or more chambers
will be moved
(such as via the generated pressure of a pumping lid) and a solution will flow
through the filter
column. In some embodiments, when a filter column in the device is in the
first position, a
solution can be pumped out of a first cavity; in some embodiments when the
device is moved
into a second position, a second solution is pumped. Devices can contain one
or more overlaps of
the filter column and one or more chambers containing liquid. In some
embodiments, the
distance and/or angle among different overlap positions can be programmed by
the device
design.
[00257] In some embodiments, a lysed sample can be flowed through a filter
column to capture
a target (e.g. DNA or RNA) on a filter column. In some embodiments, subsequent
steps involve
washing¨ e.g. the captured DNA or RNA specific to resistant or susceptible
cells can be
washed, such as with a washing buffer, and eluted off the column with elution
buffer to be
released from the column.
[00258] In some embodiments, after the target (e.g. DNA/RNA) is enriched and
eluted off the
column, the eluted DNA/RNA can be transported from the column into the next
chamber or
67
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
module, also called quantification module or device, that in some embodiments
is suitable for
quantification of target (e.g. DNA/RNA) molecules.
Other Modules and Elements
[00259] In some embodiments, the device contains an operation module, such as
for example a
module to operate devices (including integrated devices). In some embodiments,
an operation
module is configured to perform one or more of the following functions: motor
control, shaft
rotation, heating, image capture, and image processing. In some embodiments,
an operation
module comprises one or more motors and shafts. In some embodiments, an
operation module
comprises one or more rotary valves. In some embodiments, one or more layers
are connected to
a shaft and are capable of rotation. In some embodiments, one or more layers
are configured to
disconnect from the shaft. In some embodiments, one or more layers comprise a
detent ball and
remain connected to the shaft at low torques but disconnect at high torques
(i.e. when the layer is
physically stopped).
[00260] In some embodiments, one or more layers are preprogrammed to rotate a
specified
degree. In some embodiments, the operation module comprises a stopping
component to stop
one or more layers physically.
[00261] In some embodiments, the device contains an enrichment or pre-
concentration module.
In some embodiments, the enrichment module concentrates the number of
organisms. In some
embodiments, these devices contain a threshold module. In some embodiments,
the cutoff
module limits the number of organisms to a threshold value. In some
embodiments, the
enrichment and threshold module are combined. In some embodiments, the
enrichment module
is designed to process between 1 mL and 10 mL. In some embodiments, the
enrichment module
is designed to process between 100 ILIL and 100 mL. In some embodiments, the
enrichment
module is designed to process between 100 ILIL and 1 L.
[00262] In some embodiments, the device contains an incubation chamber and at
least one
detection chamber in proximity, such as within 10 cm of each other. In some
embodiments, the
device contains an incubation chamber and at least one detection chamber in
proximity, such as
within 20 cm of each other. In some embodiments, the device contains an
incubation chamber
and at least one detection chamber in proximity, such as within 1 m of each
other.
[00263] In some embodiments, the integrated device integrates one or more of
the following:
enrichment module, cutoff module, incubation module, sample prep module,
quantification
module, and operation module. In some embodiments, the integrated device
integrates the
incubation module, with the autonomous device and digital SlipChip. In some
embodiments,
modules have interlocking features. In some embodiments, modules are
interchangeable. In
68
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
some embodiments, modules useful for sample preparation and handling are
included in the
device.
[00264] In some embodiments, an integrated device has dimensions smaller than
10x10x10 cm,
or integrated device has dimensions smaller than 20x20x20 cm.
[00265] In some embodiments, the device comprises flexible materials such as,
but not limited
to PDMS, Tango+ (a 3D-printable soft material), or rubber. The flexible
materials enable the
device to perform leak-proof liquid movement of a sample among modules (e.g.,
between the
sample preparation module to the amplification module). In some embodiments,
the device
comprises channels/microchannels to interface modules. In some embodiments,
the device
comprises syringe pumps/teflon tubing. In some embodiments, the device
comprises embedded
channels in 3D-printed parts. In some embodiments, the device comprises 3D-
printed valves.
These components can also enable the device to perform leak-proof liquid
movement of a
sample among modules.
[00266] In some embodiments, a quantification device has a series of
compartments with
varying volumes. In some embodiments, a quantification device incorporates a
series of on-chip
dilutions before loading a series of single volume compartments. In some
embodiments, these
devices enable a large dynamic range without abnormally large compartment
sizes
[00267] As an example, a sample can be diluted 1:10 four consecutive times.
Each dilution is
loaded into a series of single volume digital compartments. 400 compartments
can quantify and
resolve 1.5-fold differences in concentration with a 1-log dynamic range.
Thus, the example
device consists of four sets of 400 compartments each. The four 10x dilutions
can be loaded into
these four sets of single volume compartments and will enable 1.5-fold
resolution with 4-log
dynamic range and antibiotic susceptibility testing.
[00268] In some embodiments, the devices comprise a readout module or
mechanism to
generate a readout. Platforms can be compatible with one or more readout or
detection
mechanisms. For example, a platform can be transparent or translucent in part
or in total,
allowing fluorescent measurement, detection of precipitate or gas bubble, or
other visual
observation. A platform can comprise visual detectors, such as CCDs, CMOS
sensors,
cameras, photon detectors, and other sensors. In another example, a platform
can comprise
electrical sensors, such as electrodes positioned within microwells. Platforms
can be
compatible with off-loading of samples for analysis. For example, a platform
can permit
unloading of droplets or contents of wells for mass spectrometry, sequencing,
or
electrophoresis.
69
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
[00269] In some embodiments, the method of reading the quantification module
include, but are
not limited to, fluorescence microscopy, brightfield microscopy, a camera, a
digital camera, or a
cell phone camera, among others. In some embodiments, a base station with an
camera is used to
capture the image. Image processing can be integrated in the base station or
the image file can be
transferred to a computer. In some embodiments, a cell-phone picture is taken.
Phone software
can be utilized to process the image or the image can be uploaded to a server
for image
processing.
[00270] In some embodiments, heating elements are embedded in the device, such
as those into
which an incubation module can be inserted, such as for example a bath
containing high thermal
conductivity materials. In some embodiments, amplification and detection of a
target (e.g.
RNA/DNA) can include heating elements on the device. Examples of heating
elements can
include, but are not limited to, heating by using electrical power, chemical
reaction, or phase
change materials. In some embodiments, transparent thermally conductive
materials can be used
such that images of the amplification region can be captured through the
heating unit.
[00271] In some embodiments, these devices incorporate mixing methods. In some
embodiments, jet macro-mixing can be used to mix solutions (Nealon, A. J.,
O'Kennedy, R. D.,
Titchener-Hooker, N. J., & Lye, G. J. (2006). Quantification and prediction of
jet macro-mixing
times in static microwell plates. Chemical engineering science, 61(15), 4860-
4870). In such an
approach, one or more solutions are pressurized and an opening between them
allows one
solution to flow into the other, or for both solutions to collide. In some
embodiments, one or
more solutions are gaseous mixtures, and generate bubbles to form a bubble
mixer. In some
embodiments, mixing is used to mix liquid samples and dry reagents.
Alternating positive and
negative pressures can be applied to improve mixing. In some embodiments,
mixing can be
accomplished mechanically, for example by an impeller, magnetic bead
agitation, gravity,
passive structures, etc., or combination of such methods.
[00272] In some embodiments, these devices contain a chamber or array of
chambers for
combining or mixing reagents.
[00273] In some embodiments, these devices contain special materials. In some
embodiments,
one or more materials in the device are compatible with organisms (e.g.
materials that do or do
not negatively affect viability). In some embodiments, a material or surface
coating can be added
to materials for one or more of the following purposes: to enhance thermal
conductive properties,
control surface chemistry/surface tension (hydrophobicity), enhance organism
viability, alter
diffusive properties, prevent adsorption, sealing, prevent leeching (i.e.
plastics), alter rigidity,
among others.
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
[00274] In some embodiments, these devices utilize one or more manual steps
¨such as but not
limited to addition of sample, insertion of reagents, adjusting settings,
slipping, rotation,
attaching pumping lid, actuating pumping, inserting materials, connecting
modules, initiating the
device, initiating heating, transferring fluids, removing modules capturing
images, etc.
[00275] In some embodiments, devices can be fabricated by a number of methods
including 3D
printing, injection molding, embossing, wet etching, and other methods known
in the art.
Device Uses
[00276] The digital platform in some embodiments of the device allows for
detection of lower
abundance bacteria than in current nucleic acid-based technologies, which
enables more robust
analysis of blood and CSF samples. The increased precision of digital
technology improves
monitoring of patient response to therapy.
[00277] The sample-prep module can provide rapid nucleic acid extraction and
purification
within 5 min, reducing degradation of unstable RNA.
[00278] The point-of-care module can allow for broad-based testing in clinical
populations
across a wide range of infections, and in both clinical trials and
surveillance.
[00279] The digital amplification module can allow for a clearer understanding
of low-level
infection in a more proximate timeframe than culture methods and can inform on
the
heterogeneity of response to antimicrobials.
[00280] In one embodiment, the devices can be used with sample preparation
technology to
isolate bacterial DNA and RNA rapidly and in high yield from target
microorganisms or cells,
such as for example Klebsiella pneumoniae, Pseudomonas aeruginosa, and extra-
intestinal
pathogenic E. coli and can include clinical samples and can include a variety
of bodily fluids,
such as for example urine. Sample-prep SlipChip for bacterial DNA and RNA
extraction and
purification from urine samples containing Chlamydia trachomatis has
previously been
validated. Viral RNA extraction and purification from plasma samples
containing HCV or HIV
viral particles has also been validated. In one embodiment, the devices can be
used to perform
sample preparation in less than 5 min and with samples handling a range of
volumes, such as for
example up to 0.5 mL. In some embodiments, the device can be used for rapid
detection of
samples containing low bacterial loads.
[00281] In some embodiments, the devices can be used to extract and purify
nucleic acids, such
as bacterial DNA and RNA from samples (e.g. a urine sample) spiked with a
bacterial target
(such as for example K. pneumoniae, P. aeruginosa, or E. coli) in some cases
in an extremely
short period of time (such as for example less than 5 minutes) and in some
cases with a yield
71
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
above 80% compared to standard bench methods, and at a quality suitable for
both digital and
real-time quantification.
[00282] Bacterial RNA is known to be unstable and expression levels can change
rapidly. In
cases where the quantity and quality of purified RNA can be compromised, the
devices described
in this disclosure can be used to further shorten the sample preparation
protocol, such as for
example to less than 3 min. This time frame has previously been demonstrated
for isolation of
viral RNA from blood plasma. In some embodiments, the lysis step can be
modified by adding
additional detergents or inhibitors to minimize the activity of RNase.
[00283] In some embodiments, the device can combine SlipChip sample
preparation and digital
quantification technologies for rapid, reproducible and quantitative
measurements of nucleic
acids, such as for example bacterial RNA levels in a sample, (e.g. a clinical
urine sample) spiked
with, for example, K. pneumoniae, P. aeruginosa, and E. coli from 100 CFU/mL
to lx106
CFU/mL with 3-fold resolution. In some embodiments, the devices described
herein have a
performance greater than 99% specificity.
[00284] In some embodiments, the device or platform combines more than one
module to
quantify and identify the target microorganisms in for example, clinical urine
samples.
[00285] In some embodiments, the devices will enable assays that perform both
sample prep
and digital amplification. In some embodiments, the total assay time can be
less than 60 min,
less than 30 minutes, less than 15 minutes. Current PCR protocols can be
shortened by
optimizing denaturation time, denaturing temperature, or by combining the
annealing and
extension steps(Bio-Rad). Using optimized amplification enzymes or fast
thermal cyclers, 10
minute amplification can be achieved.(Wheeler, et al., 2011, Analyst, 3707-
3712, Neuzil, et al.,
2006, Nucleic Acids Research, e77). In some embodiments, these devices can
perform sample
prep in less than 5 min, a reverse transcription step of less than 5 min, and
a digital SlipChip
workflow less than 35 min, to achieve for example a less than 45 min workflow.
In another
embodiment, this RT digital PCR instrument can be used to help optimize the
chip thermal
cycling protocol.
[00286] In some embodiments, the devices can enable rapid diagnosis of drug
resistance using
small numbers of cells originating directly from clinical samples. The devices
described here can
in some embodiments be used to answer the following questions, which are
essential to the
design of rapid AST assays that don't rely on many rounds of cell division,
and essential for
doing AST assays when a limited number of cells is available, as is often the
case for blood and
CSF: (i) What are the single-cell growth, phenotypic, and gene expression
profiles of drug-
susceptible and drug-resistant microbial populations or cells shortly upon
drug exposure? (ii) Are
72
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
there "sentinel" cells that can very rapidly (within less than 15 or even 7
minutes) predict the
susceptibility or resistance of the population or cells? (iii) How many cells
are necessary for
reliable prediction of the drug susceptibility or resistance of the clinically
relevant bacterial
population? (iv) What is the gene expression signature and the shortest drug
exposure that
reliably predicts antibiotic susceptibility and resistance when the
measurement is performed on
pooled cells, and how closely can this measurement approximate the performance
of the single-
cell assays?
[00287] In some embodiments, the devices described herein can be used to
monitor single cells
from the target organisms or cells in response to drug exposure. In some
embodiments, these
devices have the capability to monitor growth, metabolic activity, phenotypic
variation, and
levels of gene expression at the single cell level.
[00288] In some embodiments, the devices enable measurement of the
distribution of growth
rates and doubling times of susceptible strains or cells in the presence of
standard dilutions of a
drug, such as for example ciprofloxacin (a fluoroquinolone) or ampicillin
(such as a 0- Lactam).
Ciprofloxacin is regarded by clinicians as having the ability to prevent
growth immediately
(Barcina, et al., 1995, Journal of Microbiological Methods, 139-150), while
ampicillin's mode
of action is believed to allow as many as 5 generations of cell division
before lysis
occurs(Rolinson, 1980, Journal of General Microbiology, 317-323). It is well
known that
antibiotics can be rapidly lost in plastic devices, such as PDMS used for
Fluidigm chips.
Therefore, in some embodiments our devices can be composed of glass and in
some
embodiments they can be used to recover fluids(Ma, et al., 2014, PNAS, Ma, et
al., 2014,
Integrative Biology) to measure post-assay antibiotic concentrations.
[00289] In some embodiments the devices can measure gene expression by
quantifying RNA
present in single cells. The SlipChip device can analyze DNA from live
bacteria from individual
wells (Ma, et al., 2014, PNAS, Ma, et al., 2014, Integrative Biology) and can
quantify the
number of RNA copies in each well. In some embodiments, the devices can
combine these
applications to create single-cell gene expression assays.
[00290] In some embodiments, the devices can use genes reported to be
differently regulated in
response to antibiotic, such as recA and LexA (Barczak, et al., 2012,
Proceedings of the
National Academy of Sciences, 6217-6222), genes induced by OxyR and SoxS in
response to
antibiotic-induced oxidative stress(Dwyer, et al., 2014, Proceedings of the
National Academy of
Sciences, E2100-E2109), and measure genes near the origin of replication
(oriC) that become
amplified after treatment with antibiotics targeting DNA replication(Burgess,
2014, Nat Rev
Genet, 362-362, Slager, et al., 2014, Cell, 395-406).
73
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
[00291] In one embodiment, the devices can be used for specific quantification
of gene
expression markers (such as for example 16S RNA and pre-rRNA), to identify
drug
susceptibility (Mach, et al., 2011, The Journal of Urology, 148-153, Rolain,
et al., 2004, Journal
of Antimicrobial Chemotherapy, 538-541). In another embodiment the devices can
be used to
establish the smallest change detectable in gene expression with at least 20
clinical isolates under
a variety of incubation conditions and times (such as for example less than 10
min, or around 10
min, 20 min, or 30 min).
[00292] The technology described herein may, in some embodiments, optimize
and/or
accelerate these methods for resistance quantification of clinical samples. In
some embodiments,
the results of assays done on the devices described herein will be available
in minutes rather than
hours. In some embodiments, the invention enables a diverse set of
manipulations on diverse
volume scales (such as for example sample preparation to single-cell
manipulation, single-
molecule quantification, and cell-phone readout).
[00293] In some embodiments, the invention uses digital single molecule
measurements to
address antimicrobial susceptibility and provide ultra-sensitive measurements
that can radically
improve detection limits and can provide quantitative data, which is important
for differentiation
of pathogens from contamination and enabling earlier differentiation between
drug-resistant and
susceptible organisms. In some embodiments, this invention can be used for
phenotypic,
metabolic, and gene- expression profiling measurements in response to
antibiotics and can use
individual bacterial cells and can use samples originating from a clinical
setting.
[00294] In some embodiments, this invention uses high-throughput single-
bacterial-cell
measurements in the clinic to determine antibiotic susceptibility. In some
embodiments, this
invention allows differentiation of the state of individual microorganisms or
cells, such as for
example samples obtained from a clinical human sample or from an environmental
sample, and
can allow temporal quantification of their individual responses to antibiotics
and therefore ultra-
fast drug-susceptibility measurements.
[00295] In some embodiments, the devices can be used to rapidly identify
cells, quantify their
load, and provide their susceptibility profile. In some embodiments the
devices can be used to
incubate cells with drugs and then rapidly extract and quantify nucleic acids,
such as for example
RNA, in a contamination-free platform to determine drug susceptibility. In
some embodiments,
this invention enables microbial and cell identification and drug
susceptibility testing outside of
CLIA clinical laboratories.
[00296] In some embodiments, the devices enable handling of large sample
volumes over
multiple steps, enabling fast, efficient nucleic acid extraction. Sample
preparation SlipChip has
74
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
been validated previously for extraction and purification of bacterial RNA
from urine spiked
with C. trachomatis and viral RNA from blood plasma spiked with HCV viral
particles. This
device can process a 0.5 mL clinical sample, and the entire workflow, from raw
sample to
purified nucleic acid, can be completed within 5 minutes with no user
intervention. This device
has been validated for analyzing bacterial DNA from urine samples spiked with
C. trachomatis,
viral RNA from blood plasma spiked with HIV viral particles, and viral RNA
from culture of
influenza viruses.
[00297] In some embodiments, this invention includes a device for determining
drug resistance
of a cell or microorganism that incorporates nucleic acid quantification. In
some embodiments
this invention includes a device in which a sample derived from an organism
pre-incubated with
a drug is introduced into the devices described above.
[00298] In some embodiments, the devices measure the change in expression or
in copy
numbers of genes, such as for example genes close to OriC (such as for
example, competence
genes), after a sublethal dose of drug exposure. In some embodiments, gene
expression, such as
expression of the OriC-proximal genes, can be compared to the expression of
household genes or
to selected genes, such as genes located at the terminator (ter) site.
[00299] In some embodiments, the devices can assess cell competence itself in
response to
sublethal doses of a drug as an assay for drug susceptibility.
[00300] In some embodiments, the devices can assay bacterial susceptibility,
such as for
example susceptibility to [3-lactam antibiotics, by compartmentalizing cells
or microorganisms in
small volumes via stochastic confinement (e.g. via droplets or wells of small
size, such as
picoliter or nanoliter). In some embodiments, these samples are taken from
blood or urine or
CSF. In some embodiments the cells are in the presence of an antibiotic and a
fluorogenic
reporter. In some embodiments, the devices can detect persisters and
genotypically resistant, but
phenotypically silent, cells, such as for example by induction of a resistant
phenotype.
[00301] In some embodiments, the devices and methods herein can be used to
analyze a time
course of gene expression of microorganisms in a sample. For example, this
analysis can monitor
a change of gene expression in response to a drug. For example, time points of
gene expression
immediately prior to treatment with a drug and at one or more time intervals
after addition of the
drug to the microorganisms could be used (such time intervals can include one
or more of about
3 minutes, about 5 minutes, about 7 minutes, about 10 minutes, about 15
minutes, about 20
minutes).
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
[00302] In some embodiments, the devices and methods herein can include
incubation of
microorganisms at a controlled temperature, such as for example 35 C, 37 C, 38
C, 39 C, or
40 C.
[00303] Using single cell analysis will enable observation of stochastic
response times, enabling
outlier cells that respond quickly to provide earlier-than-average results.
[00304] In some embodiments, the device provides a mechanism to perform
single¨molecule
and single-cell measurements to detect small changes in relative nucleic acid
concentrations and
heterogenous cellular response to antibiotic treatment in pathogenic bacteria
(Figure 9). First, a
group of cells are subjected to antibiotic treatment, then changes in a
selected gene's expression
are quantified by two methods. For single-molecule digital amplification,
cells are lysed together
then RNA is quantified with high resolution to detect small overall changes.
For single-cell
measurements, cells are confined to individual wells in a microfluidic device
and qPCR on each
cell is used to take advantage of large, early responses in "sentinel" cells.
[00305] In some embodiments, the device can be used to assay bacteria from
isolates and
clinical samples in our devices and evaluate whether single cell analysis
reveals "sentinel cells"
that predict susceptibility or resistance earlier than possible in pooled-cell
analysis (Figure 9). In
some embodiments, the device can be used to optimize the media and growth
conditions within a
device to determine the minimum amount of time required to ensure that all
vigorous cells have
shown signs of growth. In some embodiments, the devices can be used to design
and optimize
rapid assays to determine drug susceptibility and drug resistance, for example
antibiotic
susceptibility and resistance of Klebsiella pneumonia, Pseudomonas aeruginosa,
or extra-
intestinal pathogenic Escherichia coli. In some embodiments the devices can
detect hetero-
resistance (where the tested sample contains both a susceptible strain or cell
and a resistance
strain or cell). This phenomenon is well documented for Gram-positive
bacteria(Musta, et al.,
2009, Journal of Clinical Microbiology, 1640-1644, Kim, et al., 2002, Journal
of Clinical
Microbiology, 1376-1380, Wong, et al., 1999, Clinical Infectious Diseases, 760-
767, Ariza, et
al., 1999, The Lancet, 1587-1588, Editors, 2001, Journal of Medical
Microbiology, 1018-1020)
and some Gram negatives (Pournaras, et al., 2007, Journal of Medical
Microbiology, 66-70) and
is relevant to patient treatment and outcome, although detection of
heteroresistance is not viewed
as a frequent clinical problem for Gram-negative bacteria. In some
embodiments, when
heteroresistance is observed, the devices disclosed herein can be used to
identify heteroresistance
by sample types so that they can be targeted for analysis, such as for example
by the single-cell
platform.
76
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
[00306] In some embodiments, the devices can be used to incubate a
microorganism or cell,
such as for example incubating isolates of K. pneumoniae with antibiotic
samples of, for
example, Cefazolin, Ceftriaxone, Ciprofloxacin, Piperacillin-Tazobactam,
Trimethoprim-
Sulfamethoxazole, and Meropenem and P. aeruginosa with Ciprofloxacin,
Piperacillin-
Tazobactam, and Meropenem.
[00307] In some embodiments the devices can be integrated, so that for example
the sample-
prep SlipChip and the digital SlipChip are integrated to improve
workflow/efficiency and avoid
contamination. Integration of the two chips can prevent RNA degradation and
eliminate
contamination and simplify workflow. In some embodiments the devices can be
integrated, so
that for example the devices combine the identification device and the AST
device to identify the
pathogen, its load, and its antibiotic susceptibility (Figure 10).
[00308] In some embodiments, the invention identifies and quantifies bacteria
and assesses
antimicrobial susceptibility. In some embodiments, the platform leverages
existing
thermocyclers found in most laboratories, enabling a low-cost digital PCR
capability to even the
smallest of clinical laboratories in an "open" format that would allow for
expansion of the test
menu. In some embodiments of the device, sample preparation can be performed
on a macro-
fluidic, disposable chip that does not require external power.
[00309] In some embodiments, the invention incorporates the capability to
quantify and assess
antimicrobial susceptibility into a CLIA-waived structure in order to provide
access to the
technology in primary care and global health settings. In some embodiments,
the invention uses
isothermal enzymes, which have been well studied on the SlipChip platform, and
can allow for
equipment-free testing under a range of environmental conditions. In addition,
in some
embodiments the results are cell phone readable and can be obtained by a
minimally trained user.
[00310] In some embodiments, the device can be modified for use with blood and
can also
include Acinetobacter baumannii in the test suite. In some embodiments the
device can be used
with low-abundance specimens and has RT PCR capability, which allows for more
accurate
testing of antimicrobial susceptibility even in low-abundance specimens. These
capabilities offer
significant clinical value in hospital settings.
[00311] In some embodiments, the device can rapidly diagnose an infection,
such as for
example a urinary tract infection (UTI), through species identification and
quantification, and in
some embodiments the device can also characterize the drug resistance of the
species causing the
infection. The device can thus significantly enhance clinicians' ability to
provide antibiotic
stewardship, and also to avoid inappropriate treatment when a UTI is not
present or when
bacterial counts do not warrant therapy.
77
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
[00312] In some embodiments, the device can quantify the number of bacteria
that exist at the
time of sample collection to determine if the bacterial load warrants therapy,
as physicians
typically do not treat at lower bacterial concentrations. In some embodiments,
validation can also
be done on the device. The bacterial concentration from the device can be
correlated with the
colony counts obtained using the current "gold standard" culture method for
bacterial detection
and characterization. In some embodiments, the device can be used to identify
which bacteria are
present using nucleic acid detection on a digital chip format.
[00313] In some embodiments, the device can be used to assess antimicrobial
resistance of the
identified organism to help guide choice of therapy. In some embodiments,
samples, such as
urine samples, can be incubated with a range of drugs, such as antibiotics,
and gene expression
tests can determine which drug regimen is best suited to treat the infection
(for example by
identifying to which drugs the bacteria are susceptible).
[00314] In some embodiments, the device can identify bacterial species with
greater than 99%
specificity and quantify bacterial load in urine over a dynamic range of 100
CFU/mL to
1,000,000 CFU/mL with better than 3-fold resolution.
[00315] In some embodiments of the device and methodology, the workflow allows
rapid AST
(anti- microbial susceptibility testing) for one or more species or strains or
cell types against a
panel of one or more drugs in less than 95 minutes, less than 30 minutes, less
than 15 minutes,
less than 5 minutes.
[00316] In some embodiments, the device is an integrated device capable of
performing sample
preparation and digital quantification so that it can be used for both
quantification of bacterial
load and quantification of gene expression for AST with at least 80% recovery
of nucleic acids.
[00317] In some embodiments, the device enables a workflow that combines an
identification
device and an AST device to identify the organisms, quantify their load, and
determine their
antibiotic susceptibility.
[00318] A device for sample preparation from urine that has at least 80%
recovery of nucleic
acids in comparison to standard nucleic acids in comparison to the existing
Qiagen sample
preparation kit. In some embodiments, sample preparation can be performed
automatically,
without centrifugation, in less than 5 min, whereas the Qiagen method takes 30
min.
[00319] In some embodiments, bacterial species identification can be performed
with greater
than 99% specificity for organisms in comparison to culture.
[00320] In some embodiments, quantification of live bacterial load, such as in
urine, can be
performed over a dynamic range of 100 CFU/mL to 1,000,000 CFU/mL with better
than 3-fold
resolution compared to common culture methods.
78
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
[00321] In some embodiments, the invention enables a workflow that allows
rapid AST (anti-
microbial susceptibility testing) for one or multiple species against a drug
or a panel of two or
more antibiotics in less than 95 min.
[00322] In some embodiments, the invention enables a workflow that combines
the preparation
module or device, identification and quantification module or device and the
AST module or
device to identify the organisms, quantify their load, and/or determine their
antibiotic
susceptibility, in less than 2.5 hours, less than 2 hours, less than 1 hour,
less than 30 minutes.
[00323] In some embodiments, the device provides multiplexed and quantitative
diagnostic
measurements of nucleic acids or proteins in CLIA-based and Limited Resource
Settings (LRS)
at a quality that is on par with the equipment typically used in reference
laboratories.
[00324] In some embodiments, the platform is "open" so that reagents for
other/additional
bacteria can be added and the scope of measurements expanded.
[00325] In some embodiments, the device enables multiplexed and digital
nucleic acid-based
quantitative measurement of HCV and HIV viral loads with a dynamic range of
105. In some
embodiments, the device enables multiplexed detection of pathogens (including
bacteria and
fungi).
[00326] In some embodiments, the device is a microfluidic device, such as a
SlipChip, that
enables sample preparation with one or more of the following characteristics:
a device that meets
or exceeds commercial standards for low cost fabrication, a device that
ultimately will not
require user intervention, a device that ultimately will not require
electricity to operate, a sample-
prep module or device that enables sample prep for HCV, chlamydia and
gonorrhea, and
influenza in less than 5 min, a device that uses inexpensive plastics and is
amenable to mass-
production technologies, a device in which operation and imaging can be
performed by an
untrained child, and a device in which operation and imaging can be performed
using automatic
cloud-based analysis and data transmission.
[00327] In some embodiments, the device can identify bacterial species with
greater than 99%
specificity and quantification of bacterial load in urine over a dynamic range
of 100 CFU/mL to
1,000,000 CFU/mL with better than 3-fold resolution.
[00328] In some embodiments, the device can identify and quantitatively
measure bacterial
DNA and RNA from organisms, such as for example Klebsiella pneumoniae,
Pseudomonas
aeruginosa, and extra-intestinal pathogenic Escherichia coli from clinical
samples of urine, and
can be adapted to also provide a quantitative measure of bacterial load.
[00329] In some embodiments, the device is a digital microfluidic device, such
as a digital
SlipChip, for identification and quantification of bacterial DNA and RNA
extracted from a urine
79
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
sample spiked with K. pneumoniae, P. aeruginosa and E. coli. In some
embodiments, the device
can have above 99% specificity for DNA/RNA amplification for organisms or
cells, and provide
quantification of DNA/RNA extracted over the dynamic range of 1,000 to 1x107
copies/mL with
3-fold resolution.
[00330] In some embodiments, the device is a digital microfluidic device, such
as a digital
SlipChip, can be used for quantification of live bacterial load in urine
sample by quantification
of 16S rRNA. In some embodiments, the device can incorporate a rapid
incubation step (less
than 10 min) and can evaluate renormalization of gene expression for different
sample types
under various storage conditions.
[00331] In some embodiments, the device is a digital microfluidic device, such
as a digital
SlipChip, capable of quantification of RNA markers purified using standard
bench method to
quantify live bacterial load. In some embodiments, the device is a sample-prep
device, such as a
sample-prep SlipChip that can have higher than 80% of recovery of both DNA and
RNA with
reference strains and clinical isolates of K. pneumoniae, P. aeruginosa and E.
coli. In some
embodiments, the device can recover a quality of purified DNA and RNA suitable
for both
digital device applications and real time qPCR
[00332] In some embodiments, the device can extract and purify bacterial DNA
and RNA from
urine sample spiked with reference strains of K. pneumoniae, P. aeruginosa and
E. coli with
higher than 80% recovery compared to the standard bench method in less than 5
minutes.
[00333] In some embodiments, the methods employ an integrated device with
multiple
functionalities and in other embodiments the methods employ non-integrated
devices, such as
separate sample- prep devices and digital devices for identification and
quantification. In some
embodiments, the combination of the integrated sample-prep and digital devices
for
identification perform with greater than 99% specificity and are capable of
quantification of a
bacterial load with 3-fold resolution over the dynamic range of 100 CFU/mL to
1,000,000
CFU/mL.
[00334] In some embodiments, the device can perform a rapid Antimicrobial
Susceptibility Test
(AST) for organisms, such as K. pneumoniae, P. aeruginosa and E. coli by
incubating samples
with drugs for a short period of time, then quantifying RNA expression
markers. In some
embodiments, the device can provide a sample to answer turnaround of less than
2.5 hours or
less than 2 hours or less than 1 hour. In some embodiments, the device can be
used with clinical
isolates or clinical samples.
[00335] In some embodiments, the device can quantify gene expression markers
over a dynamic
range of 100 copies/mL to 10,000,000 copies/mL. In some embodiments, the
device can be used
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
to identify the detectable minimal difference over the same dynamic range, and
this will provide
guideline for incubation time and antimicrobial susceptibility test for a
particular cell or
microorganism.
[00336] In some embodiments, the device can be used to incubate samples with
at least 20
clinical isolates of E. coli in the presence or absence of Ampicillin. In some
embodiments of the
device, bacterial RNA can be prepared and one or more RNA markers can be
quantified. In some
embodiments of the device the results will have at least 95% in agreement with
standard clinical
methods.
[00337] In some embodiments, the device can be used to incubate E. coli with a
drug, such as
an antibiotic, including Cefazolin, Ceftriaxone, Ciprofloxacin, Piperacillin-
Tazobactam,
Trimethoprim-Sulfamethoxazole, and Meropenem. In some embodiments of the
device, bacterial
RNA can be prepared and expression level of RNA markers quantified using
digital methods and
in a time frame of less than 95 min, less than 60 minutes, less than 30
minutes, less than 15
minutes. In some embodiments, the device can be used to incubate negative
urine spiked with at
least 20 clinical isolates of E. coli in the presence and absence of
Cefazolin, Ceftriaxone,
Ciprofloxacin, Piperacillin-Tazobactam, Trimethoprim-Sulfamethoxazole, and
Meropenem. In
some embodiments, the device can quantify expression level of RNA markers with
a workflow
performance of less than 5% major errors, and no very major errors.
[00338] In some embodiments, the device can incubate samples of at least one
clinical isolate in
the presence and absence of a drug of a panel of clinically relevant drugs. In
some embodiments,
the device can quantify expression level of RNA markers in bacterial DNA to
perform AST and
has less than 5% major errors, and no very major errors.
[00339] In some embodiments, the device integrates sample preparation and
digital capabilities.
The integration of the devices can prevent degradation and eliminate
contamination and enable
nucleic acid extraction, purification, and digital quantification with above
99% specificity and in
less than 55 minutes, less than 30 minutes, less than 15 minutes.
[00340] In some embodiments, the device can provide quantitative measurement
of bacterial
DNA and RNA, such as from urine samples spiked with K. pneumoniae (ATCC
700603), P.
aeruginosa (ATCC 27853), and E. coli (ATCC 25922) with above 99% specificity
and in less
than 55 minutes. In some embodiments, the device or integrated device can
provide
quantification of bacterial load at dynamic range of 100 CFU/mL to 1,000,000
CFU/mL with
greater than 3-fold resolution.
[00341] In some embodiments, the device can be used for quantification of gene
expression
level for at least 20, at least 50 or at least 100 clinical isolates with
incubation in the presence
81
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
and absence of selected drugs In some embodiments, the device performance,
including bacterial
load and AST, is comparable to CLSI reference methods. In some embodiments,
the error of
performance is less than 5% minor errors, less than 2.5% minor errors, less
than 1% minor
errors.
[00342] In some embodiments, the performance has, less than 1% major errors,
less than 0.5%
major errors, less than 0.1% major errors. In some embodiments, the device has
no very major
errors.
Kits
[00343] A kit can include a SlipChip device, and a sunk,' of a reagent
selected to participate in
nucleic acid amplification. In some embodiments, the reagent can be disposed
in a container
adapted to engage with a conduit of the first component, the conduit of the
second component, or
both. Such a container can be a pipette, a syringe, and the like. In some
embodiments, the kit
includes a heater.
[00344] Some embodiments of the device could be used to detect different
biological targets
such as, for example, proteins, bacteria, viruses, infectious agents etc.,
using nucleic acid labels.
In some embodiments the target is tagged with an oligonucleotide which can be
used for
detection. The oligonucleotide tag can be further amplified using any one of a
number of
different nucleic acid amplification strategies, such as for example, PCR,
LAMP, RPA, NASBA,
RCA, etc. The oligonucleotide tag could also be visualized using fluorescent
probes for example
as shown by Chen (Huang, Suxian, and Yong Chen.
[00345] "Polymeric Sequence Probe for Single DNA Detection." Analytical
chemistry 83.19
(2011): 7250-7254.)
EXAMPLES
[00346] These examples are provided for illustrative purposes only and not to
limit the scope of
the claims provided herein.
Example 1: Formation of a SlipChip
[00347] The procedure of fabricating desired glass SlipChips using soda lime
glass was based
on previous work. The two-step exposing-etching protocol was adapted to create
wells of two
different depths (5 gm for thermal expansion wells, 55 gm for all the other
wells). After etching,
the glass plates were thoroughly cleaned with piranha acid and DI water, and
dried with nitrogen
gas. The glass plates were then oxidized in a plasma cleaner for 10 minutes
and immediately
transferred into a desiccator for 1 hour of silanization. They were rinsed
thoroughly with
chloroform, acetone, and ethanol, and dried with nitrogen gas before use.
82
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
[00348] Plastic polycarbonate SlipChip devices were directly oxidized in a
plasma cleaner for
15 minutes after they were received from microfluidic ChipShop GmbH, and then
transferred
into a desiccator for 90 minutes of silanization. They were soaked in
tetradecane for 15 minutes
at 65 C and then rinsed thoroughly with ethanol, then dried with nitrogen gas
before use. Plastic
SlipChip devices were not reused.
[00349] The SlipChips were assembled under de-gassed oil (mineral oil:
tetradecane 1:4 v/v;
Fisher Scientific). Both top and bottom plates were immersed into the oil
phase and placed face
to face. The two plates were aligned under a stereoscope (Leica, Germany) and
fixed using
binder clips. Two through-holes were drilled in the top plate to serve as
fluid inlets. The reagent
solution was loaded through the inlet by pipetting.
Example 2: Digital Amplification in a SlipChip.
[00350] Digital PCR was performed on a SlipChip according to the protocols
described in Shen
et al. 2010). Feng Shen, Wenbin Du, Jason E. Kreutz, Alice Fok, and Rustem F.
Ismagilov,
"Digital PCR on a SlipChip," Lab Chip 2010 10: 2666-2672.
[00351] Briefly, in this published method, top and bottom SlipChip plates were
etched with
microfluidic channels and wells via photolithography and HF etching. The top
and bottom plates
were aligned in a mixture of 20% mineral oil/80% tetradecane and then clamped
to hold in place.
DNA from the extractions described above was added to PCR master mix. This
solution was
loaded into the SlipChip device with a pipette. After loading, a slip broke
the channels into 1280
individual 3nL compartments. Next, the SlipChip was clamped, sealed, and
placed on a
thermocycler for the following temperatures: 92 C for 3 minutes, 40 cycles of:
92 C for 20
seconds, 62 C for 20 seconds, and 72 C for 25 seconds. The SlipChip was
imaged, positive and
negative wells were counted, and the concentration of target DNA was
calculated using Poisson
statistics.
Example 3: Detection of differences in rDNA between treated/untreated
susceptible E. coli
over time
[00352] In one example, a ciprofloxacin-susceptible E. coli isolate from a
patient with a urinary
tract infection was pre-cultured in Bacto Brain Heart Infusion (BHI) media to
high cell density
prior to dilution and treatment with and without 2.5 ug/mL ciprofloxacin for
10, 20, and 30
minutes. DNA from treated and non-treated samples was extracted with Epicentre
QuickExtract
DNA extraction buffer. Quantitative PCR was performed with primers specific to
the target
rDNA gene for 23S. The following primers specific for 23S rDNA were used:
5'-TGCCGTAACTTCGGGAGAAGGCA-3' (SEQ ID NO: 1)
5'-TCAAGGACCAGTGTTCAGTGTC-3' (SEQ ID NO: 2)
83
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
[00353] A 1.37, 1.58, and 1.70 fold change in rDNA copy number between the
treated (right bar
at each timepoint) and non-treated (left bar at each timepoint) samples was
measured at 10, 20,
and 30 minutes (Figure 11).
Example 4: Detection of differences in rDNA between treated/untreated
susceptible and
resistant E. coli over time by qPCR and digital PCR
[00354] In one experiment, a ciprofloxacin-susceptible E. coli isolate from a
patient with a
urinary tract infection was pre-cultured in Bacto Brain Heart Infusion media
to high cell density
prior to dilution and treatment with and without 2.5 ug/mL ciprofloxacin for
30 minutes. DNA
from treated and non-treated samples was extracted with Epicentre QuickExtract
DNA extraction
buffer at 0, 15, and 30 minutes. Quantitative PCR with primers specific to the
target 23S rDNA
gene as provided in Example 3 was performed on the extracted DNA. At 15
minutes, a 1.27 fold
change in rDNA copy number between the treated (right bar at each timepoint)
and non-treated
(left bar at each timepoint) samples from the susceptible isolate was measured
(Figure 12A).
[00355] Digital with primers specific to the target 23S rDNA gene as provided
in Example 3
was performed on the extracted DNA in a SlipChip. One chip contained DNA from
the
untreated bacteria while the other chip contained DNA from the bacteria
treated with antibiotic.
The concentrations were compared and a fold-difference was calculated. Digital
PCR detected a
1.5 fold change in rDNA copy number. No significant change in rDNA copy number
was
observed for the resistant isolate (Figure 12B).
[00356] This experiment was repeated for a different E. coli isolate from a
patient with a
urinary tract infection which was also susceptible to ciprofloxacin. At 15
minutes, qPCR
measured a 1.8 fold change in rDNA copy number and digital PCR detected a 1.5
fold change in
rDNA copy number.
Example 5: Detection of differences in rDNA between treated/untreated
susceptible E. coli
over time by digital PCR
[00357] In one experiment, a ciprofloxacin-susceptible E. coli isolate from a
patient with a
urinary tract infection was pre-cultured in pooled human urine prior to
dilution and treatment in
1:1 BHI:urine with and without 0.75 ug/mL ciprofloxacin for 15 minutes. DNA
from treated and
non-treated samples was extracted with Epicentre QuickExtract DNA extraction
buffer. A 2.61
fold change in rDNA copy number between the treated and non-treated samples
was measured
using quantitative PCR on the extracted DNA with primers specific to the
target 23S rDNA gene
as provided in Example 3. Digital PCR was also performed using primers
specific to the target
23S rDNA gene as provided in Example 3 on the extracted DNA. Digital PCR
detected a 2.4
fold change in rDNA copy number. The results of the digital PCR data are shown
in Figure 13.
84
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
Example 6: Detection of differences in susceptible and resistant E. coli
treated/untreated
with tetracycline and trimethoprim/sulfamethoxazole
[00358] In one experiment, E. coli isolates from patients with urinary tract
infections and
susceptible to various antibiotics were pre-cultured in BHI or urine prior to
dilution and
treatment in 1:1 BHI:urine with and without antibiotics for various treatment
times. Treated and
non-treated samples were extracted with Epicentre QuickExtract DNA extraction
buffer. A
detectable fold change in rDNA copy number between the treated and non-treated
samples was
measured using quantitative PCR with primers specific to the target 23S rDNA
gene as provided
in Example 3. Under tetracycline treatment a 1.55 fold change in rDNA copy
number was
observed at 30 minutes (Figure 14A), under nitrofurantoin treatment a 1.62
fold change in rDNA
copy number was observed at 15 minutes, and under
trimethoprim/sulfamethoxazole treatment a
1.35 fold change in rDNA copy number was observed at 45 minutes (Figure 14B).
Example 7: Comparison of qPCR and digital PCR for detection of differences
between
resistant and susceptible cells
[00359] In this example, the enhanced resolution of digital amplification over
qPCR is shown.
Specifically, differences in nucleic acids found in bacteria that have been
treated with an
antibiotic as compared to untreated can be resolved with digital nucleic acid
quantification
(including PCR or LAMP) whereas qPCR methods (or qLAMP) may not reliably
resolve the
difference and/or may not reliably resolve the difference without using many
more replicates.
[00360] A ciprofloxacin-susceptible E. coli isolate from a patient with a
urinary tract infection
was pre-cultured in pooled human urine prior to dilution and treatment in 1:1
BHI:urine with and
without 0.75 ug/mL ciprofloxacin for 30 minutes. DNA from treated and non-
treated samples
were extracted with Epicentre QuickExtract DNA extraction buffer.
[00361] Quantitative PCR was performed on each sample with primers specific to
the target
32S rDNA gene (3 replicates per sample) with primers as provided in Example 3
and the
following Cq's were obtained: treated--22.84 +/- 0.53; untreated--22.13 +/-
0.07. Using the
method described in Weaver, et. al. "Taking qPCR to a higher level: Analysis
of CNV reveals
the power of high throughput qPCR to enhance quantitative resolution," Methods
2010 50: 271-
276, this 1.6-fold difference in rDNA copy number is not statistically
significant unless there had
been 10 qPCR replicates for each sample instead of 3.
[00362] The same samples were diluted 1:10 and loaded into a SlipChip for
digital
amplification. One chip contained DNA from the untreated bacteria while the
other chip
contained DNA from the bacteria treated with antibiotic. Digital PCR was
performed on the
extracted DNA to amplify 23S rDNA using primers provided in Example 3.
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
[00363] The results were measured and the following concentrations were
calculated using
Poisson statistics: treated--148,031 +/- 7,103 copies/mL; untreated---84,964
+/- 5,171
copies/mL. Using the statistical methods described in Kreutz et al.,
"Theoretical Design and
Analysis of Multivolume Digital Assays with Wide Dynamic Range Validated
Experimentally
with Microfluidic Digital PCR," Analytical Chemistry 2011 83: 8158-8168, a
statistically
significant difference with a p-value of 2e-13 was calculated.
[00364] Thus, digital PCR successfully resolved the treated vs. untreated
bacterial DNA while
qPCR was unable to resolve the difference in concentration with a typical
number of replicates
(three).
[00365] The statistical approach described with this experiment is applicable
more generally.
From a qPCR experiment, a standard deviation of 0.16 or greater in Cq is
typical. In order to
achieve a 1.25-fold resolution between two samples with this standard
deviation, qPCR can
require 18 replicates (Weaver et al. (2010)). For the same resolution (1.25),
one digital PCR
experiment can be performed, as long as the number of compartments in the
digital PCR
experiment is greater than 1200 (Id.).
Example 8: Target mapping of genes relative to origin of replication
[00366] The position of feoB, recA, and DnaAInhibitor protein genes was mapped
relative to
the origin of replication in a subset of 16 available genome-sequenced E. coli
strains linked to
UTI patients. The results showed a trend for FeoB gene to be located in
proximity to origin of
replication, while recA and DnaAInhibitor protein genes are positioned more
distantly from the
origin of replication (Figure 15). As a result of a replication initiation
event, feoB gene is
expected to replicate early, together with all other genes positioned close to
origin of replication
positioned at the similar distances from origin of replication as feoB gene
(e.g., malB gene
(GDB J01648)).
Example 9: DNA markers in different time points of chromosomal replication
data
[00367] In this experiment, one susceptible UTI E. coli isolate and one
resistant UTI E. coli
were treated with 2.5 ug/mL ciprofloxacin for 15 minutes. Their nucleic acids
were extracted
with QuickExtra DNA extraction kit ( Epicenter) and DNA was quantified via
qPCR with rDNA
(23S), FeoB gene, DnaA inhibiting protein gene, and RecA gene specific
primers.
[00368] Figure 16 shows Cycle threshold (Ct) for quantification of DNA
fragments copies
number in UTI clinical isolates E. coli genomes, in susceptible and resistant
of bacteria after
exposure ("treated") to a 2.5 ug/ml of ciprofloxacin for 15 minutes in BHI
medium. Table 2
provides the cycle threshold and fold change for each target between
susceptible and resistant
treated / untreated samples.
86
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
Table 2
235 CT 235 Fold FeoB FeoB dnaAinh dnaAinh recA CT
recA
Untreated Change Untreated Fold CT Fold Untreated Fold
/Treated /Treated Change Untreated Change /Treated Change
/Treated
Susceptible 20.19/ 1.57 23.3/ 1.33 23.93/ 1.03 24.81/
0.89
20.84 23.71 23.97 24.65 (1.13
up)
Resistant 20.22/ 0.94 23.19/ 0.94 23.68/ 1.16 27.19/
0.91
20.13 (1.06 up) 23.1 (1.06up) 23.89 27.05
(1.10 up)
[00369] In a susceptible strain, cells treated with ciprofloxacin showed a
1.57 fold decrease in
23S DNA, a 1.33 fold decrease in FeoB DNA, no change in dnaAinh DNA, and a
1.13 fold
increase in recA compared to cells untreated with the antibiotic.
[00370] In a resistant strain, cells treated with ciprofloxacin showed no
change in 23S DNA and
FeoB DNA, a 1.16 fold decrease in dnaAinh DNA, and a 1.10 fold increase in
recA compared to
cells untreated with the antibiotic.
[00371] In this example, less rDNA ( 23S DNA) copies and less FeoB genes
copies are
observed in the genomes of the susceptible isolates as compared to the
resistant isolates; while
for other genes fragments - dnaA inhibitor genes and recA genes positioned
more distantly from
origin of replication, there was no statistically rigorous difference between
drug treated and no
treated bacteria.
Example 10 ¨ Target mRNA for determining drug resistance or susceptibility
[00372] Our drug susceptibility assay is validated using several targets of
interest. These
include the targets FeoB and RecA RNA in isolates resistant to ciprofloxacin
[00373] Feo B expression is down-regulated in a presence of ciprofloxacin.
Despite being
downregulated at a low level it is down regulated in the bacteria which are
susceptible (non-
dividing, or dying) so it will ensure a good resolution compared to untreated
or resistant cells.
[00374] In this example, FeoB and RecA RNA levels were used to determine cells
that were
susceptible or resistant to ciprofloxacin clinical isolates after 20 min of
treatment with 2.5ug/mL
cipro in BHI medium. In this example, RNA quantification was done by qRTPCR
with FeoB and
RecA gene specific primers. In this example, FeoB expression was downregulated
in susceptible
isolates after antibiotic treatment. RecA expression in the same experiment
was not significantly
downregulated in susceptible isolates.
87
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
[00375] RNA ratios for feoB and recA allow to differentiate between
susceptible and resistant
UTI E. coli isolates after 20 minutes of antibiotic treatment.
[00376] In one example, one susceptible UTI E. coli isolate and one resistant
UTI E. coli from
overnight cultures were diluted in warm BHI medium 1:100 (10 iut in 1 mL), and
grown for-3-4
hours at 37C. Two samples of each well mixed culture were taken for antibiotic
exposure assay.
They were added to pre-warmed 1.7mL VWR micro centrifuge tubes containing A)
warm (
37C) BHI medium ( control) or B) warm ( 37C) BHI medium with added
ciprofloxacin at
concentration 2.5 g/mL; the rack for all the tubes has being also pre-warmed
to 37 C to
minimize the temperature variations. Both control and antibiotic containing
samples were
incubated for 20 minutes at 37 C. After that the samples A and B were
immediately placed on
ice, and were diluted 1/5 in RLT buffer (Qiagen). Their total nucleic acids
were extracted using
Qiagen RNAeasy Mini kit columns and buffers, and analyzed via one-step RT qPCR
to quantify
FeoB and Rec A RNA, using Maxima H- RT and SSO fast EvaGreen PCR mixture in a
presence of 0.3U/ L RNases inhibitor Superase In (Ambion) and 1 g/iut BSA
(Roche).
Samples taken from resistant isolates are marked UTI R and samples taken from
susceptible
samples are marked UTI S in the plots below. Samples incubated in a presence
of ciprofloxacin
have "cipro" added to their names.
[00377] Figure 17A and Figure 17B show RNA quantification of FeoB and RecA
genes
expression in UTI clinical isolates susceptible (S) and resistant (R) to
ciprofloxacin after 20
minutes of treatment with 2.5ug/mL of ciprofloxacin in BHI medium, versus 20
minutes of being
in BHI medium without antibiotics. Relative to susceptible cells exposed to
ciprofloxacin,
untreated susceptible cells showed a 4.86 fold increase in the expression of
the FeoB target,
observed as a 2.28 cycle difference. There was no significant change observed
the gene
expression in resistant cells. Both resistant and susceptible cells showed no
significant changes
in the expression of recA.
Example 11 ¨ Effects of Ciproflaxin on RNA expression of FeoB and RecA
[00378] Clinical isolates from UTI patients were obtained and recovered on TSA
blood agar
medium. Colonies from the blood agar plates were inoculated into 3 mL of BHI
medium, grown
overnight. One susceptible UTI E. coli isolate and one resistant UTI E. coli
from overnight
cultures were diluted in warm BHI medium 1:100 (10 iut in 1 mL), grown for
about 3 hours at
37C. Two samples of each well mixed culture were taken for antibiotic exposure
assay. They
were added to pre-warmed 1.7mL VWR micro centrifuge tubes containing A) warm
(37 C)
BHI medium (control) or B) warm (37 C) BHI medium with added ciprofloxacin at
concentration lOug/mL; the rack for all the tubes has being also pre-warmed to
37 C to minimize
88
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
the temperature variations. Both control and antibiotic-containing samples
were incubated for 20
minutes at 37 C. After that samples A and B were immediately placed on ice,
and 30 ILIL of each
sample were added to 130 ILIL of cold RLT buffer (Qiagen). Their total nucleic
acids were
extracted using Qiagen RNAeasy Mini kit columns and buffers, and analyzed via
one-step RT
qPCR to quantify FeoB and RecA RNA, using Maxima H-RT (and SSO fast EvaGreen
PCR
mixture in a presence of RNases inhibitors and BSA.
[00379] Figure 18 shows RNA quantification of FeoB and RecA genes expression
in UTI
clinical isolates susceptible and resistant to ciprofloxacin after 20 minutes
of treatment with 10
ug/mL of ciprofloxacin in BHI medium, versus 20 minutes of being in BHI medium
without
antibiotics. Results are provided in Table 3.
Table 3
FeoB RecA
CT Untreated Fold Change CT Fold Fold
/Treated Downregulated Untreated Change Change
/Treated Upregulated Ratio
Susceptible! 20.88/24.45 11.88 20.87/18.11 6.77 80.45
Susceptible 2 23.99/26.21 4.66 23.00/20.21 6.91 32.22
Susceptible 3 22.28/24.73 5.46 22.08/19.42 6.32 34.54
Resistant 20.45/20.53 1.06 22.54/22.57 0.98 1.04
[00380] Relative to susceptible cells untreated with ciprofloxacin,
susceptible cells treated
showed significant downregulation of the FeoB gene. Three different
susceptible isolates showed
11.88, 4.66, and 5.46 fold decrease in the presence of this RNA in cells. A
resistant isolate
showed no significant change. Relative to susceptible cells untreated with
ciprofloxacin,
susceptible cells treated showed significant upregulation of the RecA gene.
Three different
susceptible isolates showed 6.77, 6.92, and 6.32 fold increase in the presence
of this RNA in
cells. A resistant isolate showed no significant change. Individually either
of these changes can
be used to distinguish susceptible from resistant cells, however, taking a
ratio of the change in
FeoB to RecA provides even greater resolution between the resistant and
susceptible cells. The
susceptible strains tested showed an 80.45, 32.22, and 34.54 fold change
ratio, whereas in
resistant cells, this ratio was 1.04.
[00381] While preferred embodiments of the present invention have been shown
and described
herein, it will be obvious to those skilled in the art that such embodiments
are provided by way
89
CA 02966575 2017-05-01
WO 2016/085632 PCT/US2015/059344
of example only. Numerous variations, changes, and substitutions will now
occur to those skilled
in the art without departing from the invention. It should be understood that
various alternatives
to the embodiments of the invention described herein can be employed in
practicing the
invention. It is intended that the following claims define the scope of the
invention and that
methods and structures within the scope of these claims and their equivalents
be covered thereby.
